Gastrin interactions which impact upon gastric, colonic, pancreatic and oesophageal carcinogenesis by Tobias, Amanda Jane
Tobias, Amanda Jane (2010) Gastrin interactions which 
impact upon gastric, colonic, pancreatic and 
oesophageal carcinogenesis. PhD thesis, University of 
Nottingham. 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/11348/1/thesis_pdf.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
· Copyright and all moral rights to the version of the paper presented here belong to 
the individual author(s) and/or other copyright owners.
· To the extent reasonable and practicable the material made available in Nottingham 
ePrints has been checked for eligibility before being made available.
· Copies of full items can be used for personal research or study, educational, or not-
for-profit purposes without prior permission or charge provided that the authors, title 
and full bibliographic details are credited, a hyperlink and/or URL is given for the 
original metadata page and the content is not changed in any way.
· Quotations or similar reproductions must be sufficiently acknowledged.
Please see our full end user licence at: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf 
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
  i
 
 
 
 
 
 
 
 
 
 
Gastrin Interactions Which Impact Upon 
Gastric, Colonic, Pancreatic and 
Oesophageal Carcinogenesis 
 
Amanda J. Tobias BSc (Hons) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thesis submitted to the University of Nottingham for the 
degree of Doctor of Philosophy 
June 2009 
  ii
CONTENTS 
Page Number 
CONTENTS          i 
LIST OF FIGURES                  iv 
LIST OF TABLES        x 
ABBREVIATIONS                 xii 
ACKNOWLEDGEMENTS               xiii 
ABSTRACT                 xiv 
CHAPTER 1:  INTRODUCTION ............................................................. 1 
1.1 Carcinogenesis ......................................................................................... 3 
1.1.1 Oncogenes and tumour suppressors ..................................................... 4 
1.1.2 Apoptosis .............................................................................................. 6 
1.1.3 Inflammation ........................................................................................ 9 
1.1.4 Angiogenesis ...................................................................................... 12 
1.2 Gastrointestinal (GI) cancer ................................................................... 13 
1.2.1 Incidence ............................................................................................. 14 
1.2.2 Prognosis and treatment ...................................................................... 14 
1.2.3 Molecular pathways involved in GI cancers ...................................... 15 
1.2.3.1 Ras-Raf-MEK-ERK pathway .......................................................... 15 
1.2.3.2 The PI3/Akt pathway ....................................................................... 16 
1.2.3.3 The NFκB pathway.......................................................................... 17 
1.3 Gastric cancer ........................................................................................ 20 
1.3.1 Classification ...................................................................................... 20 
1.3.2 Incidence ............................................................................................. 21 
1.3.3 Prognosis ............................................................................................ 23 
1.3.4 Genetics .............................................................................................. 23 
1.3.5 Risk factors ......................................................................................... 24 
1.3.5.1 Helicobacter pathology .................................................................... 26 
1.3.5.2 Urease .............................................................................................. 27 
1.3.5.3 Cag pathogenicity island (PAI) ....................................................... 28 
1.3.5.4 Vacuolating cytotoxin A (VacA) ..................................................... 29 
1.3.6 Insulin-Gastrin (INS-GAS) mouse model of gastric carcinogenesis .. 30 
1.4 Colorectal cancer ................................................................................... 32 
1.4.1 Development ....................................................................................... 32 
1.4.2 Incidence ............................................................................................. 32 
1.4.3 Prognosis ............................................................................................ 34 
1.4.4 Genetics .............................................................................................. 34 
1.4.5 Hyperplastic polyps and colorectal cancer ......................................... 36 
1.4.6 Apc
min/+ 
mouse model of intestinal carcinogenesis ............................. 36 
1.5 Pancreatic cancer ................................................................................... 37 
1.5.1 Classification ...................................................................................... 38 
1.5.2 Risk factors ......................................................................................... 39 
  iii
1.6 Oesophageal cancer ............................................................................... 40 
1.6.1 Classification ...................................................................................... 40 
1.6.2 Risk factors ......................................................................................... 41 
1.6.2.1 Barrett's oesophagus ........................................................................ 42 
1.6.2.1.1 Progression of Barrett's oesophagus to adenocarcinoma .............. 42 
1.7 Gastrin ................................................................................................... 46 
1.7.1 The gastrin receptorcholecystokinin-2 (CCK-2) ................................ 48 
1.7.1.1 Structure of CCK-2R ....................................................................... 49 
1.7.1.1.1 Classical CCK-2R ......................................................................... 49 
1.7.1.1.2 Long isoform ................................................................................ 50 
1.7.1.1.3 Truncated isoform ......................................................................... 51 
1.7.1.1.4 Splice 4 variant isoform ................................................................ 52 
1.7.2 Gastrin and GI cancers ....................................................................... 52 
1.7.2.1 Gastrin and gastric cancer ................................................................ 53 
1.7.2.2 Gastrin and colorectal cancer .......................................................... 54 
1.7.2.3 Gastrin and pancreatic cancer .......................................................... 55 
1.7.2.3 Gastrin and oesophageal cancer ...................................................... 56 
1.7.2 Gastrin and cyclooxygenase ............................................................... 58 
1.8 Hypothesis ............................................................................................. 60 
 
CHAPTER 2:  MATERIALS AND METHODS .................................... 61 
2.1 Sample collection and preparation ........................................................ 63 
2.1.1 Sample processing ...................................................................... 63 
2.1.2 Sample embedding ..................................................................... 64 
2.1.3 Cutting of sections ...................................................................... 64 
2.2 Immunohistochemistry .......................................................................... 64 
2.2.1 Deparaffinising samples ............................................................. 64 
2.2.2 Endogenous peroxidase activity ................................................. 65 
2.2.3Antigen Retrieval ......................................................................... 65 
2.2.4 Serum block ................................................................................ 65 
2.2.5 Positive and negative antibodies ................................................. 66 
2.2.6 Secondary antibodies .................................................................. 66 
2.2.7 (strept)Avidin-biotin complex (ABC) protocol .......................... 66 
2.2.8 Visualisation, counterstaining and cover-slipping ...................... 67 
2.2.9 Mouse on mouse antibodies ....................................................... 67 
2.3 Staining analysis .................................................................................... 68 
2.3.1 Staining intensity ........................................................................ 68 
2.3.2 Area of staining .......................................................................... 68 
2.3.3 H-scoring staining analysis ......................................................... 69 
2.3.4 Proliferation analysis .................................................................. 69 
2.3.5 Blood vessel staining analysis .................................................... 69 
2.4 Radio Isotope Assay .............................................................................. 70 
2.5 In vivo mouse studies ............................................................................ 71 
2.5.1 INS-GAS model ......................................................................... 71 
2.5.2 Apc
Min/+
 model ............................................................................ 72 
2.6 Therapeutic intervention ........................................................................ 73 
2.6.1 G17DT immunisation ................................................................. 73 
2.6.2 COX inhibitors ........................................................................... 74 
2.7 Helicobacter infection ............................................................................ 74 
 
  iv
CHAPTER 3:  PROGRESSION OF BARRETT’S OESOPHAGUS A 
ROLE FOR GASTRIN ............................................................................. 75 
3.1 Barrett’s oesophagus .............................................................................. 76 
3.1.1 Proliferation ................................................................................ 77 
3.1.2 Serum gastrin and CCK-2 receptor levels .................................. 79 
3.1.3 X-linked Inhibitor of Apoptosis (XIAP) protein expression ...... 82 
3.1.4 Bcl-2 protein expression ............................................................. 83 
3.1.5 Akt and Phosphorylated-Akt (P-Akt) protein expression ........... 86 
3.1.6 Vascular endothelial growth factor-receptor 2 (VEGF-R2) protein 
expression ............................................................................................ 89 
3.1.7 Heparin-binding epidermal growth factor (HB-EGF) protein 
expression ............................................................................................ 91 
3.1.8 Blood Vessel Density (BVD) ..................................................... 93 
3.1.9 COX-2 protein expression .......................................................... 95 
3.2 Discussion .............................................................................................. 97 
 
CHAPTER 4:  A ROLE FOR CCK-2R IN THE PANCREATIC 
CANCER ENVIRONMENT .................................................................. 101 
4.1 Pancreatic cancer ................................................................................. 102 
4.1.1 CCK-2 receptor expression ...................................................... 102 
4.1.2 XIAP protein expression .......................................................... 106 
4.1.3 Bcl-2 protein expression ........................................................... 109 
4.1.4 COX-2 protein expression ........................................................ 111 
4.2 Discussion .................................................................................... 113 
 
CHAPTER 5:  HELICOBACTER INFECTION AND THERAPEUTIC 
INTERVENTION STUDIES IN THE INS-GAS MOUSE MODEL .. 118 
5.1 The INS-GAS mouse as a gastric cancer model of infection and 
therapeutic intervention ............................................................................. 119 
5.2 G17-diptheria toxoid (G17DT) ............................................................ 121 
5.2.1 The effect of G17DT on cancer progression in INS-GAS mice 122 
5.2.3 Discussion ................................................................................. 130 
5.3  The effect of COX inhibition on cancer progression in the INS-GAS 
mouse model .............................................................................................. 132 
5.3.1  Proliferation ............................................................................. 132 
5.3.2 Blood vessel density ................................................................. 133 
5.3.3 Discussion ................................................................................. 135 
5.1.1 Study to determine the effect of H. felis in INS-GAS mouse 
model (short term) ............................................................................. 135 
5.1.2  Long term infection with H. felis ............................................. 137 
5.1.3 Discussion ................................................................................. 143 
 
CHAPTER 6:  THERAPEUTIC INTERVENTION IN THE APC
MIN/+
 
MOUSE MODEL .................................................................................... 145 
6.1 The effect of G17DT on cancer progression in Apc
min
 mice ............... 150 
6.1.1 Proliferation .............................................................................. 150 
6.1.2 Apoptosis .................................................................................. 154 
6.1.3 BVD .......................................................................................... 156 
6.1.4 COX-2 protein expression ........................................................ 157 
6.1.5 Discussion ................................................................................. 159 
  v
6.2  The effect of COX inhibition on cancer progression in the Apc
Min/+
 
mouse model .............................................................................................. 162 
6.2.1  Polyp burden in the small and large intestine .......................... 162 
6.2.2  Proliferation ............................................................................. 163 
6.2.3  Cox-2 protein expression ......................................................... 165 
6.2.4  Blood vessel density ................................................................ 166 
6.2.5 Discussion ................................................................................. 167 
 
CHAPTER 7:  DISCUSSION ................................................................. 169 
7.1 Gastrin as a multi modal growth factor ............................................... 170 
7.2 Choice of models and tissue to investigate the role of gastrin in GI 
carcinogenesis ............................................................................................ 171 
7.3 Gastrin isoform sensitivity through the GI tract and activation of down-
stream pathways ...................................................................................... 1704 
7.4 Clinical relevance of gastrin in transgenic mouse models................. 1708 
7.5  Clinical relevance of gastrin in patient tissue samples ................... 16278 
7.6 A comparison of gastrin neutralisation and inhibition of COX-2 in 
gastric and colonic carcinogenesis ............................................................ 182 
7.7 The role of COX inhibitors in gastric and colonic cancer models ...... 185 
7.7.1 G17DT as a COX-2 inhibitor? .................................................. 186 
7.8 Gastrin neutralisation in a chemo-preventative setting ....................... 188 
7.9  Future work ......................................................................................... 162 
 
CHAPTER 8:  REFERENCES .......................................................... 16994 
 
  vi
LIST OF FIGURES 
 
 Page 
number 
Chapter 1  
Fig. 1.1 A diagrammatic representation of cancer pathways 4 
Fig. 1.2 Apoptosis signalling 8 
Fig. 1.3 Simplified diagrammatic representation of the layers 
of the GI tract 
13 
Fig. 1.4 The 20 most common cancers in the UK, 2002 14 
Fig. 1.5 A systematic representation of MAPK pathways 16 
Fig. 1.6 Systematic representation of PI3/Akt pathway 17 
Fig. 1.7 Overview of the NFκB pathway 18 
Fig. 1.8 The number of new cases of stomach cancer in the 
UK, 2002 
21 
Fig. 1.9 Correas cascade 22 
Fig. 1.10 Electronmicrograph of Helicobacter pylori 26 
Fig 1.11 Relative age standardised 5 year survival for patients 
diagnosed with colorectal cancer in England and Wales 
33 
Fig. 1.12 Diagrammatic representation of the pancreas 37 
Fig. 1.13 Progression from normal oesophagus to 
adenocarcinoma 
45 
Fig. 1.14 Conversion of pre-progastrin to mature amidated 
gastrin 17 
47 
Fig. 1.15 The position of the alternative splice sites of the 
CCK2R gene 
50 
  
Chapter 3  
Fig. 3.1 Comparison of proliferation in different grades of 
Barrett’s oesophagus 
77 
Fig. 3.2 Examples of MIB-1 staining of proliferating cells 78 
Fig. 3.3 Comparison of serum gastrin levels in patients with 
different grades of Barrett’s oesophagus 
79 
Fig. 3.4 Comparison of CCK-2R protein expression in 
different grades of Barrett’s oesophagus 
80 
Fig. 3.5 Examples of CCK-2R staining  81 
Fig. 3.6 Comparison of different levels of XIAP protein 
expression in different grades of Barrett’s oesophagus 
82 
Fig. 3.7 Examples of XIAP protein staining 83 
Fig. 3.8 Comparison of Bcl-2 protein expression in different 
grades of Barrett’s oesophagus 
84 
Fig. 3.9 Examples of Bcl-2 staining 84 
Fig. 3.10 Correlations between XIAP and VEGF-R2 protein 
expression 
85 
Fig. 3.11 Comparison of Akt protein expression in different 
grades of Barrett’s oesophagus 
86 
Fig. 3.12 Examples of Akt staining 87 
Fig. 3.13 Comparison of P-Akt protein expression in different 
grades of Barrett’s oesophagus 
88 
  vii
Fig. 3.14 Examples of P-Akt staining 88 
Fig. 3.15 Comparison of VEGF-R2 protein expression in 
different grades of Barrett’s oesophagus 
90 
Fig. 3.16 Examples of VEGF-R2 staining 90 
Fig. 3.17 Comparison of HB-EGF protein expression in 
different grades of Barrett’s oesophagus 
92 
Fig. 3.18 Examples of HB-EGF staining 92 
Fig. 3.19 Comparison of blood vessel density in different 
grades of Barrett’s oesophagus 
93 
Fig. 3.20 Examples of blood vessel staining 94 
Fig. 3.21 Correlation between XIAP and VEGF-R2 protein 
expression 
95 
Fig. 3.22 Comparison of COX-2 protein expression in 
different grades of Barrett’s oesophagus 
96 
Fig. 3.23 Examples of COX-2 protein staining 96 
  
Chapter 4  
Fig. 4.1 CCK-2R protein expression 103 
Fig. 4.2 Comparison in expression of the CCK-2R on blood 
vessels across different tissue samples 
103 
Fig. 4.3 Examples of CCK-2R staining 104 
Fig. 4.4 XIAP protein expression 106 
Fig. 4.5 Examples of XIAP staining 107 
Fig. 4.6 Positive correlation between XIAP protein expression 
and CCK-2R protein expression 
108 
Fig. 4.7 Bcl-2 protein expression 109 
Fig. 4.8 Examples of Bcl-2 staining 110 
Fig. 4.9 COX-2 protein expression 111 
Fig. 4.10 Examples of COX-2 staining 112 
  
Chapter 5  
Fig. 5.1 Example of an INS-GAS mouse 119 
Fig. 5.2 Diagrammatic representation of G17DT immunogen 121 
Fig. 5.3 H and E stained sections of INS-GAS fundus 122 
Fig. 5.4 Comparison of the levels of proliferation at different 
times points when INS-GAS mice were treated with G17DT 
compared to DT vehicle in the fundus 
124 
Fig. 5.5 Examples of BrdU staining in fundic glands in 30 
week old INS-GAS mice 
124 
Fig. 5.6 Comparison of levels of proliferation in the fundus of 
30 week old INS-GAS mice 
126 
Fig. 5.7 Comparison of blood vessel density in the fundus of  
INS-Gas mice 
127 
Fig. 5.8 Example of CD34 staining blood vessels in INS-GAS 
mice 
127 
Fig. 5.9 Comparison of COX-2 protein expression in the 
fundus of INS-Gas mice 
129 
Fig. 5.10 Representative COX-2 staining in the fundus 129 
  
  viii
Fig. 5.11 The effect of COX inhibition on proliferation in the 
fundus of INS-Gas mice 
132 
Fig. 5.12 Example of proliferating cells  133 
Fig. 5.13 The effect of COX inhibition on angiogenesis in the 
fundus of INS-GAS mice 
134 
Fig. 5.14 Example of CD34 staining of blood vessels in the 
fundus of an INS-GAS mouse 
134 
Fig. 5.15 The effect of H. felis infection on gastric unit length 
in 4wk old INS-GAS mice compared to placebo 
136 
Fig. 5.16 Comparison of serum gastrin (G17) levels in FVB 
mice and 4 week old INS-GAS mice infected with either 
placebo or H. felis 
137 
Fig. 5.17 H and E staining of the fundic region of a normal 
(FVB) mouse 
138 
Fig. 5.18 H and E staining showing examples of the fundus 138 
Fig. 5.19 The effect of H. felis infection on proliferation 140 
Fig 5.20 Proliferation in pre-cancerous lesions of 9 month old 
INS-GAS mice with and without H. felis infection 
140 
Fig. 5.21 Bcl-2 staining in the normal glands and close to pre-
cancerous lesions in the infected mice compared to uninfected 
142 
Fig. 5.22 Bcl-2 staining in the normal gastric glands and the 
interstitial tissue of pre-cancerous lesions in INS-GAS mice 
142 
  
Chapter 6  
Fig. 6.1 Examples of an Apc
Min/+
 mouse 148 
Fig. 6.2 H and E sections showing the progression from 
normal large intestine through polyp development to adenoma 
in Apc
Min/+
 mice. 
149 
Fig. 6.3 Comparison of the levels of proliferation in the crypts 
of the large and small intestine of Apc
Min/+
 mice when treated 
with G17DT. 
150 
Fig. 6.4 Examples of BrdU stained proliferating cells in 
colonic crypts of Apc
Min/+
 mice treated with DT and G17DT 
151 
Fig. 6.5 Comparison of level of proliferation in the polyps of 
the large and small intestine of Apc
Min/+
 mice treated with 
G17DT 
152 
Fig. 6.6 Examples of proliferating cells stained with BrdU 152 
Fig. 6.7 The level of Bcl-2 protein expression in the large 
intestinal crypts and polyps of Apc
Min/+
 mice 
154 
Fig. 6.8 Examples of Bcl-2 staining in crypts of Apc
Min/+
 mice 155 
Fig. 6.9 The effect of G17DT immunisation on BVD around 
crypts and within polyps of the large intestine of Apc
Min/+
  
159 
Fig. 6.10 Examples of CD34 staining of blood vessels in the 
large intestine of 16 week old Apc
Min/+
 mice 
159 
Fig. 6.11 Comparison of COX-2 protein expression in normal 
crypts and polyps of the large intestine of Apc
Min/+
 mice 
158 
Fig. 6.12 Examples of COX staining in the large intestine of 
16 week old Apc
Min/+
 mice 
158 
  
  ix
Fig. 6.13 Comparison of polyp burden in the small and large 
intestine of Apc
Min/+
 mice treated with COX inhibitors 
162 
Fig. 6.14 The effect of treating Apc
Min/+
 mice with aspirin and 
celecoxib on proliferation in the intestine 
163 
Fig. 6.15 BrdU staining of proliferating cells in the large 
intestine in Apc
Min/+
 mice given placebo or celecoxib 
164 
Fig. 6.16 The effect of aspirin and celecoxib on COX-2 
protein expression in the large and small intestine of Apc
Min/+
 
mice 
165 
Fig. 6.17 Examples of COX-2 protein staining in the large 
intestine of Apc
Min/+
 mice treated with placebo or celecoxib 
165 
Fig. 6.18 The effect of treating Apc
Min/+
 mice with aspirin and 
celecoxib on BVD in colonic crypts 
166 
Fig. 6.19 Examples of CD34 staining of blood vessels in the 
intestine of an Apc
Min/+
 mouse  
167 
  
Chapter 7  
Fig. 7.1 Gastrin mediated carcinogenic pathways 170 
Fig. 7.2 Systematic representation of how immunisation with 
G17DT may reduce proliferation and angiogenesis in a 
hypergastrinemic model 
183 
Fig. 7.3 Diagrammatic representation of where induction of 
COX-2 fits into progression of colorectal carcinogenesis 
184 
 
  x
LIST OF TABLES 
 
 Page number 
Chapter 1  
Table 1.1 Chronic inflammatory conditions linked to 
predispositions to cancer 
10 
Table 1.2 The frequency and prognosis for different 
histological types of malignant exocrine pancreatic 
tumours 
38 
  
Chapter 2  
Table 2.1 Immunohistochemistry antibodies, 
concentrations, blocks, antigen retrieval and secondary 
antibodies.  
74 
 
 
  xi
ABBREVIATIONS 
 
A 
Aberrant crypts foci = ACF 
Adenoma prevention with Celecoxib = 
APC 
Adenomatous polyposis coli = APC 
Adenomatous polyposis polyp 
prevention on Vioxx study = APPROVe 
3-amino-9-ethylcarbazole = AEC 
(strept) Avidin-biotin complex = ABC 
Azoxyymethane = AOM 
2-amino-1-methyl-6-phenylimidazo[4,5-
b]pyridine = PhIP 
 
B 
Barrett’s oesophagus = BE 
Blood vessel density = BVD 
Body mass index = BMI 
Bromodeoxyuridine = BrdU 
 
C 
Celecoxib long-term arthritis safety 
study = CLASS 
Central nervous system = CNS 
Cholecystokinin = CCK 
CCK-2 receptor intron 4 splice variant = 
CCK-2Ri4sv 
Columnar lined oesophagus = CLO 
Cyclooygenase = COX 
COX-2 specific inhibitor = coxib 
Cytotoxin associated gene A = cagA 
 
D 
Deleted in pancreatic cancer = DPC4 
3,3’-Diaminobenzidine 
tetrahydrochloride = DAB 
 
E 
Endoplasmic reticulum = ER 
Enterchromaffin-like = ECL 
Epidermal growth factor = EGF 
 
 
F 
Fas-associated death domain = FADD 
Familial adenomatous polyposis = FAP 
Food and drug administration = FDA 
 
 
G 
Gastroesophageal reflux disease = 
GERD 
Gastrointestinal = GI 
Gastrin 17 = G17 
Gastrin 34 = G34 
Gastrin 17-diptheria toxoid = G17DT 
Glycine extended gastrin =G-gly 
Glycine extended G17 = gly-17 
Glycine extended G34 = gly-34 
 
H 
Helicobacter felis= H. felis 
Helicobacter pylori = H. pylori 
Heparin-binding epidermal growth factor 
= HB-EGF 
High grade dysplasia = HGD 
 
I 
IκB kinases = IKK 
Inhibitor of apoptosis = IAP 
Insulin-gastrin = INS-GAS 
Intestinal metaplasia = IM 
Intraductal papillary mucinous 
neoplasms = IPMNs 
 
J 
 
K 
 
L 
Lymph node = LN 
 
M 
Messenger RNA = mRNA 
Metaplasia-dysplasia-adenocarcinoma 
sequence = MCS 
Metalloprotinases = MMPs 
Mitogen-activated protein kinase = 
MAPK 
Multiple intestinal neoplasms = Min 
Mutated in colorectal cancer = MCC 
 
N 
Narrow band imaging = NBI 
None steroidal anti inflammatory drugs = 
NSAIDs 
 
O 
Overnight = O/N 
 
P 
Pancreatic intraepithelial neoplasia 
PanINs 
Pathogenicity island = PAI 
Permeability transition pore = PTP 
Phosphate buffered saline = PBS 
Phosphatidylinositol-3,4,5-triphosphate 
= PIP3 
Phosphorylated Akt = P-Akt 
Polyoma virus middle T = PyMT 
Prevention of spontaneous adenomatous 
polyp = Pre-SAP 
Prostaglandin E2 = PGE2 
Protein kinase C = PKC 
Proton pump inhibitor = PPI 
 
 
  xii
Q 
 
R 
Retinoblastoma = Rb 
Room temperature = RT 
 
S 
Severe combined immunodeficiency = 
SCID 
Small interfering RNA = siRNA 
Somatostatin receptor = SSTR 
Sydney strain 1 = SS1 
 
T 
Thromboxane A2 = TXA2 
Thymidine phosphorylase = TP 
Transforming growth factor = TGF 
Tumour associated macrophages = TAM 
Tumour necrosis factor = TNF 
TNF receptor 1 = TNFR1 
TNF related apoptosis-inducing ligand 
receptor 1 = TRAIL-R1 
TNF related ligand receptor 2 = TRAIL-
R2 
Tumour node metastasis system = TNM 
 
U 
 
 
V 
Vacuolating cytotoxin A = VacA 
Vascular endothelial growth factor-
receptor 2 = VEGF-R2 
Vioxx gastrointestinal outcomes research 
= VIGOR 
 
W 
World health organisation = WHO 
 
X 
X-linked inhibitor of apoptosis = XIAP 
 
Y 
 
Z 
  xiii
Acknowledgements 
 
My first thanks go to my supervisor Professor Sue Watson for believing in 
me and keeping me going when the end seemed unreachable. 
 
Next, I must thank the members of the Division of Pre-Clinical Oncology, 
both past and present who have supported me in my lab work; Phil Clarke 
for all things histology related, Andy McKenzie for help with radio isotope 
assays, Anna Grabowska for her support and guidance, Jane Moffat for 
formatting, as well as fellow technicians and students Jane, Marian, Jamie, 
Jenny, Jacqueline and Mo. 
 
Also those outside of my department, Raj Singh and Mark Aloysius who 
obtained samples for me and Abed Zaitoun for invaluable pathology advice 
and assistance.   
 
Finally, thanks go to my family and husband, Barney, for their continuing 
support and encouragement. 
  xiv
Abstract 
Introduction 
The polypeptide hormone gastrin promotes the growth of cancer cells 
through the gastrin/CCK-2 receptor (CCK-2R) and is implicated in the 
development, progression and invasion of a number of cancer types, 
including all GI malignancies.  The aim of this thesis was to establish 
correlations between gastrin, the CCK-2R and pro-carcinogenic factors in 
the oesophageal and pancreatic cancer setting with a view to assessing their 
importance as prognostic biomarkers.  Further to this, transgenic animal 
models of gastric and intestinal cancer were used to demonstrate the 
therapeutic effects of gastrin neutralisation in comparison to a standard of 
care, COX-2 inhibition. The interactions of gastrin, the CCK-2R and 
Helicobacter pylori, the pro-carcinogenic bacterium were also investigated. 
 
Methods 
This thesis focused on correlations between gastrin and the CCK-2R and 
key tumourigenic pathways including, pro-angiogenic factors, e.g. blood 
vessel density and VEGF-R2 and anti-apoptotic factors e.g. Bcl-2 and 
XIAP.  This involved use of (i) tumour microarrays of human primary 
pancreatic cancer and lymph node metastases and pancreatitis and (ii) 
biopsies of Barrett’s oesophageal metaplasia and dysplasia together with 
normal oesophageal epithelium.  Following immunohistochemical 
characterisation of the array of factors, correlations with gastrin parameters 
were performed using Spearman 2-tailed correlation with Bonferroni 
correction. 
  xv
 
For therapeutic studies, a gastrin immunogen G17DT, which induces the 
production of neutralising anti-gastrin antibodies was administered to INS-
GAS and Apc
Min/+
 mouse models of gastric and colorectal carcinogenesis 
respectively in comparison with clinically used agents such as, COX 
inhibitors (aspirin and celecoxib).  The INS-GAS model was also utilized to 
study the effect of Helicobacter infection and gastrin interactions on gastric 
cancer progression. 
 
Blood was collected from Barrett’s patients and used to determine serum 
gastrin levels using radio isotope assay.   
 
Results 
All Barrett’s patients studied had elevated serum gastrin levels as a result of 
being on proton pump inhibitors (PPIs), as well as high levels of CCK-2 
receptor protein.  There were positive correlations between anti-apoptotic 
markers XIAP and p-Akt with serum gastrin, and between p-Akt and CCK-
2 receptor protein expression.  There were also positive correlations 
between the pro-angiogenic marker VEGF-R2 and CCK-2 receptor protein 
expression as well as blood vessel density, another indicator of 
angiogenesis, and serum gastrin.  These results indicate a role for the CCK-
2 receptor as a prognostic marker alongside other pro-carcinogenic factors 
and identify those patients in which hypergastrinaemia may have the 
potential to impact on the rate of progression. 
 
  xvi
In pancreatic cancer CCK-2 receptors were shown to be increased 4-fold in 
pancreatic cancer compared to the normal pancreas, with a key finding 
being that endothelial cells expressed greater levels of the CCK-2 receptor 
protein in pancreatic cancer tissue compared to normal pancreas.  Also key 
was the positive correlation between CCK-2 receptor expression on 
endothelial cells and tumour recurrence along with the negative correlation 
between CCK-2 receptor expression on endothelial cells and survival.  
There was also a positive correlation between CCK-2 receptor protein 
expression and XIAP although no correlation was seen with the other anti-
apoptotic marker Bcl-2, but Bcl-2 protein expression was significantly 
increased in pancreatic cancer compared to normal pancreas. 
 
In vivo G17DT immunisation reduced angiogenesis, proliferation and COX-
2 protein expression in INS-GAS mice, but only angiogenesis in Apc
Min/+
 
mice.  COX inhibition significantly reduced proliferation and angiogenesis 
in both the Apc
Min/+ 
mice, and INS-GAS mice, suggesting that inhibition of 
gastrin maybe a partial substitute for the potential shown by COX-2 
inhibitors, withdrawn due to cardiac toxicity.  Results in the INS-GAS 
mouse also demonstrated that Helicobacter infection promotes 
carcinogenesis in this model to a greater extent than hypergastrinemia alone. 
 
Conclusion 
The expression of gastrin and its receptor the CCK-2R may provide an 
additional prognostic biomarker in GI cancer to demonstrate potential issues 
in patients with hypergastrinaemia through PPI treatment or Helicobacter 
  xvii
infection and its neutralisation or that of its receptor may provide a 
mechanism to limit any potential deleterious effects of hypergastrinaemia as 
well as provide some of the therapeutic benefits seen with COX-2 
inhibitors. 
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Chapter 1 
 
INTRODUCTION 
  2
 
 
 
 
 
 
 
 
Cancer, as defined by the American Cancer 
Society, is a 
 “group of diseases characterised by uncontrolled 
growth and spread of abnormal cells. If the spread 
is not controlled, it can result in death.” 
  3
1.1 Carcinogenesis 
 
Carcinogenesis is the process by which normal cells become cancerous.  
The division of cells occurs in all most all tissue and to insure the integrity 
of both organs and tissue the balance between cell proliferation and cell 
death , normal by apoptosis ,a form of programmed cell death, is tightly 
regulated under normal circumstances.  However if this sensitive balance is 
disrupted then uncontrolled cell division occurs, this is due to mutations in 
the cells DNA, this mutated DNA is then replicated in resulting daughter 
cells further propagating uncontrolled cell division (Elmore 2007). 
 
Original research indicated that one mutation was enough to lead to 
carcinogenesis, but more recent work has shown that multiple mutations are 
required to transform a normal cell to a cancer cell, and that these mutation 
have to occur in genes vital to cell division, apoptosis and DNA repair 
(Sieber, Heinimann et al 2005).  There are two types of genes which hold 
the key to carcinogenesis, they are proto-oncogenes and tumour suppressor 
genes.  Proto-oncogenes and tumour suppressor genes are discussed in more 
detail in section 1.1.1.  Details a number of pathways that have been shown 
to be linked to carcinogenesis are shown in fig.1.1. 
 
Substances which are directly linked to cancer or it’s propagation are termed 
carcinogens.  Carcinogens have the ability to either damage genomic DNA 
or disrupt metabolic processes within a cell.  Common examples of 
carcinogens include asbestos, tobacco and gamma radiation.  Cancers have 
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also been demonstrated to originate from viral infection, but this is more of 
a phanominom in other animals than humans, with 12% of human cancers 
being linked to viral infection (Carrillo-Infante, Abbadessa 2007).  Genetic 
abnormalities which promote carcinogenesis can also occur randomly due to 
errors in DNA replication or can be inherited. 
 
 
Fig. 1.1 A diagrammatic representation of cancer pathways (Hahn 2002). 
 
 
1.1.1 Oncogenes and tumour suppressors 
 
Proto-oncogenes are normal genes whose function is activated or enhanced 
by mutation.  Mutated proto-oncogenes are referred to as oncogenes and 
their resulting protein is termed an oncoprotein.  Oncogenes either cause an 
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over-expression of an oncoprotein which is structurally identical to the wild-
type protein or structurally alter the protein and therefore its biochemical 
properties (Todd and Wong 1999).  Examples of proto-oncogenes include 
cMyc, which was first identified in Burkitt’s lymphoma and has since been 
associated with a number of human malignancies (Boxer and Dang 2001; 
Pelengaris, Khan et al. 2002) and Ras which has been identified in 
pancreatic, colon and lung cancers (Bos, Fearon et al. 1987). 
 
Genes whose cellular function is inactivated following mutation are termed 
tumour suppressor genes.  Mutations in tumour suppressor genes remove the 
natural cellular constraints on cell proliferation, cell adhesion and other 
cellular behavioural functions.  The majority of cancers have been shown to 
have mutations in the tumour suppressor gene p53 which encodes for p53 
and is often referred to as the “guardian of the genome”.  Normal p53 
monitors the integrity of the genome and in the event of DNA damage p53 
accumulates to arrest cell development at the G1 stage to allow extra time 
for repair, if the cell is unable to repair then p53 prompts cell death by 
apoptosis (Yonish-Rouach, Resnitzky et al. 1991; Lane 1992).  When p53 is 
inactivated by mutation or binding to host or viral proteins it is unable to 
promote programmed cell death, which leads to an accumulation of 
mutations and chromosomal rearrangements (Lane 1992).  An example of 
the effects of defective p53 can be seen in p53 knockout mice which 
develop numerous tumours by the age of 6 months (Donehower, Harvey et 
al. 1992). 
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From early studies it appeared that cancer may arise from as few as one 
genetic change in the genome.  However, later work has now indicated that 
cancer due to a single gene mutation is rare if not impossible, with work in 
rodents showing that oncogenes cooperate in pairs e.g. Myc and Ras, and 
that cells prepared in vitro with pairs of oncogenes drive tumour formation 
more rapidly than those observed in mice with only one oncogene (Hahn 
and Weinberg 2002). 
 
 
1.1.2 Apoptosis 
 
Apoptosis is a form of programmed cell death, which follows a series of 
biochemical events including blebbing, changes to the cell membrane, cell 
shrinkage, nuclear fragmentation, chromatin condensation and chromosomal 
DNA fragmentation (Lowe and Lin 2000).  An important feature of 
apoptosis is that there is no leakage of cell contents and therefore no 
inflammatory response. 
 
The central component of apoptosis is a proteolytic family of proteases 
termed caspases.  In response to pro-apoptotic signals enzymes participate 
in a cascade which culminates in the cleavage of a set of proteins and the 
disassembly of the cell (Thornberry and Lazebnik 1998). 
 
There are a number of signals that appear important in initiating apoptosis 
these include, depletion of growth/survival factors, hypoxia, loss of cell 
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matrix interactions, DNA damage, telomere malfunction and inappropriate 
survival signals as a result of oncogenic mutations (Lowe and Lin 2000).  In 
a high proportion of these examples it is the activation of p53 which triggers 
apoptosis e.g. when cells encounter hypoxic conditions it is the activation of 
p53 which promotes apoptosis, and if p53 is mutated then cells can survive 
hypoxic conditions aiding clonal expansion within a tumour (McCurrach, 
Connor et al. 1997) and apoptosis due to telomere malfunction is triggered 
by activation of p53, therefore cells with mutant p53 survive even though 
they are genetically unstable (Karlseder, Broccoli et al. 1999). 
 
Activation of apoptosis can occur either through extrinsic (receptor) or 
intrinsic (mitochondrial) pathways (see fig 1.2).  The extrinsic pathways are 
initiated by death receptors, which are members of the tumour necrosis 
factor (TNF) receptor gene superfamily and include CD95 (APO-1/Fas), 
TNF receptor 1 (TNFR1), TNF-related apoptosis-inducing ligand-receptor 1 
(TRAIL-R1) and TRAIL-R2 (Fulda and Debatin 2006).  Upon binding to 
their cognate ligand CD95 and the TRAIL receptors cause trimerization of 
the receptor and subsequent recruitment of adaptor molecules such as Fas-
associated death domain (FADD) (Walczak and Krammer 2000).  FADD 
then induces apoptosis through the activation of the cell death protease, 
caspase-8, which in turn initiates a protease cascade that cleaves cellular 
targets and causes apoptotic cell death (Lowe and Lin 2000).  The intrinsic 
pathway is initiated by growth factors, cytokines and DNA damage.  Its 
activation of caspase is tightly linked to permeabilisation of the outer 
mitochondrial membrane by members of the Bcl-2 family through the 
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permeability transition pore (PTP), the PTP is opened following apoptotic 
signalling and allows the release of cytochrome c from the mitochondria 
(Green and Reed 1998).  Cytochrome c then interacts with Apaf-1 and pro-
caspase-9 and initiates a protease cascade similar to that observed for the 
extrinsic pathway (Li, Nijhawan et al. 1997). 
 
FADD FADD
Casp-8 Casp-8
CD95
TR
AIL
-R
CD95-L TRAIL
FLIP
Bcl-2 Bax
Cyt c
Apaf-1
Casp-9
Bid
Caspase-3
Substrates
Smac
IAP
CAD/ICAD
DNA
Fragmentation
Apoptosis
Fig 1.2  Apoptosis signalling can be initiated through either an extrinsic or intrinsic 
pathway.  The extrinsic pathway involves the stimulation of death receptors e.g. CD95, and 
the recruitment of adaptor molecules  and caspase-8.  Caspase -8 is then activated and 
initiates apoptosis by direct cleavage of downstream effector caspases.  The intrinsic 
pathway is initiated through stress signals resulting in the release of apoptogenic factors 
e.g. cytochrome c from the mitochondria into the cytosol and triggering caspase-3 
activation.  There is negative regulation of caspase activation in the extrinsic pathway by 
FLIP and the intrinsic pathway by Bcl-2 and IAP.
Extrinsic Intrinsic
 
 
Studies in mice have shown a direct link between disruption of apoptosis 
and promotion of tumour development.  For example Bcl-2 has been shown 
to promote lymphoproliferation in transgenic mice (McDonnell, Deane et al. 
1989) and bcl-2 transgenes have been shown to accelerate mammary 
carcinogenesis (Strasser, Harris et al. 1990).  Bcl-2 is an oncogene, first 
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identified in the human leukaemia cell line 380, derived from a 16 year old 
male with acute pre-B-cell lymphoma (Tsujimoto, Finger et al. 1984), 
which promotes cell survival by blocking apoptosis (Hockenbery, Nunez et 
al. 1990). 
 
 
1.1.3 Inflammation 
 
It has long been thought that there is a link between inflammation and 
cancer with the observations by Virchow in the 1800’s that tumours often 
arose at sites of chronic inflammation (Balkwill and Mantovani 2001).  
However, this view has not been favoured until recently with evidence 
immerging in support from both epidemiological studies in humans and 
molecular studies in animal models.  Epidemiological studies have 
demonstrated that chronic inflammation can predispose individuals to some 
cancers.  Worldwide 15% of all cancer deaths are due to infectious agents 
with chronic inflammation being a major contributing factor (Balkwill and 
Mantovani 2001) (see table 1.1).  Animal models of induced gastric cancer 
via gastritis caused by infection with Helicobacter pylori (see section 1.2.5) 
(Houghton, Stoicov et al. 2004) and work in Mdr2-Knockout mice which 
develop hepatocellular carcinoma through the sequence of inflammation, 
dysplasia, dysplastic nodules, carcinoma and metastasis (Pikarsky, Porat et 
al. 2004) have also strengthened the argument for the role of inflammation 
in cancer development. 
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Malignancy Inflammatory stimulus
Bladder cancer Scistosomiasis, urinary catheters
Cervical cancer Chlamydia
Colorectal cancer Inflammatory bowel disease
Gastric cancer H. pylori induced gastritis
Hepatocellular carcinoma Hepatitis B and C virus
Kaposi's sarcoma Human herpes virus type 8
Oesophageal cancer Barrett's metaplasia
Ovarian cancer Endometriosis
Table 1.1  Chronic inflammatory conditions linked to predispositions to cancer. 
Adapted from Balkwill et al 2005 and Coussens and Werb 2002.
 
 
The original theory was that it was enhanced cell proliferation which led to 
cancer (Balkwill and Mantovani 2001), but it has now been established that 
it is the sustained proliferation of cells within an environment which is rich 
in inflammatory cells, growth factors, activated stroma and DNA-damage 
promoting agents which can promote neoplastic risk (Coussens and Werb 
2002).  Under normal physiological conditions injury to a tissue activates 
the innate immune system leading to enhanced proliferation while the tissue 
regenerates.  Once the injury is repaired then proliferation and inflammation 
reseed.  However, if the proliferating cells have sustained DNA damage, 
they may not cease to proliferate after injury repair, but instead continue to 
proliferate in a microenvironment which is rich in inflammatory cells and 
growth/survival factors (Coussens and Werb 2002).  As described by 
Dvorak (Dvorak 1986) tumours can be considered wounds that do not heal. 
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Macrophages are key components of the innate immune system, they are 
differentiated monocytes bought to the injury site by chemo-attractant 
cytokines termed chemokines and once activated are the main source of 
growth factors and cytokines in the local microenvironment which influence 
endothelial, epithelial and mesenchymal cells (Coussens and Werb 2002).  
Macrophages can change their functional profile repeatedly in response to 
their environment (Watkins, Egilmez et al. 2007)  Depending on the 
response macrophages are either termed M1 or M2, M1 macrophages have 
anti-tumour activity and are triggered by exposure to lipopolysaccharides or 
IFN-γ, whereas exposure to IL-4 and IL-3 cause macrophages to become 
M2 and support tumour growth (Mantovani, Sozzani et al. 2002).   
 
In nearly all tumours the major constituent of the infiltrate is tumour-
associated macrophages (TAM), macrophages which reside in the tumour 
microenvironment.  TAMs are M2 type macrophages, whose survival can 
be prolonged by cytokines produced by the tumour (Sica, Schioppa et al. 
2006).  Under normal activation conditions TAMs can kill tumour cells or 
destroy tissue based on vascular endothelium reactions following activation 
of IL-2, interferon and IL-12 (Balkwill and Mantovani 2001; Brigati, 
Noonan et al. 2002; Tsung, Dolan et al. 2002).  However, TAMs have also 
been shown to promote tumour cell proliferation, angiogenesis, metastasis 
and activate oncogenes in cancer cells (Mantovani, Bussolino et al. 1992; 
Chen, Yao et al. 2003).  The role of TAMs has been highlighted in the 
transgenic Polyoma virus middle T (PyMT) mouse model, which develop 
mammary cancer.  When PyMT mice have a mutated CSF-1 gene, a gene 
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involved in macrophage recruitment, the development of late stage invasive 
carcinoma and pulmonary metastases is significantly attenuated (Wahl and 
Kleinman 1998). 
 
Macrophages are not the only inflammatory cells to be linked to 
carcinogenesis, studies have also indicated the involvement of neutrophils, 
mast cells, eosinophils and activated T-lymphocytes, which are thought to 
contribute to malignancy by releasing extracellular proteases, pro-
angiogenic factors and chemokines (Coussens and Werb 2002). 
 
 
1.1.4 Angiogenesis 
 
Angiogenesis itself is a normal process for the formation of new blood 
vessels in developing organs and as part of wound healing and in these 
circumstances it is a highly regulated process. However, unregulated 
angiogenesis has been linked to a number of diseases, including arthritis, 
diabetes related blindness and tumour development (Folkman 1990).  In a 
normal situation blood vessels are established from endothelial precursors, 
this network is then expanded on by sprouting or intussusceptions, where 
interstitial tissue columns are inserted in to the lumen of pre-existing vessels 
and the lumen partitioned (Patan, Munn, et al 1996).  In a tumour situation 
vessels develop by sprouting or intussusceptions of pre-existing vessels and 
tumour cells have also been shown to grow around existing vessels to form 
a perivascular cuff (Yancopoules, Davis et al 2000). 
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Angiogenesis allows tumours to grow beyond the limit otherwise imposed 
by the pre-existing vasculature and is considered a vital step in the evolution 
of solid tumours (Hanahan and Folkman 1996).  The vascularisation of 
tumours has been a known phenomenon since the turn of the 1900’s, but the 
mechanism of their eliciting new capillary growth from the host was not 
realised until the 1950’s (Merwin and Algire 1956).  Current understanding 
is that when levels of pro- and anti-angiogenic molecules are in a balanced 
state then the angiogenic switch is “off” and is only switched “on” when this 
balance is swayed in the favour of pro-angiogenic molecules (Bouck, 
Stellmach et al 1996).  This switch can be triggered be a number of 
situations including hypoxia, inflammation, the activation of oncogenes and 
inactivation of tumour suppressor genes (Kerbel 2000).  
 
Vessels created as a result of tumour angiogenesis are not as well 
constructed or organised as those created during normal angiogenesis due to 
a poorer coordination of regulatory factors.  Tumour vessels lack some of 
the normal protective mechanisms usually acquired during growth, their 
walls tend to have numerous holes with a discontinuous or absent basement 
membrane and inter endothelial junctions are inferior (Hashizume, et al 
2000, Hobbs, Monsky et al 1998).   
 
Members of the pro-angiogenic vascular endothelial growth factor family 
(VEGF) have been shown to play a prominent role in tumour angiogenesis, 
causing the initial vessel dilation seen during angiogenic sprouting, as well 
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as stimulating endothelial cell proliferation, migration and assembly 
(Yancopoules, Davis et al 2000).   
 
 
1.2 Gastrointestinal (GI) cancer 
 
GI cancers account for 20% of all cancer incidences worldwide (MacFarlane 
and Stover 2007).  GI cancer is a term that encompasses malignant 
conditions of the GI tract including the oesophagus, stomach, liver, 
intestines and anus as well as the biliary glands and pancreas.  In basic terms 
the GI tract is a long hallow tube which extends from the oral cavity to the 
anus.  This tube is comprised of 4 layers; mucosa, submucosa, muscularis 
externa and serosa (fig 1.3). 
 
Serosa
Muscularis
externa
Submucosa
Mucosa
Circular 
muscle
Longitudinal 
muscle
Fig. 1.3 Simplified diagrammatic representation of the layers which 
comprise the GI tract.
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1.2.1 Incidence 
 
Colorectal cancer is the 3
rd
 commonest cause of cancer in the UK 
(www.cancerresearchuk.org) and the commonest form of GI cancer, 
followed by stomach (gastric), oesophageal and pancreatic (Fig 1.4). 
 
 
Fig. 1.4 The 20 most common cancers in the UK, 2002. 
http://info.cancerresearchuk.org/cancerstats/incidence/commoncancers/ 
 
 
1.2.2 Prognosis and treatment 
 
Overall the prognoses for GI cancers are poor; this is normally as a 
consequence of late presentation of the disease due to lack of symptoms in 
the early stages.  Currently out of all the GI cancers the prognosis is best for 
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colorectal this is due to a number of screening programmes that have been 
established (Mitka 2008).  The 5 year survival rate for GI cancers is poor 
and treatment follows the pattern of surgery, where appropriate, followed by 
either chemotherapy, radiotherapy or both.  For these reasons therapeutic 
modalities are urgently needed in this area. 
 
 
1.2.3 Molecular pathways involved in GI cancers 
 
A number of molecular pathways have been highlighted as being important 
in the development, progression and metastasis of pancreatic cancer; these 
include Ras-Raf-MEK-ERK, PI3K/Akt and NFκB. 
 
 
1.2.3.1 Ras-Raf-MEK-ERK pathway 
 
The Ras-Raf-MEK-ERK pathway is one of the Mitogen-Activated Protein 
Kinase (MAPK) pathways that transfer and amplify messages from the cell 
surface to the nucleus, triggering a range of responses including cell 
proliferation, differentiation and survival (Kolch 2000).  A systematic 
representation of the pathway can be seen in fig.1.5. 
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Fig. 1.5 A systematic representation of MAPK pathways adapted from Kolch 2000.
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1.2.3.2 The PI3K/Akt pathway 
 
The PI3K/Akt pathway, like the Ras-Raf-MEK-ERK, regulates many of the 
normal cellular processes that are critical for tumorigenesis.  PI3K catalyses 
the production of phosphatidylinositol-3,4,5-triphosphate (PIP3) at the 
membrane of the cell.  PIP3 then helps in the recruitment and activation of a 
number of downstream targets including Akt (Luo, Manning et al. 2003) as 
represented in fig.1.6.  Akt promotes cell survival by inhibiting proapoptotic 
factors e.g. Bad, forkhead and p53 and activating pro-survival protein such 
as NFκB.  Akt regulates the cell cycle progression by indirectly stabilising 
cyclin D1 and Myc.  Akt stimulates protein synthesis and cell growth by 
activating the MTOR through inhibition of tuberin/hamartin complex. 
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Fig.1.6 Systematic representation of PI3/Akt pathway adapted from Luo, Manning  
et al 2003 for more detailed description see text.  
 
 
1.2.3.3 The NFκB pathway 
 
NFκB is a family of transcription factors which are involved in the 
regulation of a number of biological processes.  In normal cells activation of 
NFκB only occurs after appropriate stimuli and results in the up-regulation 
of transcription of the target genes, afterwards NFκB is returned to its 
inactive state.  Therefore the activation of NFκB is both an inducible and 
transient process.  In tumour cells molecular alterations cause impaired 
regulation of NFκB activation, resulting in a loss of inducability and 
constitutive activation of NFκB (Dolcet, Llobet et al. 2005). 
 
 
  19
Fig. 1.7 Overview of the NFkB pathway taken from 
www.ambion.com/tools/pathway/pathway.php?pathway=N
F-KappaB%20Family%20Pathway on 2.1.08
 
 
Fig 1.7 shows an overview of the NFκB pathway.  A key step in this 
pathway is the phosphorylation of the IκB, which is regulated by IκB 
kinases (IKK).  The IKK complex is comprised of two kinase subunits, 
IKKα and IKKβ, and an associated modulatory protein IKKγ.  
Phosphorylation of specific residues in the activation loop of each IKK 
subunit results in phosphorylation of the IκB proteins, causing ubiquitation 
and subsequent degradation by 26S proteasome (Brockman, Scherer et al. 
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1995; Lin, Brown et al. 1995).  This process leads to NFκB translocation to 
the nucleus, where it binds to the promoter regions of the target genes 
resulting in gene expression (Yamamoto and Gaynor 2001). 
 
The transcriptional activation of NFκB can also be regulated by the 
phosphorylation of p65, a member of the Rel family.  IKK’s have been 
shown to directly phosphorylate the serine residue in the p65 transactivation 
domain, as well as either directly or indirectly with the ability of PI3 
inducible Akt to stimulate p65 transactivation (Yamamoto and Gaynor 
2001).  Work by Heissmeyer (Heissmeyer, Krappmann et al. 1999) showed 
that IKK can also be activated by phosphorylation of the NFκB precursor 
p105 which leads to enhanced processing and nuclear translocation of p50. 
 
NFκB is involved in a number of cellular processes including cell cycle 
control, stress adaptation, inflammation and control of apoptosis.  
Dysregulation of NFκB in tumour cells is thought to lead to tumorigenesis 
and promote metastasis, as well as being linked to chemoresistance (Wang, 
Abbruzzese et al. 1999; Arlt, Gehrz et al. 2003). 
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1.3 Gastric cancer 
 
1.3.1 Classification 
 
Early classification of gastric cancer was based on histological appearance, 
which divided gastric cancer into 2 subtypes:  (1) intestinal or well-
differentiated adenocarcinoma and (2) diffuse gastric cancer.  Intestinal-type 
gastric cancer consists of gland-like structures that mimic intestinal glands, 
whereas the diffuse type is more poorly differentiated and lacks any gland 
structures.  Intestinal type is more strongly linked to environmental and 
dietary factors, compared to diffuse type which is often familial in 
distribution (Lauren 1965). 
 
Since this early classification, gastric cancer has also been classified based 
on mucin expression and this distinguishes 4 types of gastric cancer: The 
gastric or foveolar type (G-type), the intestinal type (I-type), the gastric and 
intestinal mixed type (GI-type) and the neither gastric or intestinal 
phenotypes (N-type) (Fiocca, Villani et al. 1987; Tatematsu, Ichinose et al. 
1990; Tatematsu, Tsukamoto et al. 2003). 
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1.3.2 Incidence 
 
 
Fig. 1.8  The number of new cases of stomach cancer in the UK, 2002. 
http://info.cancerresearchuk.org/cancerstats/incidence/commoncancers/ 
 
As shown in fig. 1.4, gastric (stomach) cancer is the 7
th
 most common 
cancer in the UK, causing nearly 6000 deaths a year with risk increasing 
with age (fig. 1.8). 
 
In recent years the incidence of gastric cancer has appeared to be falling in 
both the US and Western Europe.  This is thought to be as a result of a 
decrease in the frequency of distal lesions and an increase in the frequency 
of adenocarcinoma of the proximal stomach.  The reason for this fall in the 
US and Western Europe and not in the far East, South America, central 
Europe and developing countries, is thought to be in part due to dietary 
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change, for example increased consumption of fresh fruit and vegetables 
and a decrease in the consumption of salt (Levi, Lucchini et al. 2004). 
 
Gastric cancer, specifically the intestinal type adenocarcinoma, develops 
through a series of discrete steps described by Correa (Correa 1992) now 
known as the atrophy-metaplasia-dysplasia-carcinoma sequence.  This 
sequence involves the slow transformation of the gastric mucosa via chronic 
gastritis, multifocal and glandular atrophy, various degrees of intestinal 
metaplasia and dysplasia (fig. 1.9). 
 
Diffuse type adenocarcinoma are not typically associated with these changes 
and are often present with diffuse thickening of the stomach wall, rather 
than a discernible mass (Solcia, Fiocca et al. 1996). 
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Fig. 1.9 Correas cascade showing pathological changes from gastritis to 
gastric dysplasia to gastric cancer.  Adapted from Konturek 2003.
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1.3.3 Prognosis 
 
The prognosis for gastric cancer is poor, as 80% of patients are 
asymptomatic during the early stages, with most cases only being 
discovered after local invasion has advanced.  It is due to these reasons that 
the 5 year survival rate for gastric cancer is low, being approximately 20%.  
However early tumour resection can achieve 5 year survival rates of around 
90% (Karpeh M. 2001; Layke and Lopez 2004). 
 
 
1.3.4 Genetics 
 
Distinct genetic changes appear to be associated with distinct phenotypes, 
particularly in the case of the I-type and the G-type.  In the I-type gastric 
cancer, p53 mutations and allelic deletions of the Adenomatous Polyposis 
Coli (APC) gene are seen more frequently than in the G-type gastric 
carcinoma (Muller, Dammann et al. 1989; Uchino, Noguchi et al. 1993; 
Kushima, Muller et al. 1996; Wu, Kushima et al. 1998; Endoh, Sakata et al. 
2000).  In contrast, microsatellite instability is seen more often in the G-type 
than the I-type gastric cancer (Endoh, Sakata et al. 2000).  As well as this, 
alterations of p73 appear more predominately associated with the G-type 
gastric cancer (Yokozaki, Shitara et al. 1999). 
 
The majority of gastric cancers are sporadic, but approximately 1-3% of all 
gastric cancer cases are linked to hereditary gastric cancer predisposition 
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(Inberg, Lauren et al. 1965).  Germline mutations in the CDH1 gene, which 
produces E-cadherin, account for a third of all hereditary diffuse gastric 
cancers.  Other genetic mutations that are linked to an increased risk of 
gastric cancer are mutations of the p53, APC and BRCA2 genes, which are 
all involved in tumour suppression (Watanabe, Enjoji et al. 1978; 
Jakubowska, Nej et al. 2002; Oliveira, Ferreira et al. 2004).  The molecular 
nature of a major proportion of familial gastric cancer is presently unknown 
(Oliveira, Seruca et al. 2003). 
 
 
1.3.5 Risk factors 
 
As well as genetics there are also other risk factors associated with gastric 
cancer; they include age, gender, race and diet.  Gastric cancer is observed 
more often in males over 60yrs of African American origin who have a high 
salt, low fruit and vegetable diet (Layke and Lopez 2004).  In addition to 
this individuals with a history of gastritis have also been shown to be at 
increased risk (Sipponen, Kekki et al. 1985). 
 
Since 1994, when the World Health Organisation (WHO) classified 
Helicobacter pylori (H. pylori) as a class 1 pathogen, it has become clear 
that this bacterium is one of the most prominent risk factors for spontaneous 
gastric cancer and is also linked to peptic ulcer disease (1994). 
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First isolated in 1982 by Australian scientists Barry Marshall and Robert 
Warren (Marshall and Warren 1984) and originally classified as 
Campylobacter pylori due to its similarities to the Campylobacter genus and 
being found in the pyloric region of the stomach (Pajares and Gisbert 2006).  
Subsequently a number of experiments were carried out to confirm this 
classification, these included electron microscopy (Jones, Curry et al. 1985), 
measuring the percentage of guanine and cytosine in bacterial DNA and 
fatty acid content, as well as sequencing the 16s ribosomal RNA and 
carrying out DNA-DNA hibridation.  This led to its reclassification as 
Helicobacter pylori in 1989 (Pajares and Gisbert 2006). 
 
H. pylori is a gram negative spiral shaped bacterium with a distinctive 
morphology (fig. 1.10).  It is unipolar with a length of between 2.5-4µm and 
a width of 0.5-1µm (Goodwin and Armstrong 1990), with 1-4 flagella at one 
pole.  Each flagella is 2.5µm long and 30nm wide with a membranous 
terminal bulb, which is essentially an extension of the outer membrane and 
is used for motility (Josenhans, Labigne et al. 1995). 
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Fig 1.10 Electronmicrograph of Helicobacter pylori taken from 
www.migg.files.wordpress.com 
 
Colonisation of the gastric mucosa by H. pylori alters the events of the 
gastric epithelial cell cycle, which may affect the threshold of 
carcinogenesis (Martin and Green 1995; Suzuki, Mori et al. 1997; Suzuki, 
Seto et al. 1998).  H. pylori is thought to colonise around half the world’s 
population, however not all those infected go on to develop gastric cancer, 
which may in part be due to strain specific virulence factors (Danesh 1999). 
 
 
1.3.5.1 Helicobacter Pathology 
 
In colonising the acidic environment of the stomach H. pylori has found a 
niche, in which most bacteria would not survive.  One of the ways it 
overcomes the acidity of the environment gastric is to embed itself in the 
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mucus layer of the gastric mucosa, creating a physical barrier.  However, 
before it can do this it first has to overcome the initial exposure to acidity, 
resist peristalsis and gain entry to the protective mucosa.  When the circular 
genome sequence for H. pylori was completed it showed the presence of 
approximately 1500 proteins, many of which are responsible for 
overcoming the problems previously stated (Tomb, White et al. 1997). 
 
 
1.3.5.2. Urease 
 
H. pylori possess an urease enzyme, which since it is not an acidophile, is 
key to its survival in the median pH1.4 of the stomach.  Urease is a cytosolic 
metalloenzyme with a dodecameric quaternary structure and a molecular 
weight of 550kDa.  H. pylori expresses a urea transport protein with unique 
acid-dependent properties that activates the rate of urea entry to the 
cytoplasm  The urea is taken up into the cytoplasm by a proton-gated 
channel and here the urease enzyme catalysis its hydrolysis to ammonia and 
carbon dioxide (Weeks, Eskandari et al. 2000).  The resulting ammonia 
serves to buffer the cytosol and periplasm as well as creating a neutral layer 
around the bacterial surface (Scott, Marcus et al. 2002). 
 
The significance of urease was demonstrated by Eaton et al (Eaton, Brooks 
et al. 1991) when they showed that bacteria deficient in the enzyme were 
unable to colonise the gastric mucosa.  Further relevance of this enzyme was 
confirmed when its percentage of approximately 5% (already considered 
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high) of the bacteria’s total protein content increased to 10% under certain 
culture conditions (Bauerfeind, Garner et al. 1997). 
 
 
1.3.5.3Cag pathogenicity island (PAI) 
 
H. pylori  produces a number of virulence factors, one of which is the cag 
PAI, which is present in around 60% of US strains (Tomb, White et al. 
1997), with cag+ strains linked to an increased risk of atrophic gastritis and 
distal gastric adenocarcinoma compared to cag- strains (Crabtree, Wyatt et 
al. 1993; Kuipers, Perez-Perez et al. 1995). 
 
The cag PAI contains around 30 genes, which are inserted into the 
glutamate racemase gene.  It is divided into two regions, termed cag I and 
cag II located either side of the intervening sequence (Censini, Lange et al. 
1996; Busler, Torres et al. 2006). 
 
Of the 30 plus genes on the cag PAI several of them encode products with 
similar homology to components of type IV secretion systems.  The type IV 
secretion system acts as a syringe and following H. pylori adherence to 
epithelial cells in vitro the product of the terminal gene in the island, 
cytotoxin associated gene A (cagA), is translocated into the host cell where 
it under goes Src-dependent phosphorylation and activates a phosphatase 
(SHP-2), leading to cellular morphological changes of the host cell (Kusters, 
van Vliet et al. 2006).   
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The CagA protein is 145 kDa and causes a number of the cytoskeletal 
rearrangements which leads to the formation of the attachment pedestal, 
which is integral to the bacterium’s adhesion ability (Segal, Cha et al. 1999; 
Figueiredo, Machado et al. 2005). 
 
Orsini et al (Orsini, Ottanelli et al. 2003) showed higher gastric 
inflammation in patients infected with cag PAI positive H. pylori strains 
compared to cag PAI negative strains.  Similar finding have also been 
reported in animal models (Thompson, Danon et al. 2004). 
 
 
1.3.5.4 Vacuolating cytotoxin A (VacA) 
 
Another important virulence factor is VacA, which causes cytoplasmic 
vacuolation of gastric epithelial cells (Smoot, Resau et al. 1996).  VacA is 
approximately 95kDa and is produced by about 60% of the world’s wild 
type H. pylori.  Strains that produce VacA are classed as toxigenic and those 
that do not non-toxigenic. 
 
The vacA gene is naturally polymorphic and differences are present mainly 
in two areas: the signal region, encoding the signal peptide and the N 
terminus of the mature protein (which maybe either s1 or s2 type) and the 
mid region, encoding the part of the p58 domain (m1 or m2 type) (Atherton, 
Cao et al. 1995).  In HeLa cells s1/m1 strains have been shown to cause 
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more extensive vacuolation than s1/m2 strains, with s2/m2 being non-
vacuolating (Atherton, Cao et al. 1995).  This maybe of clinical importance 
as s2/m2 strains are less frequently associated with peptic ulceration and 
gastric carcinoma compared to s1/m1 or s1/m2 strains (Atherton, Peek et al. 
1997; Rudi, Kolb et al. 1998; Strobel, Bereswill et al. 1998; van Doorn, 
Figueiredo et al. 1998) 
 
Satin et al (Satin, Norais et al. 1997) showed that VacA increases 
extracellular secretion of acidic hydrolases inducing large acidic vacuoles, it 
also impairs the degradative power of late endosomes and lysosomes.  They 
concluded that a deficiency in intracellular digestion may create a condition 
similar to starvation in gastric cells, worsened by the associated deficiency 
in the lysosomal-targeting hydrolases, which in turn would contribute to cell 
damage induced by other bacterial products or by factors released during 
chronic inflammation. 
 
 
1.3.6 Insulin-Gastrin (INS-GAS) mouse model of gastric carcinogenesis 
 
INS-GAS mice are a transgenic model of gastric cancer that over-express 
the amidated form of gastrin (G17), and therefore have elevated levels of 
circulating G17.  The increase in G17 is under the control of a rat insulin I 
promoter.  These mice spontaneously develop atrophic gastritis, intestinal 
metaplasia and dysplasia, with adenocarcinoma observed in 75% of mice at 
an approximate age of 20 months.  The development of adenocarcinoma can 
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be induced in 85-100% of mice in 8 months when infected with H. felis and 
in 100% of mice in 8 months when infected with H. pylori (Wang, Dangler 
et al. 2000). 
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1.4 Colorectal cancer 
 
1.4.1 Development 
 
Colorectal cancer is the result of malignant transformation of the colorectal 
epithelium resulting from a multistep, multipathway, multifocal process that 
requires sequential or concomitant damage to several genes within and 
across cellular generations.  Colorectal cancers arise from single crypt 
lesions and progress to adenomatous polyps and later to invasive 
carcinomas (Fearon, Hamilton et al. 1987; Groden, Thliveris et al. 1991).  
The adenomatous polyposis coli (APC) gene mutation, either inherited or 
acquired, is considered an early and central event in the majority of cancers, 
which is then followed later by an accumulation of somatic mutations 
(Fearnhead, Wilding et al. 2002). 
 
 
1.4.2 Incidence 
 
Colorectal cancer is a common disease with an incidence rate of 5%, 
making it the third leading cause of cancer death worldwide and therefore an 
important public health issue.  There have been significant improvements in 
five year survival from colon cancer over the last 30 years (fig. 1.11). 
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Fig 1.11 Relative age standardised 5 year survival for patients 
diagnosed with colorectal cancer in England and Wales.  Adapted 
from http://info.cancerresearchuk.org/cancerstats/incidence/commo
ncancers/
 
Incidence rates of colorectal cancer vary widely in different geographical 
areas, with relatively low rates in Asia, Africa and parts of Latin America, 
but with high rates in “Western” countries including Northern Europe, 
Australia, New Zealand and the US (Parkin and Muir 1992).  
Epidemiological studies have suggested that specific components of the 
Western diet are risk factors in colorectal cancer pathogenesis; these include 
dietary fat and red meat, but fruit, vegetables and dietary fibre are thought to 
be protective (Potter 1997). 
 
Colorectal cancer can be observed in one of three specific patterns; sporadic, 
inherited and familial.  Sporadic disease with no familial or inherited 
predisposition accounts for 70% of colorectal cancer in the population.   
Probably as a result of the normal ageing process, as well as environmental 
and dietary factors, sporadic cancer is most common in those over 50 years 
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of age.  Fewer than 10% of colon cancer patients have an inherited 
predisposition for the disease.  Up to 25% of colon cancer cases fall into the 
least understood category of familial colon cancer.  Familial colon cancer is 
described as colon cancer, which occurs in families at an incidence that is 
too frequent to be classed as sporadic but not in a pattern consistent with 
inherited cases (Calvert and Frucht 2002). 
 
 
1.4.3 Prognosis 
 
With early detection and/or improved treatments the general prognosis for 
those diagnosed with colon cancer is improving.  Figures released by 
Cancer Research UK in 2003 suggest that survival rates for colorectal 
cancer are increasing (fig. 1.6). 
 
 
1.4.4 Genetics 
 
The molecular basis for sporadic colon cancer was described by Fearon and 
Vogelstein (Fearon and Vogelstein 1990) as a multistep model for 
carcinogenesis.  This model describes an accumulation of genetic events, 
each conferring a selective growth advantage to an affected colon cell as 
follows: 
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• Colorectal cancer is a result of mutational activation of oncogenes 
and the inactivation of tumour suppressor genes. 
• Somatic mutation in at least 4 or 5 genes of a cell are required for 
malignant transformation. 
• The biological behaviour of the tumour is determined by the 
accumulation of multiple genetic mutations rather than the sequence 
of the mutations. 
• Features of the tumorigenic processes of colon cancer are applicable 
to other solid tumours. 
 
A common form of inherited colon cancer is familial adenomatous 
polyposis (FAP) and is a result of a germline mutation in the tumour 
suppressor gene APC.  FAP is a dominantly inherited syndrome where the 
affected person develops hundreds to thousands of colonic polyps.  
Although the transition of polyps to cancer is low the vast number virtually 
assures development of colon cancer at an early age (Fearnhead, Wilding et 
al. 2002). 
 
An example of familial colon cancer can be seen in the Ashkenazi Jewish 
population, which is probably due to an I1307K APC germline mutation.  In 
this case the relative risk of tumour is much lower than in FAP because, 
unlike this germline mutation, which causes protein structure abnormalities, 
the I1307K APC germline mutation causes a predisposition to sporadic 
mutations at distant sites of the gene (which then cause protein structure 
abnormalities) at a later stage of development (de la Chapelle 2004). 
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1.4.5 Hyperplastic polyps and colorectal cancer 
 
Hyperplastic polyps are the most common type of polyp in the human colon 
and rectum, but relatively little is known about the aetiology, natural history 
or growth rates of these polyps.  The main reason for this is due to an 
accepted belief that they are benign and have little or no malignant potential 
(Winawer, Fletcher et al. 1997).  The recommendation of the American 
College of Gastroenterology is that hyperplastic polyps found during 
endoscopy are not an indication for subsequent colonoscopy (Bond 1993). 
 
 
1.4.6 Apc
Min/+
 mouse model of intestinal carcinogenesis 
 
As previously described (Section 1.3.4) the APC gene is a tumour 
suppressor gene, the loss of which has been shown to play a key role in 
colorectal carcinogenesis (Powell, Zilz et al. 1992).  The Apc
Min/+
 mouse 
lineage was originally established by treating a C57BL/6 male mouse with 
the mutagen ethylnitrosourea, which resulted in a mutation that predisposed 
the mouse to spontaneous intestinal cancer.  The mutant gene was found to 
be dominantly expressed and fully penetrant with affected mice developing 
multiple intestinal neoplasms (Min) throughout the length of the intestinal 
tract within several weeks of birth (Moser, Pitot et al. 1990).  The dominant 
mutation is located in Apc, the mouse homolog of the human APC gene, and 
causes a truncation of the gene product at amino acid 850, homozygous 
Apc
Min/Min
 mice die as embryos (Su, Kinzler et al. 1992). 
  38
1.5 Pancreatic cancer 
 
In industrialised western countries pancreatic cancer is the fourth leading 
cause of cancer death, and although in recent years the five year survival 
rate has significantly increased, it is still at a very low 5% (Jemal, Siegel et 
al. 2006).  There are a number of factors which account for this high death 
rate; early diagnosis is rare, the tumours grow rapidly and aggressively and 
are unresponsive to chemotherapy, radiotherapy and immunotherapy 
(Buchler, Friess et al. 1991). 
 
Fig 1.12 Diagrammatic representation of the human pancreas (A) showing a cross 
section of islands of Langerhans (B).  
Taken from http://www.ucpancreas.org/pancreas.htm 1.12.07
Common bile duct
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Duct
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As shown in fig. 1.12 the pancreas is composed of numerous acini 
(exocrine) cells grouped around central ducts and endocrine cells, which 
make up the islets of Langerhans. 
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1.5.1 Classification 
 
The commonest form of cancer affecting the exocrine pancreas, and also the 
most difficult to treat, is pancreatic ductal adenocarcinoma (Parkin, Bray et 
al. 2001).  This form of pancreatic cancer gives rise to three distinct cancer 
precursor lesions:  Mucinous cystic neoplasms, intraductal papillary 
mucinous neoplasms (IPMNs) and pancreatic intraepithelial neoplasia 
(PanINs).  PanINs can be further classified into early and late lesions, 
beginning with PanIN-1A, 1B (hyperplasia) and progressing to PanIN-2 and 
then to PanIN-3 or carcinoma in situ (Ghaneh, Costello et al. 2007).  A 
comprehensive list of different histological variants of malignant tumours of 
the exocrine pancreas is shown in table 1.2. 
 
Table 1.2 The frequency and prognosis for different histological types of 
malignant exocrine pancreatic tumours
goodRarePancreatablastoma
Favourable<1Pseudopapillary carcinoma
Variable2Acinar cell carcinoma
Patients tend to present with 
preinvasive lesions
1-3Intraductal pappillary-mucinous neoplasm-
invasive carcinoma
Similar to ductal3Mucinous cystadenacarcinoma
Similar to ductal<1Serous cystadenocarcinoma
Other malignancies
Poor<1Osteoclast-like giant cell tumour
Poor<1Mixed ductal-endocrine carcinoma
More aggressive than ductal<1Adenosquamous carcinoma
Poor<1Signet ring cell carcinoma
Poor<1Mucinous non-cystic carcinoma
Poor2Adenosquamous
Poor2Mucinous non cystic
Worse than ductal5Undifferentiated carcinoma
Ductal adenonocarcinoma variant
Long term survival rare80Ductal adenocarcinoma
PrognosisFrequency (%)Histological type
Adapted from Ghaneh, Costella et al 2007 using WHO statistics
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1.5.2 Risk factors 
 
There are a number of risk factors associated with the development of 
pancreatic cancer, the largest being increasing age, new onset diabetes 
mellitus, obesity, chronic and hereditary pancreatitis, and an inherited 
predisposition for pancreatic cancer (Ghaneh, Costello et al. 2007). 
 
A single centre, medical-surgical, prospective cohort study in 2002 showed 
that the risk of pancreatic cancer is significantly (p<0.001) increased in 
patients with chronic pancreatitis compared to age and sex matched controls 
(Malka, Hammel et al. 2002).  Observations have shown that patients may 
have chronic pancreatitis up to 20yrs before developing pancreatic cancer 
and these patients are more likely to have a severe form of the disease with 
higher calcification of the glands and an increased risk of complications 
(Ghaneh, Costello et al. 2007).  There is also a 70-fold greater risk in 
patients with hereditary chronic pancreatitis, an autosomal dominant disease 
caused by a mutation in the PRSS1 gene (Howes, Lerch et al. 2004). 
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1.6 Oesophageal cancer 
 
The incidence of oesophageal cancer has dramatically increased in the last 
three decades and is the 9
th
 leading cause of cancer death in the UK.  It is 
twice as common in men as women, with a 2% increase year on year in 
men, while the incidence remains static in women 
(http://info.cancerresearchuk.org/cancerandresearch/ cancers/oesophageal/ 
last updated 25.6.07).  Recent advances in surgical technique and new 
therapeutic approaches have slightly increased the 5 year survival rate from 
4% in the 1960’s to 14% now, although the rate of relapse remains high 
(Syrigos, Zalonis et al. 2008). 
 
 
1.6.1 Classification 
 
Oesophageal cancer progression follows the metaplasia-dysplasia-
adenocarcinoma sequence (MCS) and the progression and severity are 
classified using the tumour, node, metastasis (TNM) system, which 
characterises primary tumour size, lymph node involvement and cancer 
spread.  Tumour size is scored 1-4; 1 being small tumour and 4 being large; 
lymph nodes are scored 0-3; 0 being no cancer positive lymph nodes and 3 
being many positive lymph nodes and metastasis is scored 0-1; 0 being no 
spread and 1 being spread (www.cancerhelp.org.uk/help/default.asp? 
page=102#the_TNM_ last updated 25.6.07).  The TNM system is used to 
break oesophageal cancer progression into four major pathological stages:  
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Stage I invasion of cancer cells up to the submucosa; stage 2 invasion into 
but not through the musculari propria; stage 3 invasion beyond the 
muscularia propria into the adventitia; stage 4 invasion into adjacent 
structures (ie, aorta, pleura, lung) (Shimpi, George et al. 2007). 
 
 
1.6.2 Risk factors 
 
Oesophageal cancer is more frequent in people over 50, with, as previously 
mentioned, higher occurrence in males (see section 1.5).  Obesity is 
associated with oesophageal cancer with increased risk linked to a body 
mass index (BMI) over 25.  This risk is then increased at a BMI of 30-35 
with an even greater risk with a BMI over 35 (Abnet, Freedman et al. 2008).  
Diets high in red and/or processed meat and low in fruit and vegetables are 
also linked to increased risk (Gonzalez, Jakszyn et al. 2006; Cross, 
Leitzmann et al. 2007).  Finally, prolonged gastroesophageal reflux 
(GERD), a condition where there is abnormal reflex of gastric acid and bile 
into the oesophagus causing mucosal damage, is associated with progression 
to oesophageal cancer (DeVault and Castell 2005).  The initial injury from 
acid reflux causes oesophagitis characterised by inflammation and irritation, 
this can then develop into metaplastic, premalignant lesions referred to as 
Barrett’s oesophagus (BE).  GERD-derived BE is considered a major risk 
factor of oesophageal cancer (Isomoto, Nishi et al. 2007). 
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1.6.2.1 Barrett’s oesophagus 
 
First described in 1950, Barrett’s oesophagus is the metaplastic change in 
the epithelium of the distal oesophagus from normal squamous epithelium 
to specialised columnar-intestinal type epithelium that contains goblet cells 
(Barrett 1950).  This change in epithelial cell type is a result of chronic 
gastric reflux (Spechler and Goyal 1986; Winters, Spurling et al. 1987), 
which causes injury to the epithelium initiating the release of inflammatory 
cytokines, resulting in an altered chemical environment of the oesophagus.  
The oesophageal epithelium is maintained by stem cells, the only permanent 
resident of the oesophagus, through their production of daughter cells.  
However, the changes in the chemical environment cause the stem cells to 
produce intestinal columnar type cells, which are more resistant to acid than 
the normal squamous epithelium (Jankowski, Wright et al. 1999).  Increased 
proliferation rates lead to more efficient colonisation of the distal 
oesophagus, and therefore there is a selection pressure for cells which have 
acquired p53 mutations, an anti-oncogene that normally restricts cell growth 
(Wijnhoven, Tilanus et al. 2001). 
 
 
1.6.2.1.1 Progression of Barrett’s oesophagus to adenocarcinoma 
 
The prevalence of Barrett’s oesophagus in the general population aged over 
50 years is between 5-9% (Geboes and Van Eyken 2000) with an estimated 
4% of these going on to develop oesophageal adenocarcinoma (Louis 2007).  
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The length of the Barrett’s segment is roughly correlated to the risk of 
progression to dysplasia and adenocarcinoma, with longer Barrett’s 
segments corresponding with increased risk (Weston, Krmpotich et al. 
1997).   
 
The progression of Barrett’s metaplasia to adenocarcinoma is associated 
with a number of gene structure and expression, and protein expression 
changes.  One of the earliest molecular events is thought to be the selection 
and propagation of metaplastic clones with specialised intestinal metaplasia 
via pathways involving mitogen activated protein kinases (MAPKs) (Souza, 
Shewmake et al. 2002) and protein kinase C (PKC) (Triadafilopoulos 2001).  
These effects are further amplified by the inhibition of apoptosis and 
promotion of cellular proliferation by cyclooxygenase-2 (COX-2) (Shirvani, 
Ouatu-Lascar et al. 2000).  The inhibition of apoptosis occurs late in 
Barrett’s and then only in a select few cells with high grade dysplasia, but 
the previously mentioned alterations, along with the acquired mutations in 
p53, push metaplastic cells along the MCS (Jankowski, Wright et al. 1999). 
 
Approximately 75% of patients presenting with low grade dysplasia regress 
and show no signs of dysplasia at subsequent biopsies, however around 20% 
go onto develop high grade dysplasia, from which development of 
oesophageal adenocarcinoma is inevitable (Chang and Katzka 2004).  The 
progression from metaplasia to dysplasia is in part, due to alterations in the 
expression of cytokines and growth factors (Jankowski 1993), as well as 
alterations in cell cycle-associated genes, such as an increase in cyclin D1, 
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hypermethylation and mutation of p16, and the push of cells from G0 to G1 
(Jankowski, Wright et al. 1999).  Mutations are also seen in the following 
genes; APC, mutated in colorectal cancer (MCC), deleted in pancreatic 
cancer (DPC4), and retinoblastoma (Rb).  Random errors in replication 
become more frequent and multiple aneuploidy is seen.  As well as these 
alteration there is also an increase in; microsatellite instability, expression of 
metalloproteinases (MMPs), epidermal growth factor receptor (EGFR) and 
transforming growth factor α (TGFα), all of which continue to push the 
oesophageal epithelium along the MCS towards malignance (Wijnhoven, 
Tilanus et al. 2001).  The progression from normal oesophagus to 
adenocarcinoma is summarised in fig. 1.13. 
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Fig. 1.13 Progression from normal oesophagus to 
adenocarcinoma.  Endoscopic pictures from 
www.endoatlas.com/atlas_es downloaded 4.2.08
Normal oesophagus
Oesophagitis
High grade dysplasia
Metaplasia
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Acid reflux
P53 mutations
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1.7 Gastrin 
 
Gastrin, a polypeptide hormone, is the principle mediator of food stimulated 
gastric acid secretion, responsible for at least 50% of the postprandial phase 
acid release in the stomach (Kovacs, Walsh et al. 1989).  Under normal 
conditions gastrin is synthesised primarily by G-cells located in antral 
mucosal region of the stomach and its synthesis and secretion is tightly 
regulated.  In the antral mucosal region gastrin is found in storage granules 
at the base of the cell.  The G-cells possess a typical flask-like endocrine 
cell shape and secrete gastrin onto the mucosal surface via the narrow neck 
of the cell (Watson and Steele 1993).  Gastrin also plays a more general role 
in the control of the acid-secreting capacity of the stomach, through control 
of gastric cell proliferation, differentiation and maturation (Dockray, Varro 
et al. 2001).  Another important action of gastrin is the stimulation of 
mucosal growth in the stomach that results in hyperplasia of the 
enterochromaffin-like (ECL) and parietal cells (Crean, Marshall et al. 1969). 
 
Located on chromosome 17q the gastrin gene (Lund, Geurts van Kessel et 
al. 1986) and its transcription is regulated by both somatostatin and the 
somatostatin receptor (SSTR), as well as by various signalling molecules 
including ligands of epidermal growth factor (EGF) (Merchant, Demediuk 
et al. 1991; Howell, Ziober et al. 1995). 
 
Following transcription of the gastrin gene the resulting messenger RNA 
(mRNA) is transcribed to pre-progastrin, a 101 amino acid peptide (Wiborg, 
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Berglund et al. 1984).  This is an immature gastrin peptide, which contains a 
signal peptide at its N-terminal end, which targets it to the endoplasmic 
reticulum (ER).  When the pre-progastrin arrives at the ER the signal 
peptide is cleaved and this results in an 80 amino acid progastrin which 
moves into the Golgi secretary pathway (Walter and Lingappa 1986).  
Depending on cell type the progastrin is either stored, as described earlier in 
secretary granules or, in a cancer situation, it can be secreted in an 
uncontrolled constitutive fashion as non-processed gastrin.  The stored 
progastrin is converted via enzyme catalysed reactions into glycine-
extended gastrin-34, a 34 amino acid protein, which can be processed 
further to either glycine-extended gastrin-17 (gly-17) or matured amidated 
gastrin-17 (G17) (Smith and Watson 2000).  This conversion of pre-
progastrin is represented diagrammatically in fig.1.14. 
 
Pre-progastrin
Signal 
peptide
Amino 
terminal 
extension
Carboxy 
terminal 
extension
Progastrin
Glycine –extended gastrin-34
Gly-G17
G17
Gastrin-34
SO4
SO4
SO4
SO4SO4
SO4
NH2
NH2
Fig 1.14 Conversion of pre-progastrin to mature amidated gastrin 17 
(G17)
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1.7.1 The gastrin receptor cholecystokinin-2(CCK-2) 
 
On the basis of their pharmacological properties and specificities for 
binding, CCK receptors have been sub-divided into two types CCK-1 
(CCK-A) and CCK-2 (CCK-B) receptors, both of which belong to the seven 
transmembrane G-protein-coupled receptor superfamily.  The two sub-types 
of receptors share 50% amino acid homology.  CCK-1 receptors are located 
mainly in the periphery, but are also found in some regions of the brain.  
The main population of central CCK receptors are of the CCK-2 subtype, 
which are also found in the stomach and vagus nerve (Hill, Campbell et al. 
1987).  In the stomach CCK-2 receptors are mainly expressed in the parietal 
and ECL cells.  They are distributed throughout the human GI tract, 
pancreas, lung and some neuroendocrine tissues (Zhou, Chen et al. 2004). 
 
It has been shown that the CCK 2 receptor also serves as a gastrin receptor, 
and binds both gastrin and CCK with almost the same affinity, compared to 
CCK-1 receptor which has a much greater affinity for CCK than gastrin.  
The receptor is highly conserved across a number of species including 
human, dog, guinea pig, rabbit and rat, with an overall amino acid identity 
of 72% (Noble and Roques 1999). 
 
The CCK-2 receptor mediates the effects of gastrin, and is therefore 
principally involved in controlling gastric acid secretion and maintaining the 
normal cellular composition and function of the gastric mucosa. 
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1.7.1.1 Structure of CCK-2R 
 
The human CCK-2 receptor is encoded for by a 5 exon gene over 10 
kilobases (Nishida, Miyata et al. 1994) that has been identified on 
chromosome 11.  Further to this in situ hybridisation has specifically shown 
the human CCK2R gene to be on the distal short arm of chromosome 11 
(11p15.4) (Song, Brown et al. 1993).  There are four different isoforms of 
the receptor. 
 
 
1.7.1.1.1 Classical CCK2R 
 
Under physiologically normal conditions the human CCK-2R gene encodes 
for the classical 74kDa glycoprotein, which is found mainly on GI derived 
cell-lineages; these include parietal and neuroendocrine cells (Schmitz, 
Goke et al. 2001), ECL cells (Bakke, Qvigstad et al. 2001) and islet cells in 
the pancreas (Reubi 2003).  As highlighted by Reubi (Reubi 2003) there are 
discrepancies in the incidence of CCK2-receptor in stomach and colon 
carcinomas, with early studies reporting a presence compared to more recent 
work which has failed to show CCK2-receptor proteins in these tumour 
types.  An explanation to this may lay in the existence of different isoforms, 
long, truncated and splice 4, of the receptor. 
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1.7.1.1.2 Long isoform 
 
The long isoform, which differs from the classical receptor by the addition 
of a 5 amino acid cassette, GGAGP, insertion at the end of exon 4 (Song, 
Brown et al. 1993) was the first CCK2R isoform to be identified.  As 
represented diagrammatically in fig.1.15 the addition of this pentapeptide 
cassette is considered to be due to the existence of two different splice donor 
sites at the end of exon 4.  When the receptor is spliced at the G/gt 
consensus site then the 15 nucleotides after this junction are excluded from 
the mRNA, therefore encoding for the short classical form of the receptor.  
However, if the receptor is spliced at C/gt then the resulting mRNA contains 
the additional 15 nucleotides and results in the long isoform (Song, Brown 
et al. 1993). 
 
Human gene
Human cDNA
Short form
Long form
GGG CTG CCA GGT GGG GCT GGA CCA Cgtgagcaa…(192/207)…gtgctcag GG GCT GTT
G      L       P
G      L       P     G      G        A     G      P    
Exon 2 Exon 3 Exon 4 Exon 5
I II III IV V VI VII
Fig 1.15 The position of the alternative splice sites in the CCK2R gene
Adapted from Song, Brown et al 1993
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1.7.1.1.3 Truncated isoform 
 
The truncated isoform of the CCK2 receptor is a result of alternative usage 
of the novel exon 1b, which gives this isoform different binding properties 
compared to the classical short isoform.  Exon 1b is approximately 5.5kb 
upstream of exon 2 (Miyake 1995).  This isoform is truncated due to the 
lack of an N-terminal extracellular domain, the actual amino acid sequence 
is the same as the classical isoform and therefore there is no change in the 
translated protein (McWilliams, Watson et al. 1998).  The truncation causes 
the loss of three putative N-glycosalation sites and therefore a change in 
molecular size and structure.  Work by Miyake (Miyake 1995) using 
competition assays points to the N-terminal extracellular domain not being 
involved in ligand binding but being important for ligand selectivity. 
 
The truncated and classical isoforms have been shown to be co-expressed in 
the human brain and gastric fundus, which may suggest involvement in the 
same physiological pathways (McWilliams, Watson et al. 1998).  The 
truncated isoform has been shown to be exclusively expressed in the gastric 
tumour cell line, AGS (Miyake 1995), compared to the classical isoform 
which is exclusively expressed in LIM 1215, RD 19 and MCF 7B 
(McWilliams, Watson et al. 1998).  McWilliams (McWilliams, Watson et 
al. 1998) suggests that, “tumour cells may uncouple the co-expression of the 
receptor isoforms and that their malignant functions may differ”. 
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1.7.1.1.4 Splice 4 variant isoform 
 
First described in 2000 and designated CCK-BRi4sv (now CCK-2Ri4sv) by 
Hellmich et al (Hellmich, Rui et al. 2000), the CCK-2R intron 4 splice 
variant was identified in colorectal cancers and adenomatous polyps but not 
normal colonic mucosa, and it was hypothesised that it may stimulate 
colorectal cancer cell proliferation through a gastrin independent 
mechanism.  CCK-2Ri4sv has since been identified in pancreatic cancer 
cells, but not normal pancreas (Ding, Kuntz et al. 2002). 
 
It has been demonstrated that this isoform of CCK-2R is as a result of a 
decrease in U2AF35.  U2AF35 is the small subunit of the heterodimeric 
splicing factor U2AF which is also composed of the larger subunit U2AF65.  
U2AF35 specifically recognises the 3’-end dinucleotide AG and is essential 
for pre-mRNA splicing and the removal of intron 4, therefore a decrease in 
U2AF35 generates receptors that retain the 69 amino acids encoded for by 
intron 4 of the gene, with the overall result being a receptor with an 
elongated intracellular third loop (Ding, Kuntz et al. 2002). 
 
 
1.7.2 Gastrin and GI cancers 
 
It is now widely accepted that gastrin promotes the growth of cancer cells 
both in vitro and in vivo through CCK-2 receptors, and that the expression 
of both the gastrin gene and the CCK-2 receptor are closely related to the 
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development, progression and invasion of cancer cells in GI cancers 
(Watson, Durrant et al. 1989; Clerc, Leung-Theung-Long et al. 2002; 
Watson, Morris et al. 2002). 
 
 
1.7.2.1 Gastrin and gastric cancer 
 
The exact role of gastrin in the development of gastric cancer has yet to be 
elucidated, but as discussed in section 1.2.6, INS-GAS mice that over-
express G17 develop gastric adenocarcinoma a process which is accelerated 
by H. felis infection (Wang, Dangler et al. 2000) and hypergastrinemia has 
been shown to occur early in the course of human H. pylori infection (Levi, 
Beardshall et al. 1989).  Added to this the gastrin gene has been shown to 
be activated in cells isolated from human gastric tumours (Watson, Durrant 
et al. 1991) and in vitro stimulates growth of gastric cancer cell lines TMK-
1 and AGS, (Ochiai, Yasui et al. 1985; Iwase, Evers et al. 1997) as well in 
xenograft models (Watson, Durrant et al. 1991).  Iwase et al (Iwase, Evers 
et al. 1997) also showed that gastric carcinoma growth could be stimulated 
by gly-G17. 
 
Gastrin has not only been shown to directly promote the growth of the 
gastric epithelium, but also to increase the expression of other members of 
the epidermal growth factor family, including HB-EGF, TGF-α and 
amphiregulin, which are linked to gastric carcinogenesis (Henwood, Clarke 
et al. 2001). 
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1.7.2.2 Gastrin and colorectal cancer 
 
Hypergastrinemia has been reported in colorectal cancer patients, suggesting 
that gastrin may act as an endocrine proliferative agent, although the source 
of gastrin is undefined (Aly, Shulkes et al. 2004).  Elevated levels of gastrin 
precursors in the serum of colorectal patients have also been reported when 
H. pylori status was controlled for (Ciccotosto, McLeish et al. 1995; 
Siddheshwar, Gray et al. 2001).  This fits with work by Konturek et al 
(Konturek, Bielanski et al. 2002), which showed a decrease in serum 
concentrations of gastrin precursors, but not G17  after colon cancer 
resection. 
 
Two studies have shown that CCK-2 receptor mRNA is only expressed in a 
small sub-set of colorectal carcinomas (Reubi, Waser et al. 1999; Schmitz, 
Otte et al. 2001).  The CCK-2Ri4sv was reported in 100% of colorectal 
carcinomas by Hellmich et al (Hellmich, Rui et al. 2000), but this was a 
small sample size (n=8); in a larger sample size (n=79) Schmitz et al 
(Schmitz, Otte et al. 2001) was unable to detect CCK-2Ri4sv. 
 
Recent work now suggests that progastrin maybe synthesised by colorectal 
carcinoma tissue, but it is unable to process it to G17, and that the level of 
processing is dependent on the tumour.  Of interest gastrin precursors are 
found in high concentrations in developing embryonic colorectal tissue, but 
not G17, suggesting that there maybe a developmental link between colon 
cancer and gastrin (Aly, Shulkes et al. 2004). 
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1.7.2.3 Gastrin and pancreatic cancer 
 
Gastrin has been shown to stimulate the growth of pancreatic cancer through 
the CCK-2 receptor (Smith, Rickabaugh et al. 1993; Smith, Liu et al. 1994) 
and further work by Smith (Smith, Shih et al. 1996) showed not only that 
gastrin is produced by pancreatic tumour cells in vitro, but also in 
xenografts of pancreatic cancer, demonstrating that gastrin acts as an 
autocrine growth factor. 
 
A number of studies have shown gastrin transiently in neonatal pancreatic 
islets, suggesting a role for gastrin in pancreatic development and that it 
may play a part in mediating some developmental changes (Brand and 
Fuller 1988).  There is conflicting data in the literature regarding the 
expression of CCK-2 receptor in normal pancreatic tissue and pancreatic 
adenocarcinoma.  Tang et al (Tang, Biemond et al. 1997) showed that the 
CCK-2 receptor was expressed in normal pancreatic tissue, but not in 
pancreatic cancer, whereas work by de Weerth et al (de Weerth, von 
Schrenck et al. 1999) concluded that most human pancreatic cancer cell 
lines of ductal origin express CCK-2 receptor mRNA.  Work by Caplin et al 
(Caplin, Savage et al. 2000) demonstrated that normal pancreatic tissue did 
not express the CCK-2 receptor, nor progastrin, glycine-extended or 
amidated gastrin, but that pancreatic cancer cells showed moderate to high 
CCK-2 receptor expression in 95% of cases, progastrin in 91%, glycine 
extended in 55% and amidated in 23%.  This led them to conclude that 
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gastrin fits with the oncofoetal expression hypothesis; i.e. gastrin is 
expressed in pancreatic tissue during foetal development and oncogenesis. 
 
 
1.7.2.4 Gastrin and oesophageal cancer  
 
Based on the similarities between the genetic alterations seen in the 
development of oesophageal and colonic adenocarcinomas, principally the 
APC mutations, it is fair to hypothesise that, as in colonic carcinogenesis, 
gastrin may play a role in the progression of Barrett’s oesophagus to 
oesophageal adenocarcinoma.  However, data on this topic is conflicting. 
 
CCK-2 receptor mRNA has been shown to be expressed in normal and 
inflamed squamous mucosa, Barrett’s metaplasia and oesophageal 
adenocarcinoma.  The levels of expression in Barrett’s mucosa were 2-fold 
higher than those of the normal squamous mucosa (Haigh, Attwood et al. 
2003).  Moore et al (Moore, Jepeal et al. 2004) have identified CCK-2 
receptor mRNA in three human oesophageal cell lines, SEG-1, BIC and 
SKGT-4 and our group has also shown CCK-2 receptor mRNA expression 
in OE19 (oesophageal adenocarcinoma stage III), OE21 (oesophageal 
squamous carcinoma stage III) and OE33 (Barrett’s metaplasia-derived 
oesophageal adenocarcinoma stage II) cell lines, and that there is an increase 
in the expression of gastrin, CCK-2 receptor and CCK-2 receptor i4sv gene 
mRNA in Barrett’s samples compared to normal oesophagus (Harris, Clarke 
et al. 2004).  A dose-dependent increase in proliferation in SEG-1 cells 
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when incubated with G17 has been shown (Haigh, Attwood et al. 2003).  
This fits with work in male Sprague-Dawley rats that showed gastrin 
increased proliferation in the oesophageal mucosa (Van Nieuwenhove, De 
Backer et al. 1998; Van Nieuwenhove, Chen et al. 2001). 
 
However, there is other data which states that CCK-2 receptor could only be 
detected in normal oesophagus and tissue surrounding oesophageal tumour, 
and not in oesophageal cancer samples (Clerc, Dufresne et al. 1997).  Also 
one group were unable to observe gastrin protein expression in Barrett’s 
metaplasia using immunohistochemistry (Griffin and Sweeney 1987).  Some 
of these differences could be attributed to the type of tumours examined e.g. 
the work by Clerc et al (Clerc, Dufresne et al. 1997) looked mainly at 
squamous cell carcinoma and, unlike oesophageal adenocarcinoma, it is not 
derived from Barrett’s metaplasia. 
 
The role of gastrin in Barrett’s progression is important, because individuals 
with GERD are often prescribed proton pump inhibitors (PPI’s), which 
lower gastric acid secretion and as a result have been shown to increase 
gastrin levels resulting in hypergastrinemia.  PPI’s have been associated 
with increased risk of oesophageal adenocarcinoma which may be mediated 
through the CCK-2 receptor (Lagergren, Bergstrom et al. 1999). 
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1.7.3 Gastrin and cyclooxygenase 
 
Cyclooxygenase (COX), also known as prostaglandin H synthetase, is a rate 
limiting enzyme involved in prostaglandin synthesis through the conversion 
of arachadonic acid into prostaglandins.  There are two isoforms of the COX 
enzyme which share over 60% identity at the amino acid level.  COX-1, 
which is constitutively expressed in many tissues and regulates and 
maintains normal cellular function, and COX-2, which is the inducible form 
of the enzyme, and is only expressed after stimulation by a variety of 
growth factors (Smith, Hawcroft et al. 2000).  More recently a third COX 
isoform has been described, COX-3.  COX-3 shares all the of the catalytic 
and important structural features of COX-1 and -2, but has an insertion of 
intron 1 downstream of the initiating methionine (Chandrasekharan, Dai et 
al. 2002). 
 
COX-2 has been shown to be over-expressed in a number of pre-malignant 
tissues and malignant tumours, including gastric, colorectal, pancreatic and 
oesophageal (Dannenberg, Altorki et al. 2001).  In the APC
Δ716
 mouse 
model when the COX-2 gene is knocked down there is an 86% reduction in 
tumour burden this is reduced to 66% when there is only single gene 
knockdown (Oshima, Dinchuk et al. 1996).  Inhibition of COX-2 by 
specific COX-2 inhibitors reduces proliferation and angiogenesis and 
induces apoptosis in human gastric cell lines (Sawaoka, Tsuji et al. 1999). 
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Gastrin has been shown to increase expression of COX-2 in a dose 
dependent manner in KATO III cells, a gastric epithelial cell line which 
have a genomic deletion of p53 and mutations of k-sam and c-met 
(Konturek, Kania et al. 2003).  Yao et al (Yao, Song et al. 2002) showed 
that specific inhibition of COX-2 with NS-398 inhibited the trophic effects 
of gastrin in colon cancer MC-26 cells that possess both COX-2 and 
functional gastrin receptors. 
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1.8 Hypothesis 
 
Down-stream effects of amidated gastrin on angiogenesis and apoptosis are 
mediated via the CCK-2 receptor by multiple factors within different 
signalling pathways.  Therefore it is hypothesised that: 
 
• Correlations exist between gastrin and CCK-2 receptor expression 
and pro-carcinogenic factors and their expression could act as 
biomarkers of progression.  This will be investigated in the 
oesophageal setting with Barrett’s metaplasia and dysplasia, since 
the department has access to screening samples. 
• Gastrin and CCK-2 receptor expression correlations with pro-
angiogenic and anti-apoptotic factors are established in full blown 
cancer.  The department has access to a large pancreatic tissue 
microarray (TMA) which will be used to assess this in the pancreatic 
cancer setting. 
• Inhibition of gastrin will reduce multiple pro-carcinogenic factors 
concurrently.  Mouse models will be used to evaluate this; the INS-
GAS mouse model of gastro-oesophageal cancer and the Apc
Min/+
 
mouse model of intestinal carcinogenesis.  The latter model will also 
be used to compare gastrin neutralisation to a standard of care 
modality; COX-2 inhibition. 
  62
 
 
 
 
Chapter 2 
 
MATERIALS AND 
METHODS 
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2.1 Sample collection and preparation  
 
2.1.1 Sample processing 
All samples were collected in formal calcium and fixed (approx 24hrs 
depending on sample thickness). 
 
Fixed samples were placed into histology cassettes and processed overnight 
on the TP1020 tissue processor (Leica microsigation, UK). 
 
Samples were processed on the following programme under vacuum and 
agitation; 
 60 minutes in 70% ethanol 
 60 minutes in 90% ethanol 
 60minutes in 100% ethanol 
 60minutes in 100% ethanol 
 60minutes in 100% ethanol 
 60minutes in 100% ethanol 
 60minutes in 100% xylene  
 60minutes in 100% xylene 
 60minutes in 100% xylene 
 120 minutes in 60
o
C embedding wax 
 120 minutes in 60
o
C embedding wax 
 
The samples, permeated with molten wax were transferred to the embedding 
station. 
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2.1.2 Sample embedding 
 
The samples were placed in pre-heated (60
o
C) moulds and then molten wax 
poured over the top, a labelled cassette was then placed on top and the 
assembly left to cool evenly to 4
 o
C.  Once set the wax forms a solid matrix 
to aid sectioning. 
 
 
2.1.3 Cutting of sections 
 
Sample blocks were trimmed and then chilled, 4µm sections cut using a 
rotary microtome (Leica microsigation, UK).  Sections were then placed in a 
37
o
C flotation bath to stretch and then transferred onto polysine slides and 
air dried overnight. 
 
2.2 Immunohistochemistry 
 
2.2.1 Deparaffinising samples 
 
In order to stain the samples for analysis with immunohistochemistry, the 
samples were first deparaffinised.  Samples were placed in a slide rack and 
immersed in two changes of 100% xylene for 3 minutes each, followed by 
two immersions in 100% ethanol for 2 minutes each.  If samples were to be 
blocked immediately for endogenous peroxidase activity they went straight 
into the hydrogen peroxide block if they were under going antigen retrieval 
first they were rinsed in running tap water. 
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2.2.2 Endogenous peroxidase activity 
 
Endogenous peroxidase activity was blocked with hydrogen peroxide 
solution diluted in methanol and rinsed in two washes of 100% ethanol 
followed by running tap water if the blocking step was carried out before 
antigen retrieval or distilled water followed by a rinse in distilled water and 
then two rinses of phosphate buffered saline (PBS) pH 7.6 if the blocking 
step was carried out after antigen retrieval. 
 
 
2.2.3Antigen Retrieval 
 
Antigen retrieval was undertaken because the configuration of the tissue 
proteins, and significantly, for immunohistochemistry, the antigenic sites are 
changed during tissue processing (Thomas Boenisch 2001).  Samples were 
placed in a plastic slide rack and dish and immersed in the appropriate 
solution and the appropriate antigen retrieval protocol followed (table 2.1).  
The samples were then quenched in running tap water for 2-3 minutes and 
rinsed in 2 washes of PBS pH 7.6 for a further minute each. 
 
 
2.2.4 Serum block 
 
To prevent any cross reactivity with the species that the secondary antibody 
was raised in samples were incubated with the appropriate serum (table 2.1) 
and then rinsed in two washes of PBS pH7.6.  In addition to the serum block 
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a streptavidin/biotin block (Vector) was also used prior to staining for COX-
2, CD34 and XIAP. 
 
 
2.2.5 Positive and negative antibodies 
 
Samples were incubated with the required primary antibody and a 
corresponding sample was incubated with the appropriate negative IgG at 
matched concentration to the primary (table 2.1).  Where incubation was 
over-night at 4
o
C, samples were covered with parafilm coverslips and 
placed in a humid chamber to prevent drying out.  After incubation samples 
were rinsed in two washes of PBS pH 7.6. 
 
 
2.2.6 Secondary antibodies 
 
Samples were incubated with the appropriate secondary (table 2.1) diluted 1 
in 300 in distilled water for 30 minutes at room temperature and then rinsed 
twice in PBS pH 7.6. 
 
 
2.2.7 (strept)Avidin-biotin complex (ABC) protocol 
 
To amplify the signal from the bound antibody, an ABC kit (Dako 
Cytomation, UK) was used.  The (strept)avidin and biotinylated enzymes 
were mixed at an optimal ratio and incubated at 4
o
C for 30 minutes before 
use.  The complex was then dropped onto the samples and incubated at 
room temperature for 30 minutes and then rinsed twice in PBS pH7.6. 
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2.2.8 Visualisation, counterstaining and cover-slipping 
 
For all antibodies, except CCK-2R, 3,3’-Diaminobenzidine 
tetrahydrochloride (DAB) was used to visualise the staining.  DAB reacts 
with ABC and produces a brown colour, incubation time ranged from 3-10 
minutes depending on intensity.  Following incubation with DAB samples 
were rinsed in running tap water and counter-stained with filtered Meyers 
haematoxylin (RA Lamb, UK) before being rinsed in running tap water and 
dehydrated through 3 times 100% ethanol rinses and 2 xylene rinses and 
cover-slipped with DPX mounting media.  CCK-2R staining was visualised 
with 3-amino-9-ethylcarbazole (AEC), which reacts with ABC to produce a 
red colour  Samples were incubated for 10 minutes and then rinsed in 
running tap water and counterstained with filtered Meyers haematoxylin 
(RA Lamb, UK) before being rinsed in running tap water and cover-slipped 
with aqueous Vectormount (Vector, UK). 
 
 
2.2.9 Mouse on mouse antibodies 
 
Where antibodies raised in mice were used on mouse tissue (BrdU and Bcl-
2) the animal research kit (ARK
TM
) (Dako Cytomation, UK) was used.  
Samples were deparaffinised as described in section 2.2.1 and antigen 
retrieval preformed if required (table 2.1).  Samples were then incubated 
with a pre-diluted hydrogen peroxidase solution for 5 minutes and rinsed 
twice in PBS pH 7.6.  Then the primary antibody, which has been pre-
incubated with modified biotinylated anti-mouse immunoglobulin and a 
blocking reagent containing normal mouse serum, that binds any residual 
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biotinylation reagent and prevents interactions between immunoglobulins 
endogenous to the sample was added to the sample for 15 minutes.  Samples 
were then rinsed twice in PBS pH 7.6 and streptavidin-peroxidase added for 
15 minutes before rinsing twice in PBS pH 7.6 and visualising with DAB, 
counterstaining and cover-slipping as described in section 2.2.8. 
 
 
2.3 Staining analysis 
 
2.3.1 Staining intensity 
 
Intensity of staining was assessed using the Leica QWin image analysis 
software (Leica Microsystems, UK) and the area of interest defined.  The 
programme gave units of absorption; these results were then subtracted from 
the maximum absorbance value possible (255) to give the final result in 
reflectance units, the lower the reflectance unit the lower the intensity of 
staining. 
 
 
2.3.2 Area of staining 
 
Area of staining was assessed using the Leica QWin image analysis 
software (Leica Microsystems, UK).  The stained area is expressed relative 
to the whole tissue. 
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2.3.3 H-scoring staining analysis 
 
The semi-quantitative H-scoring system was used were the intensity and 
area of staining needed to be assessed.  H-scoring was preformed using a 
pre-designed programme on the Leica QWin image analysis software (Leica 
Microsystems, UK).  This programme measures intensity as well as area of 
staining.  Areas of high staining are multiplied by 3, areas of medium 
staining by 2 and areas of low staining by 1, these results are then added 
together to give the H-score (Lessey, Yeh et al. 1996; Wang, Ko et al. 
2008). 
 
 
2.3.4 Proliferation analysis 
 
BrdU/Mib1 labelled proliferating cells in the normal and pre-cancerous 
lesions were manually counted per gland to give a BrdU/Mib1 labelling 
index (percentage proliferating cells per gland). 
 
 
2.3.5 Blood vessel staining analysis 
 
BVD hotspots were assessed manually by counting the number of “events” 
(the number of times a blood vessel appears within the field of view) per 
field at 40x magnification, with a total of 10 fields of view analysed per 
section. 
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2.4 Radio Isotope Assay 
 
A set of standards were prepared using human G17 (Ananspec) which were 
serially diluted from 1mg/ml stock solution to 10000, 5000, 1000, 750, 
500,250, 100, 75, 50, 25, 10, 5 and 1pg/ml in gastrin depleted, heat 
inactivated human serum (Sigma, UK) containing 200KIA Trasylol/ml 
(Bayer, UK).  These standards were then stored on ice until further use.  
Rabbit anti-human G17 (Dako cytomation, UK) was diluted 1 in 5000 in 
PBS and stored on ice until required.  
125
I-G17 (PerkinElmer, UK) was 
diluted from 2 x 10
-8
M stock solution to 4 x 10
-11
M (decay adjusted) and 
stored on use until required. 
 
The following PEG (MW 10000)-coated glass tubes were prepared in 
triplicate: 
 
 Standards/samples: 50µl standard/sample, 50µl antibody, 50µl 125I-G17, 
50µl PBS 
 Total binding: 50µl mouse serum, 50µl antibody, 50µl 125I-G17, 
50µl PBS 
 Reagent blank: 50µl mouse serum, 50µl l 125I-G17, 100µl PBS 
 Background:  50µl mouse serum, 50µl antibody, 100µl PBS 
 Total counts:  50µl l 125I-G17, 150µl PBS 
 
All samples were vortexed, covered with parafilm and incubated at 4oC for 
72hrs. 
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50µl newborn calf serum (Sigma, UK) containing 250µl of 25% PEG 
(8000) was added to the tubes and vortexed, followed by centrifugation at 
1500rpm at 4
o
C for 30 minutes to harvest the samples.  The supernatant was 
then aspirated off and the pellet counted on the gamma counter. 
 
 
2.5 In vivo mouse studies 
 
All in vivo experiments were performed in the Division of Pre-Clinical 
Oncology, University of Nottingham and were carried out under the Home 
Office licence number 40/2323 granted after local ethical approval.   
 
Mice were housed in sterile insolators illuminated by fluorescent lights set 
to give 12 hours light/dark cycle.  The room was air-conditioned by a 
system designed to maintain an air temperature range of 23 ± 2ºC.  Mice 
were group housed in plastic cages with irradiated bedding and provided 
with nesting materials and environmental enrichment.  They were fed 
irradiated 2019 rodent diet (Harlan) and autoclaved water was offered ad 
libitum. 
 
2.5.1 INS-GAS model 
 
The INS-GAS mouse model of gastric adenocarcinoma as described by 
Wang et al in 1993 (Wang, Bonner-Weir et al. 1993; Wang, Koh et al. 
1996) was re-derived in the Division of Pre-clinical Oncology to remove 
specific pathogens.  End-stage disease was characterised and found to occur 
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at week 40 in the colony, of note a side effect of the INS-GAS transgene is 
obesity. 
 
At termination the stomach was removed and opened up along the longest 
curvature and any contents scraped out.  The stomach was then rinsed twice 
in sterile PBS, before being sectioned and placed flat in biopsy bags.  The 
tissue was then left to fix overnight in formal calcium before being 
processed, embedded and sectioned as previously described. 
 
 
2.5.2 Apc
Min/+
 model 
 
An in-house APC
Min
 mouse breeding colony used in this study (Watson and 
Smith 2001).  The model has been used experimentally, since 1984 onwards 
when CP Holroyde used it to represent terminal colorectal cancer and 
associated cachexia (Holroyde, Skutches et al. 1984). The mice exhibit 
multiple intestinal neoplasia (Min) and concurrent hypergastrinaemia.  
Genetic screening by PCR ensured that all the mice entering the breeding 
colony had the mutant allele. 
 
Genotyping was carried out using DNeasy tissue kit (Qiagen) to extract 
DNA from tail snips.  2µl of the resulting DNA was then added to 44µl 
megamix blue (Helena Biosciences), along with 2µl of the forward primer, 
5’ TCT CGT TCT GAG AAA GAC AGA AGC T 3’(MWG Biotech) and 
2µl of the reverse primer, 5’ TGA TAC TTC TTC CAA AGC TTT GGC 
TAT 3’(MWG Biotech).  PCR reaction was then carried out on ABI 
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thermocycler under the following conditions initialisation at 95
o
C for 5mins 
then 30 cycles of denaturing at 95
o
C for 30secs, annealing at 54
o
C for 60sec 
and extension at 72
o
C for 2mins samples were then held at 4
o
C until being 
stored  The PCR product was then digested using restriction enzyme HindIII 
(Roche) overnight at 37
o
C before being run out on a 2% agarose gel and 
visualised with ethidium bromide. 
 
Depending on the study, at termination, the stomach was removed as 
described in section 2.5.1 or the intestine was dissected out.  For the 
intestine tumour burden in each mouse was counted using a dissecting 
microscope in the small and large intestine respectively. The small and large 
intestines were collected, stored and fixed separately in formal calcium for 
approximately 24 hrs. They were then rolled up into a “swiss roll” and 
placed in histology cassettes and processed and embedded as previously 
described. 
 
 
2.6 Therapeutic intervention 
 
2.6.1 G17DT immunisation 
 
Mice were given a course of either 250mg/kg G17DT or DT vehicle at 0, 1 
and 3 weeks and then at 3-weekly intervals thereafter, this was based on 
data achieved in previous studies with the Division of Pre-Clinical 
Oncology (Smith, Justin et al. 2000; Gilliam, Watson et al. 2004).  The DT 
part was used as a control to determine that any effects seen were as a result 
of a response to the G17 and not the DT.  At the study end point mice were 
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fasted overnight and then administered with bromodeoxyuridine (BrdU) 1hr 
before termination.  Unfortunately due to the volume of serum required for 
measuring serum gastrin levels it was not possible to do so in all studies. 
 
 
2.6.2 COX inhibitors 
 
Mice were given either 37.5mg/ml aspirin in drinking water (1.5mg/kg), 
0.75mg/ml celecoxib in drinking water (3mg/kg) or placebo for duration of 
9 months.  At the study end point mice were fasted overnight and then 
administered with bromodeoxyuridine (BrdU) 1hr before termination. 
 
 
2.7 Helicobacter infection 
 
The following H. pylori strains were used Sydney Strain 1 (SS1), NCTC 
11637 and B128 7.13 rederived from B128 by Rick Peek and cultured on 
5% horse blood agar.  H. felis (strain: ATCC49179), was cultured on 5% 
horse blood agar slopes with Brucella broth overlays.  All bacteria were 
incubated kept at 37ºC with 5% CO2 and 86% N2.  Swabs of these were 
taken and put in Brucella broth (Oxoid UK) and the optical density adjusted.  
Mice were given 0.1ml containing 1x10
8
 colony forming units.  All bacteria 
were provided by the Institute of Infections, Immunity and Inflammation, 
University of Nottingham.  The mice were orally dosed on days 1, 3 and 5 
of the study with 1ml bacterial suspension by oral gavage.  Control mice 
were given an equal volume of uninfected Brucella broth. 
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Antibody Hydrogen peroide Antigen retrival Antihgen retrival Serum block Primary antibody Matched IgG concentration  Secondary antibody
 block solution protocol concentration negative
Rabbit anti-human COX-2 0.6% in methanol None None 20% swine serum 10mg/l Rabbit serum Swine anti-rabbit biotinylated 
(Cayman, USA) 30mins (Dako Cytomation, UK) 30mins 1hr at RT (Dako Cytomation, UK) (Dako Cytomation, UK) 
Rabbit anti-mouse COX-2 0.6% in methanol Trypsin 37oC for 20mins 5% swine serum 5mg/l Inactivated primary antobody Swine anti-rabbit biotinylated 
(Cayman, USA) 30mins (Dako Cytomation, UK) 10mins  2hrs at RT  (Dako Cytomation, UK) (Dako Cytomation, UK) 
Mouse anti-BrdU 10mM Citric acid microwave at 98oC for 15mins 5.5mg/l Mouse serum 
 (Dako Cytomation, UK)  pH 6.0 followed by1M HCl acid (Dako Cytomation)
 at 55oC for 6-8mins
Mouse anti-Mib-1 0.6% in methanol  10mM Citric acid microwave at 98oC for 20mins 20% rabbit serum 2.7mg/l Univeral mouse negative Rabbit anti-mouse biotinylated 
 (Dako Cytomation, UK) 30mins pH 6.0 (Dako Cytomation, UK) 15mins  1hr at RT (Dako Cytomation, UK) 
Rat anti-mouse CD34 3% in methanol 10mM Citric acid Pre-heat solution to 98oC none 1.25mg/l Rat IgG anti-rat IgG biotinylated 
(Becton Dickinson, UK) 15mins  pH 6.0 then microwave for 10mins at 98oC  O/N at 4oC  (Becton Dickinson, UK) (Becton Dickinson, UK)
Mouse anti-CD31 6% in methanol 10mM Tris plus microwave at 98oC for 15mins 20% rabbit serum 4.5mg/l Universal mouse negative Rabbit anti-mouse biotinylated 
(Dako Cytomation, UK) 15mins 1mM EDTA pH 9.0 (Dako Cytomation, UK) 30mins 1hr at RT  (Dako Cytomation, UK) (Dako Cytomation, UK)
Mouse anti-Bcl-2 0.6% in distilled water 10mM Citric acid microwave at 98oC for 20mins 20% rabbit serum 5.6mg/l Universal mouse negative Rabbit anti-mouse biotinylated 
(Dako Cytomation, UK)  15mins pH 6.0 (Dako Cytomation, UK) 30mins  1hr at RT (Dako Cytomation, UK) (Dako Cytomation, UK)
Rabbit anti-VEGF-R2 1% in distilled water Protinase K 10mins at RT 20% swine serum 2.5mg/l Rabbit serum Swine anti-rabbit biotinylated 
(Abcam, UK) 15mins (Dako Cytomation, UK) 15mins  1hr at RT  (Dako Cytomation, UK) (Dako Cytomation, UK)
Mouse anti-XIAP 1% in methanol 10mM Citric acid Pre-heat solution to 98oC 10% rabbit serum 1mg/l Universal mouse negative Rabbit anti-mouse biotinylated 
 (Cayman, USA) 15mins  pH 6.0 then microwave for 10mins at 98oC (Dako Cytomation, UK) 15mins  O/N at 4oC (Dako Cytomation, UK) (Dako Cytomation, UK) 
Mouse anti-Akt 1% in distilled water 10mM Citric acid microwave at 98oC for 15mins 10% rabbit serum 20mg/l Universal mouse negative Rabbit anti-mouse biotinylated
(Dako Cytomation, UK)  15mins  pH 6.0 (Dako Cytomation, UK) 30mins O/N at 4oC (Dako Cytomation, UK)  (Dako Cytomation, UK) 
Mouse anti-phospho-Akt 1% in distilled water 10mM Citric acid microwave at 98oC for 15mins 10% rabbit serum 20mg/l Universal mouse negative Rabbit anti-mouse biotinylated 
(Dako Cytomation, UK) 15mins  pH 6.0 (Dako Cytomation, UK) 30mins  O/N at 4oC  (Dako Cytomation, UK) (Dako Cytomation, UK)
Goat anti-CCK2R 0.6% in methanol 10mM Citric acid microwave at 98oC for 15mins 20% rabbit serum 4mg/l Goat serum Rabbit anti-goat biotinylated 
(Everset biotech, UK)  15mins  pH 6.0  (Dako Cytomation, UK) 30mins O/N at 4oC  (Dako Cytomation, UK) (Dako Cytomation, UK)
Goat anti-HB-EGF 3% in methanol 10mM Citric acid Pre-heat solution to 90oC 20% rabbit serum 4mg/l Goat serum Rabbit anti-goat HRP
(Santa Cruz, USA) 15mins pH 6.0 then microwave for 20mins at 90oC (Dako Cytomation, UK) 30mins 1hr at RT (Dako Cytomation, UK) (Dako Cytomation, UK)
 
Table 2.1 immunohistochemistry antibodies, concentrations, blocks, antigen retrieval and secondary antibodies.   
(RT = Room temperature, O/N = Over night) 
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Chapter 3 
 
PROGRESSION OF 
BARRETT’S 
OESOPHAGUS A ROLE 
FOR GASTRIN 
 
  76
3.1 Barrett’s oesophagus 
 
Barrett’s oesophagus is a recognised pre-malignant condition (Hirota, Loughney et al. 
1999), which can progress down the multistep pathway of metaplasia to dysplasia and 
finally to oesophageal adenocarcinoma (Jankowski, Wright et al. 1999).  To reduce 
the number of individuals that progress from Barrett’s to adenocarcinoma, 
surveillance programmes are in place; however, unlike other cancer surveillance 
programmes, they do not appear to be having a great effect on reducing the number of 
individuals that progress to adenocarcinoma (Gerson and Triadafilopoulos 2002).  
Therefore, an alternative approach is required, such as identifying possible biomarkers 
that can predict an individual’s chance of progressing from Barrett’s to 
adenocarcinoma.   
 
With gastrin and its receptor emerging as players in the development of pre-malignant 
and malignant lesions of the GI tract (Aly, Shulkes et al. 2004), this study aimed to 
evaluate the role of gastrin and its receptor on the progression of Barrett’s oesophagus 
to oesophageal adenocarcinoma.  This was achieved by analysis of anti-apoptotic and 
angiogenic factors in relation to gastrin and CCK-2R. 
 
Pinch biopsies and whole blood were obtained with informed ethical constant from 
Barrett’s patients attending Dr. Ragunath’s endoscopy clinic.  The biopsies were 
independently classified by a pathologist according to histological type; columnar 
lined oesophagus (CLO), intestinal metaplasia (IM) and high grade dysplasia (HGD).  
Staining intensity was assessed using reflectance units as described in section 2.3.1.  
Whole blood was centrifuged to obtain the serum and biopsies were formalin fixed 
and paraffin embedded.  A gastrin radioimmune assay was used to quantify serum 
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levels of G17 and immunohistochemistry was used to determining the protein levels 
of various markers. 
 
 
3.1.1 Proliferation 
 
Proliferation was assessed using the MIB1 antibody (Dako Cytomation, UK) that 
stain for the Ki-67 antigen.  Ki-67 is preferentially expressed by cells during all active 
phases of the cell cycle (G1, S, G2 and M phases), but not during the resting phase 
(G0) or DNA repair (Gerdes, Lemke et al. 1984).  Proliferation was assessed in the 
columnar cells of CLO and the lesions of IM and HGD. 
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Fig. 3.1 comparison of proliferation in different grades of Barrett’s oesophagus 
(CLO n=5, IM and HGD n=19).  p<0.001 using Wilcoxon signed rank. Boxes 
represent spread of data from third to first quartile, horizontal line represents the 
median; error bars extend to highest and lowest data values within upper and lower 
limits, * represent outliers.
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A
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D E
Fig. 3.2 Examples of MIB-1 staining of proliferating cells in 
CLO (A), IM (B-C) and HGD (D-E). 
 
 
There was a significant 1300-fold (p<0.001) increase in proliferation in IM and HGD 
combined, compared to CLO (fig 3.1).  In the CLO tissue there was very little staining 
of the columnar cells.  In IM and HGD there was specific nuclear staining of the 
goblet and dysplastic cells respectively; there was also occasional staining of stromal 
cells (fig 3.2). 
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3.1.2 Serum gastrin and CCK-2 receptor levels 
 
A RIA was used to quantify serum levels of G17 and a specific CCK-2 receptor 
antibody was used to stain for the gastrin receptor. 
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Fig. 3.3 Comparison of serum gastrin levels in patients with different 
grades of Barrett’s oesophagus (CLO n=5, IM and HGD n=19). Boxes 
represent spread of data from third to first quartile, horizontal line 
represents the median, error bars extend to highest and lowest data values 
within upper and lower limits.
 
 
There was no significant difference between serum gastrin levels in individuals with 
CLO compared to those with IM and HGD (see fig 3.3).  All the individuals in this 
study had elevated serum gastrin levels compared to normal fasting levels of 
<40pg/ml (Corleto, Goebel et al. 2003) with 90% of individuals being 
hypergastrinaemic. 
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Fig. 3.4 Comparison of CCK-2R protein expression in different grades of Barrett’s 
oesophagus (CLO n=5, IM and HGD n=19).  p<0.005 using Wilcoxon signed 
rank. Boxes represent spread of data from third to first quartile, horizontal line 
represents the median, error bars extend to highest and lowest data values within 
upper and lower limits, * represent outliers.
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Fig. 3.5 Examples of CCK-2R staining in CLO (A-B), IM (C-
D) and HGD (E-F).
A B
C D
E F
 
 
There was a significant 1.1-fold decrease (p<0.005) in CCK-2 receptor protein 
expression in IM and HGD compared to CLO (see fig 3.4).  Examples of CCK-2 
receptor staining patterns are shown in fig. 3.5; in the CLO tissue staining of the 
columnar cells was cytoplasmic, there was also diffuse staining of the stromal tissue.  
In the IM samples there was a similar pattern of staining in the goblet cells as seen in 
the columnar, but the stromal staining was weaker.  The most intense staining was 
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seen in HGD, although only in a few samples, in both the cytoplasm and nucleus of 
dysplastic cells. 
 
 
3.1.3 X-linked Inhibitor of Apoptosis (XIAP) protein expression 
 
XIAP is a member of the inhibitor of apoptosis (IAP) protein family and inhibits 
cellular apoptosis via inhibition of caspase -3, -7 and cytochrome c-mediated 
activation of caspase-9 (Kluger, McCarthy et al. 2007).  A specific XIAP antibody 
(AbCam, UK) was used to stain for XIAP protein. 
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Fig. 3.6 comparison of levels of XIAP protein expression in different grades of Barrett’s 
oesophagus (CLO n=5, IM and HGD n=19).  p<0.005 using Wilcoxon signed rank. Boxes 
represent spread of data from third to first quartile, horizontal line represents the median, error 
bars extend to highest and lowest data values within upper and lower limits, * represent outliers 
(A).  Positive correlation between XIAP protein expression and serum gastrin levels in CLO 
tissue p<0.05, rs=0.582 using spearman 2-tailed correlation (B).
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Fig 3.7 Examples of XIAP protein staining in CLO (A), IM (B) and HGD (C) 
tissue.
A
B
C
 
 
There was a significant 1.6-fold increase in XIAP protein expression in IM and HGD 
compared to CLO (see fig. 3.6A) with a positive correlation, although not significant 
when Bonferroni correction was applied, between XIAP protein expression and serum 
gastrin levels in CLO (p<0.05, rs=0.582) (see fig. 3.6B).  The pattern of staining in 
CLO was weak cytoplasmic staining at the base of the columnar cells and there was 
no stromal staining.  In IM and HGD there was moderate to strong staining of the 
goblet cells and dysplastic cells respectively, with weak staining of cytoplasm in the 
stromal cells; also in the IM there was some nuclear staining of the stromal cells (See 
fig 3.7). 
 
 
3.1.4 Bcl-2 protein expression 
 
Bcl-2 is an anti-apoptotic member of the Bcl-2 family and protein levels were 
assessed using a specific Bcl-2 antibody. 
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Fig. 3.8 comparison of Bcl-2 protein expression in different grades of 
Barrett’s oesophagus (Clo n=5, IM and HGD n=19).  p<0.001 using 
Wilcoxon signed rank. Boxes represent spread of data from third to first
quartile, horizontal line represents the median, error bars extend to 
highest and lowest data values within upper and lower limits, * represent 
outliers.
 
 
Fig. 3.9 Examples of Bcl-2 staining in CLO (A), IM (B) and HGD (C) 
tissue.
A
B
C
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Fig 3.8 shows that there was a significant 85.5-fold increase (p<0.001) in Bcl-2 
protein expression the IM and HGD compared to CLO.  As shown in fig. 3.9 there 
was no staining in the columnar cells of the CLO samples, but there was strong 
cytoplasmic staining in the goblet cells of IM with moderate cytoplasmic and strong 
nuclear staining of certain stromal cells.  In the HGD there was moderate cytoplasmic 
staining of the dysplastic and some stromal cells, but no nuclear staining. 
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Fig 3.10  Correlation between XIAP and VEGF-R2 protein expression p=0.024, 
rs=0.544 (A) and XIAP and Bcl-2  protein expression p<0.001, rs=0.757 (B) using 
Spearman 2-tailed correlation.
A B
 
 
There was a significant positive correlation (after Bonferroni correction) p<0.001 
between Bcl-2 and XIAP protein expression and a positive correlation between 
VEGF-R2 and XIAP protein expression (Fig. 3.10). 
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3.1.5 Akt and Phosphorylated-Akt (P-Akt) protein expression 
 
Akt is involved in the regulation of cell cycle, survival and metabolism by binding 
and regulating a number of downstream effectors including NFκB and members of 
the Bcl-2 protein family.  P-Akt is the phosphorylated activated form of Akt (Song, 
Ouyang et al. 2005).  Akt and P-Akt protein expression levels were assessed by 
staining with specific antibodies (Dako Cytomation, UK). 
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Fig. 3.11 comparison of Akt protein expression in different grades of 
Barrett’s oesophagus (Clo n=5, IM and HGD n=19). Boxes represent 
spread of data from third to first quartile, horizontal line represents the 
median, error bars extend to highest and lowest data values within upper 
and lower limits, * represent outliers.
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Fig. 3.12 Examples of Akt staining in CLO (A), IM (B) and HGD (C).
A
B
C
 
 
The intensity levels of Akt protein expression were similar in all three grades of 
Barrett’s tissue assessed, with no significant difference (see fig. 3.11).  There was 
intense staining in the cytoplasm of columnar, stromal and endothelial cells, with 
clear gradation from intense to weak from the base to the apex of the columnar cells.  
Staining was also intense in the dysplastic cells of HGD (fig 3.12).  
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Fig. 3.13 comparison of P-Akt protein 
expression in different grades of Barrett’s 
oesophagus (CLO n=5, IM and HGD n=19) 
Boxes represent spread of data from third to first 
quartile, horizontal line represents the median, 
error bars extend to highest and lowest data 
values within upper and lower limits, * represent 
outliers (A).  There were positive correlations 
between CCK-2R and P-Akt protein expression 
in CLO, p<0.05, rs 0.582(B) and IM and HGD 
p<0.001, rs 0.5 (C) using Spearmans 2-tailed 
correlation.
CLO
 
 
Fig. 3.14 Examples of P-Akt staining in CLO (A), IM (B) and HGD (C).
A
B
C
 
 
  89
As shown in Fig. 3.13A, as for Akt there is no significant difference between the 
intensity of staining of P-Akt between the different histological tissue types, but there 
was a significant positive correlation between P-Akt and CCK-2R protein expression 
in CLO (p<0.005, rs=0.582) and IM and HGD (p<0.001, rs=0.5) (see fig. 3.13B and 
C).  In the CLO there was graduated cytoplasmic staining of the columnar cells with 
the strongest at the base.  There was also nuclear staining of the columnar cells and 
weak staining of the stromal cells and some endothelial cells.  In comparison, in both 
the IM and HGD there was no nuclear staining, only cytoplasmic staining of the 
goblet cells and dysplastic cells respectively.  There was some weak stromal staining 
in the HGD, but not the IM (fig. 3.14). 
 
 
3.1.6 Vascular endothelial growth factor-receptor 2 (VEGF-R2) protein 
expression 
 
VEGF-R2 is a member of a receptor tyrosine kinase family and its activation plays an 
important role in a number of biological processes including; embryonic development, 
cell proliferation, migration and differentiation (Holmqvist, Cross et al. 2004).  A 
specific VEGF-R2 antibody (AbCam, UK) was used to assess the level of VEGF-R2 
protein expression. 
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Fig. 3.15 comparison of VEGF-R2 protein expression in different grades of 
Barrett’s oesophagus (CLO n=5, IM and HGD n=19), p<0.001 using Wilcoxon
signed rank. Boxes represent spread of data from third to first quartile, horizontal 
line represents the median, error bars extend to highest and lowest data values 
within upper and lower limits, * represent outliers (A).  Significant positive 
correlation between VEGF-R2 and CCK-2R protein expression in IM and HGD 
p<0.001, rs 0.522 (B).
CLO
 
 
Fig. 3.16 Examples of VEGF-R2 staining in CLO (A), IM (B) and HGD (C).
A
B
C
 
 
There was a stepwise increase in VEGF-R2 protein expression from CLO to HGD 
with a significant 1.3-fold increase (p<0.001) in VEGF-R2 protein expression in IM 
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and HGD compared to CLO, with a significant positive correlation between VEGF-
R2 and CCK-2R protein expression in IM and HGD (p<0.001, rs=0.522) results are 
summarised in Fig. 3.15.  In CLO there was very weak diffuse staining of the 
columnar and stromal cells.  In IM, staining was localised to the membrane of the 
goblet cells with strongest staining at the apex of the cell; there was also very weak 
diffuse staining of the stromal cells.  Like IM, HGD also showed strongest staining at 
the apex of the cells, this time the dysplastic cells, but staining was also cytoplasmic 
as well as membranous and again there was weak stromal staining (see fig 3.16). 
 
 
3.1.7 Heparin-binding epidermal growth factor (HB-EGF) protein expression 
 
HB-EGF is a member of the epidermal growth factor (EGF) superfamily ligands and 
is linked to angiogenesis (Mehta and Besner 2007).  A specific HB-EGF antibody 
(Santa Cruz, USA) was used to assess HB-EGF protein expression. 
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Fig. 3.17 comparison of HB-EGF protein expression in different grades of 
Barrett’s oesophagus (CLO n=5, IM and HGD n=19). Boxes represent 
spread of data from third to first quartile, horizontal line represents the 
median, error bars extend to highest and lowest data values within upper 
and lower limits.
LO
 
 
Fig. 3.18 Examples of HB-EGF staining in CLO (A), IM (B) and HGD (C).
A
B
C
 
 
There was no significant difference between levels of HB-EGF protein expression in 
CLO compared to IM and HGD (fig 3.17).  In the CLO there was moderate staining in 
the stroma including endothelial cells.  In the columnar cells, staining was graduated 
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with the strongest staining as the base of the cell.  The IM showed strong cytoplasmic 
staining of the goblet cells and diffuse staining in the stroma.  In the HGD there was 
no staining of the dysplastic cells, only cytoplasmic staining of occasional stromal 
cells (fig 3.18). 
 
 
3.1.8 Blood Vessel Density (BVD) 
 
CD31 was used to assess BVD as a measure of angiogenesis.  Blood vessels are 
comprised of endothelial cells and it is these which express the epitope which binds 
CD31.  As shown in fig. 3.20 cross-sectioned blood vessels appear as circles and 
longitudinal blood vessels appear as tubes. 
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Fig. 3.19 comparison of blood vessel density in different grades of Barrett’s 
oesophagus (CLO n=5, IM and HGD n=19), p<0.005 using one way ANOVA. 
Boxes represent spread of data from third to first quartile, horizontal line 
represents the median, error bars extend to highest and lowest data values 
within upper and lower limits, * represent outliers (A).  Significant positive 
correlation between blood vessel density and serum gastrin levels in Clo
tissue, p<0.05, rs=0.632 using Spearman 2-tailed correlation (B).
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Fig. 3.20 Examples of blood vessel staining in CLO (A), IM (B) and HGD (C).
A
B
C
 
 
As fig. 3.19 shows there was a significant 1.9-fold increase (p<0.005) in BVD in IM 
and HGD compared to CLO with a positive correlation, although not significant when 
Bonferroni correction was applied, between BVD and serum gastrin levels in CLO 
(p<0.05, rs=0.632).  Fig. 3.20 clearly shows that there are less new blood vessels in 
the CLO than the IM and to a lesser extent the HGD. 
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Fig 3.21  Correlation between XIAP and VEGF-R2 protein expression p=0.024, 
rs=0.544 (A) and XIAP and Bcl-2  protein expression p<0.001, rs=0.757 (B) using 
Spearman 2-tailed correlation.
A B
 
 
There were significant positive correlations between BVD and proliferation (p<0.02) 
and BVD and XIAP protein expression (p<0.01) after Bonferroni correction (fig. 
3.21). 
 
 
3.1.9 COX-2 protein expression 
 
COX-2 the rate limiting enzyme in the synthesis of prostaglandin from arachadonic 
acid is over-expressed in a number of pre-malignant tissues and malignant tumours 
(Dannenberg, Altorki et al. 2001).  A specific COX-2 antibody (Caymen, USA) was 
used to measure COX-2 protein expression. 
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Fig. 3.22 comparison of COX-2 protein expression in different grades of 
Barrett’s oesophagus (Clo n=5, IM and HGD n=19).  p<0.001 using Wilcoxon
signed rank. Boxes represent spread of data from third to first quartile, 
horizontal line represents the median, error bars extend to highest and lowest 
data values within upper and lower limits.
 
 
Fig. 3.23 Examples of COX-2 protein staining in CLO (A), IM (B) and 
HGD (C).
A
B
C
 
 
There was a significant 1.6-fold decrease (p<0.001) in COX-2 protein expression in 
IM and HGD compared to CLO (fig. 3.22).  Staining was mainly stromal with some 
endothelial staining in all tissue types.  In the CLO there was weak cytoplasmic 
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staining of occasional columnar cells.  In the IM staining was more intense in the 
stroma and there was cytoplasmic staining of the goblet cells.  The HGD showed 
mainly stromal staining with some staining of dysplastic cells (fig 3.23). 
 
 
3.2 Discussion 
 
Across all patients in this study, serum gastrin levels were elevated above those of 
normal fasting serum gastrin levels.  An explanation for this is that all patients, as is 
standard with Barrett’s patients, were on proton pump inhibitors (PPIs).  PPIs work by 
blocking gastric acid secretion, but this then causes an increase in serum gastrin as 
shown in a number of studies on the long term effects of the PPI Lansoprazole 
(Muller, Dammann et al. 1989; Brunner, Hell et al. 1995). 
 
High expression of the CCK-2 receptor protein was seen in all tissue types, which is 
in agreement with work by Haigh et al (Haigh, Attwood et al. 2003) which showed 
that CCK-2 receptor expression was increased in Barrett’s metaplastic tissue 
compared to normal oesophageal tissue.  However, there was slightly lower CCK-2 
receptor protein expression in IM and HGD compared to CLO, possibly because the 
high levels of circulating gastrin reduce the need for high levels of the receptor or lead 
to down regulation of the receptor. 
 
The anti-apoptosis markers XIAP and Bcl-2 were significantly increased in IM and 
HGD compared to CLO, with positive correlation between XIAP protein expression 
and serum gastrin in CLO.  XIAP is the best-characterised and considered the most 
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potent member of the Inhibitor of Apoptosis Protein (IAP) family and differs from 
other members by its ability to directly bind to and inhibit activated caspase-3, -7 and 
-9 (Eckelman, Salvesen et al. 2006).  There is currently nothing in the literature about 
the role of XIAP in the progression of Barrett’s oesophagus, but overexpression of 
XIAP has been observed in a number of cell lines including those of colon, ovarian, 
renal and prostate origin (Tamm, Kornblau et al. 2000).  However, the results 
presented here relating to Bcl-2 protein expression are in agreement with current 
research, which demonstrates an up-regulation of Bcl-2 expression from Barrett’s 
metaplasia to neoplasia (Shimizu, Vallbohmer et al. 2006), and therefore supports the 
data observed for XIAP and the significant positive correlation seen between Bcl-2 
and XIAP protein expression in individual patients.   
 
Another anti-apoptotic marker Akt and its activated form P-Akt, a member of the 
serine/threonine specific protein kinase family, have been shown to be increased in 
the progression of Barrett’s adenocarcinoma (Beales, Ogunwobi et al. 2007), but they 
were not up-regulated in progression from CLO to IM and HGD in this study.  
Previous work within our group has shown that Akt is activated by gastrin in Barrett’s 
metaplastic tissue (Harris, Clarke et al. 2004) and therefore due to the elevated levels 
of serum gastrin in the individuals in this study any trend may have been masked.  
There was a positive correlation between p-Akt and CCK-2 receptor protein 
expression in both CLO and IM and HGD, and between p-Akt and serum gastrin in 
IM and HGD, suggesting that activation of Akt by gastrin occurs later in the 
progression of Barrett’s. 
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VEGF-R2 is established as a receptor expressed on endothelial cells, which binds 
VEGF and stimulates angiogenesis (Ferrara, Gerber et al. 2003).  However, as shown 
in this study, VEGF-R2 has also been shown to be expressed on non-endothelial cells 
(Liang and Hyder 2005), suggesting a possible role for VEGF in the progression of 
tumours through proliferation and cell survival (Masood, Cai et al. 2001).  Blocking 
binding of VEGF to VEGF-R2 has been shown to reduce proliferation in a number of 
breast cancer cell lines and VEGF may protect cells from apoptosis by the up-
regulation of Bcl-2 (Liang, Brekken et al. 2006).  In this study there was a significant 
increase in VEGF-R2 protein expression in IM and HGD compared to CLO and a 
positive correlation between VEGF-R2 and CCK-2 receptor protein expression in IM 
and HGD, which may indicate that high levels of gastrin acting through the CCK-2 
receptor results increase VEGF-R2 expression, which in turn up-regulates Bcl-2 and 
XIAP in Barrett’s tissue.  Although in this study no correlation was seen between 
VEGF-R2 and Bcl-2 protein expression, a positive correlation was seen between 
VEGF-R2 and XIAP protein expression. 
 
Angiogenesis is an essential part of the carcinogenesis process and previous work in 
our group has shown that HB-EGF expression can be up-regulated by the binding of 
gastrin to the CCK-2 receptor leading to increased angiogenesis (Clarke, Dickson et 
al. 2006), but in this study no clear trend was observed between HB-EGF and 
progression to dysplasia, although there was a correlation between BVD and 
progression.  There was also a positive correlation between BVD and serum gastrin in 
CLO, indicating that serum gastrin promotes angiogenesis early in Barrett’s 
oesophagus, but not via an increase in HB-EGF. 
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This work showed a significant decrease in COX-2 protein expression in IM and 
HGD compared to CLO.  Current data on COX-2 expression and progression in 
Barrett’s suggests that there is no relationship (Abdalla, Lao-Sirieix et al. 2004).  In 
vivo studies have shown that gastrin stimulation can increase COX-2 mediated 
prostaglandin expression and proliferation via the CCK-2 receptor in Barrett’s 
oesophagus (Abdalla, Lao-Sirieix et al. 2004), but no correlation between the gastrin 
parameters and COX-2 were observed in this study. 
 
In summary serum gastrin levels positively correlate with XIAP protein expression 
and BVD, and CCK-2R protein expression positively correlates with P-Akt and 
VEGF-R2 protein expression in Barrett’s tissue. 
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Chapter 4 
 
A role for CCK-2R in the 
pancreatic cancer 
environment 
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4.1 Pancreatic cancer 
 
Pancreatic cancer is the 4
th
 highest cancer killer in the USA with the highest fatality 
rate of all cancers, although the five year survival rate has increased significantly 
between 1974-2001 it still remains around 5% (Jemal, Siegel et al. 2006).  This poor 
prognosis is in part due to the late presentation of the disease and one of the reasons 
why a better understanding and a more targeted therapeutic approach to the disease is 
required. 
 
Studies have shown that gastrin via the CCK-2 receptor can stimulate pancreatic 
cancer growth (Smith, Rickabaugh et al. 1993; Smith, Liu et al. 1994).  However, 
data on the expression of CCK-2 receptors in the normal pancreas and pancreatic 
adenocarcinoma is conflicting.  Therefore, formalin-fixed paraffin-embedded tissue 
microarrays of human pancreatic cancer, pancreatitis, cancer positive and negative 
lymph nodes and resectioned normal tissue obtained from Mr. D. Lobo, Medical and 
Surgical Sciences, University of Nottingham were used in this study to determine the 
levels of CCK-2 receptor protein expression in the pancreatic cancer environment, as 
well as levels of anti-apoptotic factors and COX-2 using immunohistochemistry. 
 
 
4.1.1 CCK-2 receptor expression  
 
As in section 3.1.1 a specific CCK-2 receptor antibody was used to stain for the 
gastrin receptor.   
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Fig. 4.1 CCK-2R protein expression. Boxes represent spread of data from third to 
first quartile, horizontal line represents the mean, error bars extend to highest 
and lowest data values within upper and lower limits, * represent outliers (normal 
n=31, pancreatitis n=106, cancer n=95, lymph node negative n=64, lymph node 
positive n=50).  +p<0.001 using one way ANOVA.
Normal
Pancreatitis
Cancer Cancer +ve LN
Cancer -ve LN
0
1
2
3
Tissue type
Le
ve
l o
f s
ta
in
in
g
+ +
 
 
Fig. 4.2 Comparison in the expression of the CCK-2R on blood vessels 
across the different tissue samples.  Bars represent  percentage of sections 
showing positive CCK2R expression on blood vessels.
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Fig 4.3 Examples of CCK-2R staining in normal pancreas (A), 
Pancreatitis (B), cancer tissue (C-E) and endothelial cells (D).
A (x20) B (x20)
C (x10) D (x20)
E (x10) F (x20)
 
 
Fig. 4.1, shows that there was a significant increase (p<0.001) in CCK2R protein 
expression in pancreatic cancer tissue compared to normal pancreas and in lymph 
nodes that contain cancer cells compared to those that did not.  In conjunction with 
this fig. 4.2 shows that there was an increase in the number of samples that expressed 
the CCK-2 receptor on endothelial cells in cancer tissue (7-fold), lymph nodes that 
contain cancer cells (5.9-fold) and pancreatitis (3.2-fold) compared to normal 
pancreatic tissue. 
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Examples of CCK-2 receptor staining in normal, pancreatitis and pancreatic cancer 
tissue are shown in fig 4.3.  Staining can clearly be seen in the abnormal cancer cells 
and in the endothelial cells (fig 4.3F). 
 
Along side this work analysis of patient data was carried out on the same samples by 
Dr. Mark Aloysius (personal communication), which demonstrated that in the 
pancreatic cancer samples there was a significant negative correlation between patient 
survival and CCK-2R protein expression (rs=-0.188, p=0.033), and between patient 
survival and CCK-2R localisation on endothelial cells (rs=-0.188, p=0.033).  There 
was also a significant positive correlation (rs=0.233, p=0.008) in cancer samples 
between recurrence and CCK-2R protein expression, and between recurrence and 
CCK-2R localisation on endothelial cells.  All analysis was carried out using 
Spearman’s 2-tailed correlation with Bonferroni correction. 
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4.1.2 XIAP protein expression 
 
A specific XIAP antibody was used to stain for XIAP protein expression.   
 
Fig. 4.4 XIAP protein expression.  Boxes represent spread of data from third to first 
quartile, horizontal line represents the mean, error bars extend to highest and 
lowest data values within upper and lower limits, * represent outliers (normal n=26, 
lymph node negative n=49, lymph node positive n=40, pancreatitis n=85, cancer 
n=73).
Cancer -ve LN
Cancer +ve LNCancer
Pancreatitis
Normal
3
2
1
0
Tissue type
Le
ve
l o
f s
ta
in
in
g
 
 
  107
Fig. 4.5 Examples of XIAP staining in normal pancreatic 
tissue (A and B), negative lymph node (C and D) and well 
differentiated pancreatic cancer (E-H).
A B
C D
E F
G H
 
 
As shown in fig. 4.4 the level of XIAP protein expression in pancreatitis and cancer is 
similar to that seen in the normal tissue.  There was a 21.3 fold decrease in XIAP 
protein expression in lymph node tissue which does not contain cancer cells compared 
to lymph node tissue which does.  High levels of staining were only seen in 
pancreatitis and cancer and not normal pancreas.  There was weak cytoplasmic 
staining of occasional acinar cells in normal pancreatic tissue (fig 4.5A and B) and the 
negative lymph nodes showed very weak or negative staining for XIAP (fig 4.5C and 
D).  In pancreatic cancer there was cytoplasmic staining of the cancer cells, which 
tended to be weak (fig 4.5E and F), but occasional samples showed strong 
cytoplasmic staining (fig 4.5G and H). 
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Fig. 4.6 positive correlation between XIAP protein expression and 
CCK-2R protein expression rs=0.354, p=0.003 using spearman 2-
tailed correlation.
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There was a significant (p=0.003) positive correlation, after Bonferroni correction was 
applied, between XIAP protein expression and CCK-2R protein expression (fig. 4.6).  
There was also a significant (p=0.003, rs=0.354) positive correlation, after Bonferroni 
correction was applied, between XIAP protein expression and CCK-2R localisation 
on endothelial cells. 
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4.1.3 Bcl-2 protein expression 
 
A specific Bcl-2 antibody was used to stain for Bcl-2 protein expression.   
 
Fig. 4.7 Bcl-2 protein expression. Boxes represent spread of data from third to first 
quartile, horizontal line represents the mean, error bars extend to highest and 
lowest data values within upper and lower limits, * represent outliers (normal n=26, 
lymph node negative n=49, lymph node positive n=40, pancreatitis n=88, cancer 
n=73). +p<0.05 using one way ANOVA.
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Fig. 4.8 Examples of Bcl-2 staining in normal pancreatic 
tissue (A and B), negative lymph node (C and D), well 
differentiated pancreatic caner (E and F) and poorly 
differentiated pancreatic cancer (G and H).
A B
C D
E F
G H
 
 
Fig 4.7 shows that there was a significant 1.59-fold (p<0.05) reduction in Bcl-2 
protein expression in pancreatic cancer tissue compared to normal pancreatic tissue.  
Although when the level of staining was averaged across samples of each tissue type 
there was a decrease in Bcl-2 staining in pancreatic cancer, high levels of staining 
were observed in occasional pancreatitis and cancer samples but no examples of high 
staining were seen in samples of normal pancreas.  Normal pancreas showed weak to 
medium cell membrane staining for Bcl-2 (fig 4.8A and B).  In cancer negative lymph 
nodes there was strong staining of the lymphoid cells (fig 4.8C and D).  The level of 
staining seen in the pancreatic cancer samples was dependent on the type of cancer, 
with well differentiated cancer showing high levels of staining, and poorly 
differentiated cancers showing low levels of staining as illustrated in fig 4.8E-F. 
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4.1.4 COX-2 protein expression 
 
A number of studies have shown increased COX-2 expression in pancreatic cancer 
tissue.  Molina et al 1999 (Molina, Sitja-Arnau et al. 1999) showed elevated levels of 
both COX-2 mRNA and protein in human pancreatic adenocarcinomas and cell lines, 
derived from pancreatic tumours, this work is supported by similar findings by Okami 
et al 1999 (Okami, Yamamoto et al. 1999) that showed that 54% of pancreatic 
carcinomas over-expressed COX-2 mRNA and 44% showed strong COX-2 protein 
expression compared to normal pancreas.  Therefore it was decided use a specific 
COX-2 antibody to ascertain if these pancreatic samples also showed this correlation 
in relation to COX-2 protein expression. 
 
Fig. 4.9 COX-2 protein expression. Boxes represent spread of data from 
third to first quartile, horizontal line represents the mean, error bars extend 
to highest and lowest data values within upper and lower limits, * represent 
outliers (normal n=22, lymph node negative n=45, lymph node positive 
n=31, pancreatitis n=73, cancer n=55).  *p<0.001 using one way ANOVA. 
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A B
C D
E F
Fig. 4.10 Examples of COX-2 staining in normal 
pancreatic tissue (A and B), pancreatitis (C and D) and 
well differentiated pancreatic cancer (E and F).  
 
COX-2 protein expression showed a significant (p<0.001) 2.2 fold increase in 
pancreatitis and a 2.9-fold increase in pancreatic cancer tissue, compared to normal 
pancreatic tissue (see fig. 4.9).  High levels of staining were only detected in 
pancreatitis and cancer and not normal pancreas.  There appeared to be no COX-2 
protein expression in the acinar cells of the normal pancreas (fig 4.10A and B) as is 
the case in pancreatitis, but there was staining of the connective tissue between the 
acinar cells (fig 4.10C and D).  In pancreatic cancer there was diffuse cytoplasmic 
staining of the cancer cells, but no stromal staining (fig 4.10 E and F). 
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4.2 Discussion 
 
The current standard of care for patients presenting with advanced pancreatic cancer 
is gemcitabine, which increases 12 month survival from 2% with the previous 
standard of care agent 5-Fluorouracil to 18% (Burris, Moore et al. 1997).  For these 
reasons a better understanding of this disease is required in order to develop more 
targeted therapeutic approach. 
 
Caplin et al (Caplin, Savage et al. 2000) showed that CCK-2 receptors were only 
expressed in pancreatic cancer cells and not normal pancreatic cells.  This has been 
confirmed in this work, which showed there was a 4-fold increase in CCK-2 receptor 
protein expression in pancreatic cancer as well as an increase in positive lymph nodes 
compared to resectioned normal tissue.  There was some expression of CCK-2 
receptor protein in the normal pancreatic tissue.  This has also been described by 
another group and an explanation for this is likely to be due to the normals being 
resection normals, which also suggests that locally mediated growth by gastrin may 
also be of relevance to surrounding tissue and regulation mediated by factors from 
nearby neoplastic cells (Goetze, Nielsen et al. 2000). 
 
Results presented in this work showed that CCK-2 receptors were present on 
endothelial cells and that the presence of endothelial cells expressing CCK-2 receptors 
was higher in cancer than the normal pancreas.  Work in rats has shown that CCK-2 
receptors are present on vascular endothelial cells and macrophages in the lungs 
(Cong, Li et al. 2003; Alvarez, Ibiza et al. 2006).  The presence of CCK-2 receptors 
on endothelial cells in pancreatic cancer supports other work within our group, which 
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has shown that gastrin acting through the CCK-2 receptor enhances endothelial cell 
activity in models of angiogenesis (Clarke, Dickson et al. 2006) further supporting the 
role of gastrin and its receptor in angiogenesis. 
 
COX-2 a downstream target of gastrin, has been shown to be over-expressed in 
pancreatic cell lines and pancreatic cancers compared to the normal pancreas (Ding, 
Tong et al. 2001).  The data presented in this work supports this, showing a 
significant increase in COX-2 protein expression in pancreatic cancer compared to 
normal pancreas.  The pattern of COX-2 staining presented in this work is in 
accordance with that observed by Yip-Schneider et al., (Yip-Schneider, Barnard et al. 
2000) who showed that COX-2 protein was not present in normal acinar cells, and in 
pancreatic cancer expression is localised to the cancer cells with no expression in the 
surrounding stroma.  No significant correlation was seen between COX-2 and CCK-2 
receptor protein expression in pancreatic cancer, indicating that up-regulation of 
COX-2 in pancreatic cancer is not mediated through the CCK-2 receptor. 
 
Another down stream target of gastrin, XIAP, considered the most potent member of 
the Inhibitor of Apoptosis Protein (IAP) family, blocks apoptosis through interactions 
with initiator caspase-9 and effector caspases 3 and 7 (Mori, Doi et al. 2007) and is 
expressed at low levels in most normal adult tissue (Yang, Cao et al. 2003).  
Moderately high levels of XIAP protein expression have been described in pancreatic 
cancer cell lines MIA PaCa, BXPC-3 and Panc-1 (Yang, Cao et al. 2003) and XIAP 
has been shown to be over-expressed in 77% of pancreatic cancers (Karikari, Roy et 
al. 2007). 
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In this study high levels of XIAP protein expression were only seen in pancreatitis 
and cancer tissue and not in normal pancreatic tissue, but overall there was no 
significant increase in XIAP expression in pancreatitis or cancer tissue compared to 
normal pancreas.  This lack of significance maybe due to the normal pancreas 
biopsies being taken from individuals that had pancreatic cancer and are therefore not 
true normals.  There was a significant positive correlation with CCK-2 receptor 
protein expression and XIAP expression in pancreatic cancer.  In gastro-oesophageal 
cell lines gastrin has been linked to increased expression of XIAP (Harris 2005).  
Therefore in a subset of patients gastrin may drive over-expression of XIAP via the 
CCK-2 receptor in pancreatic tissue.  There was also a significant positive correlation 
in pancreatic cancer with CCK-2 receptor protein localisation in endothelial cells and 
XIAP protein expression highlighting a possible role in angiogenesis.  Endothelial cell 
expression of CCK-2 receptors and XIAP has not previously been linked, however, 
the proangiogenic factor VEGF has been linked to up-regulation of XIAP (Tran, Rak 
et al. 1999), and as shown in my work in Barrett’s oesophagus, VEGF-R2 positively 
correlates with serum gastrin levels.  It is therefore plausible, that in pancreatic cancer 
serum gastrin acting via the CCK-2 receptor on endothelial cells up-regulates VEGF-
R2 expression, which leads to an increase in XIAP and an overall increase in 
angiogenesis. 
 
Another mediator of apoptosis, which may also be a downstream target of gastrin, is 
Bcl-2, an anti-apoptotic member of the Bcl-2 family.  In the large intestine high 
gastrin expression has been linked to increased Bcl-2 expression (Mao, Wu et al. 
2005).  In this work no correlations were seen between CCK-2 receptor protein 
expression or endothelial cell localisation and Bcl-2, but a significant decrease in Bcl-
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2 protein expression was seen in pancreatic cancer compared to normal pancreas.  
There was also higher Bcl-2 protein expression in well differentiated cancer samples 
compared to poorly differentiated. 
 
The results relating to Bcl-2 expression in this work are in agreement with work 
published by Campani et al (Campani, Esposito et al. 2001) who showed lower levels 
of Bcl-2 protein expression in pancreatic cancer compared to normal pancreas, with 
25% of cancers showing high expression.  They also showed that expression was 
higher in well differentiated tumours compared to poorly differentiated.  Other work 
has also shown that Bcl-2 protein expression is absent from pancreatic cancer tissue 
with higher expression in the normal pancreas (Evans, Cornford et al. 2001). 
 
Pancreatic carcinomas, which express high levels of Bcl-2 have been linked to better 
overall survival (Sinicrope, Evans et al. 1996) and cells with a high Bcl-2 protein 
content are more susceptible to gemcitabine cytotoxicity.  However, it is unclear 
whether gemcitabine exposure increases levels of Bcl-2 protein expression (Bold, 
Chandra et al. 1999).  Furthermore, there is evidence to suggest that it’s the 
relationship between Bcl-2 and pro-apoptotic member of the BCL-2 family, Bax, 
which is important and not Bcl-2 on its own.  Combined high levels of Bcl-2 and Bax 
have been linked to improved survival and proposed as strong prognostic markers in 
pancreatic cancer patients that have undergone marginal resection (Magistrelli, 
Coppola et al. 2006).  For this reason in future work it maybe prudent to measure Bax 
expression along side Bcl-2. 
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In pancreatic cancer tissue CCK-2 receptor protein expression significantly positively 
correlated with tumour recurrence following surgical resection, as did CCK-2 receptor 
protein localisation in endothelial cells.  Added to this there was a significant negative 
correlation in pancreatic cancer samples between survival and both CCK-2R protein 
expression and CCK-2R localisation in endothelial cells.  There is currently no other 
data available on the link between CCK-2 receptor over-expression and cancer 
recurrence and survival in pancreatic cancer.  These results therefore indicate that 
CCK-2 receptor expression could be a marker for recurrence and reduced survival in 
pancreatic cancer.  This is supported by work in gastric cancer, which has shown that 
gastrin producing tumour cells in intestinal type gastric cancer have been linked to 
cancer recurrence (Stephens, Hopper et al. 2007). 
 
In summary CCK-2R protein expression and CCK-2R localisation on endothelial cells 
was significantly elevated in pancreatic cancer compared to normal pancreas.  CCK-
2R protein expression significantly positively correlated with XIAP protein 
expression, as well as cancer recurrence. 
  118
 
 
 
 
Chapter 5 
 
Helicobacter infection 
and therapeutic 
intervention studies in 
the INS-GAS mouse 
model 
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5.1 The INS-GAS mouse as a gastric cancer model of infection and therapeutic 
intervention 
 
 
Fig.5.1 Example of an INS-GAS mouse
 
 
The transgenic INS-GAS mouse (fig. 5.1), which over-expresses amidated gastrin, 
was developed to investigate the importance of gastrin secretion in gastric 
carcinogenesis.  The INS-GAS mouse contains a gastrin transgene, made up of an 
insulin promoter upstream of the human gastrin coding sequence, resulting in an over 
expression of gastrin in the pancreatic β-cells and elevated (around 150pM) serum 
levels of human amidated gastrin.  INS-GAS mice show hyperplasia of the gastric 
mucosa associated with significant increases in the levels of both transforming growth 
factor α (TGF-α) and heparin binding epidermal growth factor (HB-EGF).  From 5 
months onwards initial hyperacidity is replaced with hypoacidity accompanied by a 
steady decline in parietal cells.  By 20 months there is a marked gastric hypertrophy 
due to foveolar hyperplasia, with invasive carcinomas seen in the gastric fundus.  
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Although INS-GAS mice develop atrophy followed by the onset of gastric cancer the 
process is relatively slow requiring nearly the entire lifetime of the mouse, suggesting 
that other cofactors and/or genetic events are needed.  Neoplastic progression appears 
to progress through the intermediate stages of intestinal metaplasia, dysplasia, 
carcinoma in situ and invasive cancer, similar to that seen in human gastric 
carcinogenesis(Correa 1992).   
 
Wang et al (Wang, Dangler et al. 2000) showed that infection with Helicobacter 
resulted in the rapid (~ 6 month) onset of atrophy and gastric cancer, and in the study 
more than half of the infected INS-GAS mice developed invasive carcinoma.  Some 
degree of atrophy was observed in Helicobacter infected FVB/N wild-type mice in 
the absence of any increase in plasma gastrin levels, but this was less than the atrophy 
seen with hypergastrinemia in the absence of infection. 
 
Comparison of the INS-GAS mouse with the MTI/G-gly mouse, a transgenic model, 
which over-expresses the glycine extended form of gastrin (G-gly), and with a double 
transgenic mouse obtained by crossing the two lines of mutant mice to give an INS-
GAS/G-gly mouse, which over-expresses both the amidated and the glycine extended 
forms of gastrin, has shown that G-gly synergises with amidated gastrin to stimulate 
acid secretion and inhibit parietal cell loss (Cui, Koh et al. 2004). 
 
Infection of INS-GAS mice with H. pylori and H. felis has been shown to be gender 
specific with gastric cancer developing more readily in males than females, which 
appears consistent with the greater incidence of gastric carcinoma in men (Fox, 
Rogers et al. 2003; Cui, Koh et al. 2004). 
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5.2 G17-diptheria toxoid (G17DT) 
 
G17DT is an anti-gastrin vaccine that neutralises G17 and gly-G17 hormones, which 
as discussed in section 1.6.2 are implicated in a number of GI cancers.  G17DT is 
comprised of nine N-terminal amino acids of G17; that are attached by spacer peptides 
to a diphtheria toxiod (DT), a large carrier protein (fig. 5.2).  G17DT is administered 
in a liquid suspension and elicits an immune response resulting in the production of 
antibodies, which cross react with and neutralise the target hormones G17 and gly-
G17 preventing them from stimulating cells (2003). 
 
N-Terminal End
GASTRIN
N-Terminal End  
GASTRINDT
PEPTIDE 
SPACER
PEPTIDE 
SPACER
Fig 5.2 Diagrammatic representation of G17DT immunogen
 
 
In a phase II study of G17DT in gastric carcinoma 85% of patients achieved an 
antibody response of greater than 3 units with a median of 15.25 units at 12 weeks; 
this fell to a median of 1.0 unit prior to booster injections and increased to a median 
response of 7.7 four to five weeks post booster (Gilliam, Watson et al. 2004).  In a 
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phase II study of patients with advanced pancreatic cancer given 250µg dose of 
G17DT 50% achieved antibody titres after 4 weeks and 72% by 6 weeks with peak 
antibody titre occurring at 8 weeks, titres then dropped at varying rates over the 
following weeks (Brett, Smith et al. 2002). 
 
 
5.2.1 The effect of G17DT on cancer progression in INS-GAS mice  
 
It was hypothesised that by immunising INS-GAS mice with the anti-gastrin 
immunogen G17DT, which binds to and neutralises G17 and gly-G17, that cancer 
progression could be slowed or even prevented in this model. 
 
A B C
D E F
Fig 5.3  H and E stained sections of INS-GAS fundus from DT treated groups at 10, 
20 and 30wks (A-C) and G17DT treated groups at 10, 20 and 30wks (D-F).
 
 
Fig. 5.3 shows the progression of the normal murine fundic mucosa from an organised 
structure made up of isthmus (gastric pit) containing the mucus cells, neck region 
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containing the parietal cells and the base containing the chief cells (A and D), to 
disorganised foveolar hyperplasia (C).  These changes are more marked in the DT 
treated group, with a loss of parietal cells in the neck region at 20weeks (B) and a 
thickening of mucosal surface as a result at 30weeks (C).  There is an increase in 
inflammatory cells at 20wks (E) in the G17DT group, followed by some thickening of 
the muscosa at 30weeks (F), but there is no loss of parietal cells in the neck region or 
gastric hypertrophy characterised by the thickened gastric folds seen in the DT treated 
group. 
 
 
Proliferation 
 
Over-proliferation of cells in the gastric mucosa is linked to gastric cancer progression 
and therefore a key area to investigate in order to assess the chemoprophylaxis 
potential of G17DT.  Glands in the fundus and antrum were analysed separately to 
give BrdU labelling indices for both. 
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Levels of Proliferation in the Fundus of InsGas Mice 
Treated with G17DT
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Fig 5.4  Comparison of the levels of proliferation at different time points when INS-
GAS mice were treated with G17DT compared to DT vehicle in the fundus (A) and 
antrum (B).  Mean results for 5 animals per group are shown along with standard 
error bars.  * p<0.05 using one way ANOVA.
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Fig 5.5 Examples of BrdU staining of fundic glands in 30 week old INS-GAS mice 
treated with DT (A) and G17DT (B).
A B
 
 
In the DT-treated group the BrdU labelling index remains around 2.5 for the length of 
the study in both the fundus and the antrum, with a slight dip at 20 weeks in the 
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fundus.  In comparison the BrdU labelling index for the G17DT treated group is 
consistently lower at around 1.0.  In the fundus at 30 weeks the level of proliferation 
is a significant 2.5-fold (p<0.05) lower in the G17DT treated group than the DT 
treated group (fig 5.4); this is at the point when hyperplasia starts to develop in the DT 
treated group (fig 5.3). 
 
Fig 5.5 visually compares the level of staining of proliferating cells in the fundus of 
INS-GAS mice treated with G17DT relative to that in mice treated with DT and it is 
clear that there are fewer stained cells in the G17DT treated mouse, indicating less 
proliferation.  Also of note is the location of these proliferating cells.  In the G17DT 
treated mouse they are in the mid-region of the gland, which is normal; however, in 
the DT-treated mouse some proliferating cells can be seen slightly lower than the mid-
region, which is considered abnormal and a possible indicator of an early step in the 
cancer carcinogenesis sequence.   
 
Due to there being a significant decrease in the level of proliferation in the fundus of 
in the 30 week old mice treated with G17DT, it was decided to further analyse the 
epithelial cell proliferation in this group by examining proliferation in pre-cancerous 
lesions as well as normal glands.  Fig. 5.6 shows that in both the normal glands and 
pre-cancerous lesions G17DT treatment resulted in significantly reduced proliferation 
of 3.9% in the normal glands and 7.6% in the pre-cancerous lesions (p<0.005 and 
p<0.002 respectively) compared to the DT control group. 
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Fig. 5.6 Comparison of levels of proliferation in the fundus of 30 week old  INS-GAS 
mice treated with G17DT or DT in normal glands and pre-cancerous lesions.  Mean 
results for 5 animals per group are shown with standard error bars.  
* p<0.005, **p<0.002 using a one way ANOVA.
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Blood Vessel Density (BVD) 
 
Angiogenesis is necessary for cancer progression because tumours require a good 
blood supply to continue to grow (Rmali, Puntis et al. 2007).  As a measure of 
angiogenesis, sections were stained with CD34, an antibody, which stains new blood 
vessels.  The number of events per view was manually counted in 10 hotspots 
throughout the fundus of the section to give a mean BVD per section.  BVD was used 
as a measure of angiogenesis, with a decrease in BVD being representative of reduced 
angiogenesis. 
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Fig. 5.7  Comparison of Blood Vessel Density (BVD) in the fundus of INS-GAS 
mice treated with either G17DT or  DT.  Mean results for 5 animals per group are 
shown along with standard error bars.  * p<0.01 using a one way ANOVA.
*
 
 
Fig 5.8 Example of CD34 staining blood vessels (arrows) in INS-GAS mice treated 
with DT (A) and G17DT (B).
A B
 
 
Fig. 5.7 shows that there was a trend to a reduction in BVD, although not significant, 
in both the 10 and 20 week old INS-GAS mice treated with G17DT compared to DT.  
However in the 30 week old INS-GAS mice treated with G17DT there was a 
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significant 4.1 fold (p<0.01) reduction in BVD compared to DT.  In the DT treated 
mice there tended to be numerous blood vessels between the glands compared to the 
DT treated mice where blood vessels were mainly in the submucosa (Fig 5.8).  This 
suggests that immunisation with G17DT may reduce angiogenesis in this model. 
 
 
COX-2 protein expression 
 
COX-2 has been shown to be associated with tumour development and progression 
(Sinicrope and Gill 2004).  Increased COX-2 expression has also been linked to 
increased levels of gastrin (Guo, Cheng et al. 2002; Konturek, Kania et al. 2003).  
Therefore, by lowering gastrin levels with G17DT treatment it was hypothesised that 
an effect on COX-2 levels might be observed.  Sections were stained for COX-2 and 
10 hotspots within the fundus analysed using the QWin software to give a mean H-
score per section.   
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Fig. 5.9 comparison of COX-2 protein expression in the fundus of INS-GAS mice 
treated with G17DT or DT.  Mean results for 5 animals per group are shown along 
with standard error bars.  * p<0.001 using a one way ANOVA.
*
 
 
Fig. 5.10  Representative COX-2 staining in the fundus of 10 week old 
INS-GAS mice treated with DT (A) and G17DT (B), and 30 week old INS-
GAS mice treated with DT (C) and G17DT (D).
A B
C D
 
 
Fig. 5.9 shows that at weeks 10 and 20 in the DT group the levels of COX-2 protein 
expression remain low with a sharp 4 fold increase at 30 weeks.  In comparison the 
levels of COX-2 protein expression in the G17DT treated group are maintained at a 
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low level even at 30 weeks, resulting in significantly lower expression than that of the 
DT treated group at the 30 week time point.  Fig 5.10A and B shows that at 10wks the 
level of staining is comparable between the DT and G17DT treated groups with the 
most intense staining in the pit.  At 30 weeks fig. 5.10C and D clearly show that there 
is prominent staining of the superficial interstitial cells and co-localisation with 
epithelial cells compared to lower levels of superficial interstitial cell staining and co-
localised epithelial cell staining in the G17DT treated  
 
 
5.2.3 Discussion 
 
Gastrin has been shown to stimulate the in vitro growth of the gastric cell line AGS 
(Szabo, Rumi et al. 2000).  Specific inhibition of the gastrin gene with small 
interfering RNA (siRNA) has been shown to cause a reduction in cell survival in 
representative cell lines of gastric, colorectal and pancreatic adenocarcinoma 
(Grabowska, Hughes et al. 2007).  Therefore, it was hypothesised that neutralisation 
of G17 and gly-G17 with the immunogen G17DT may slow or prevent cancer 
progression in mouse models of gastric. 
 
Immunisation of INS-GAS mice with G17DT resulted in significant decreases in 
proliferation of both the normal gastric glands and pre-cancerous lesions.  This further 
confirms the role of gastrin as a stimulator of proliferation in gastric cancer models 
and highlights the potential therapeutic role of G17DT. 
 
Angiogenesis, the formation of new blood vessels, is a key stage in the progression of 
all cancers.  G17 and gly-G17 have been shown to stimulate angiogenesis in HUVECs 
  131
to the same extent as VEGF through isoforms of the CCK-2 receptor and these pro-
angiogenic effects are thought in part to be mediated by HB-EGF gene expression 
(Clarke, Dickson et al. 2006).  In the fundus of the INS-GAS mouse G17DT 
significantly reduced BVD.  Therefore, G17DTs’ ability to reduce BVD compared to 
DT alone is further evidence of G17 and gly-G17s role in the angiogenic process of 
gastric cancer progression and that this may be true for other GI cancers. 
 
G17DT maintained low COX-2 protein expression levels expected in the normal 
gastric mucosa through out the time course of the study compared to the DT treated 
group, which showed a rapid increase of COX-2 protein expression at 30 weeks.  This 
sudden increase of COX-2 protein expression at 30 weeks in the DT treated group 
may be in response to inflammation and gastric mucosal damage caused by 
hypergastrinemia, demonstrating that G17DT immunisation may be protective against 
inflammation and mucosal damage in the stomach. 
 
In human gastric cancer specimens COX-2 has been shown to positively correlate 
with angiogenesis and tumour metastasis to lymph nodes (Murata, Kawano et al. 
1999; Mao, Wang et al. 2007).  This would suggest that the reduction in BVD seen in 
the G17DT treated INS-GAS mice may be mediated through a reduction in COX-2.  
However, immunohistochemistry showed that COX-2 protein was expressed in a 
number of cell types not just ECL and parietal, which express the CCK-2 receptor, 
indicating that gastrin may also indirectly up-regulate COX-2 in the gastric mucosa. 
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5.3 The effect of COX inhibition on cancer progression in the INS-GAS mouse 
model 
 
There are data to suggest that chronic use of general COX inhibitors like aspirin and 
specific COX-2 inhibitors like rofecoxib may reduce the risk of GI cancers, including 
gastric cancer (Jiang and Wong 2003; Leung, Ng et al. 2006).  Therefore, it was 
hypothesised that treating INS-GAS mice with aspirin or celecoxib may slow or 
prevent cancer progression, by reducing proliferation and angiogenesis. 
 
 
5.3.1 Proliferation 
 
As explained in section 5.1.2.1 BrdU was used to stain proliferating cells and then the 
number of proliferating cells per gland assessed. 
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Fig. 5.11  The effect of COX inhibition on proliferation in the fundus of INS-GAS 
mice.  Mean results for 5 animals per group shown with standard error bars.
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Fig. 5.12  Example of proliferating cells stained with BrdU from the fundus of an 
INS-GAS mouse
 
 
Fig.5.11 shows that although both aspirin and celecoxib reduced proliferation in the 
fundus compared to placebo this reduction was not significant.  Fig. 5.12 shows 
staining of proliferating cells in the fundus region of the stomach.  The expected 
region of proliferation in the fundic gland is the mid-region and as can been seen in 
fig. 5.12 some proliferating cells are present towards the base of the gland, due to the 
hyperproliferative state of the INS-GAS fundus as a result of hypergastrinimia, this 
was the case in both the placebo and the aspirin and celecoxib treated groups. 
 
 
5.3.2 Blood vessel density 
 
As previously described in section 5.1.2.2 CD34 staining was used to assess blood 
vessel density as a measure of angiogenesis. 
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Fig. 5.13  The effect of COX inhibition on angiogenesis in the fundus of 
INS-GAS mice. Mean results for 5 animals per group shown with 
standard error bars.  
 
 
Fig. 5.14  Example of CD34 staining of blood vessels in the fundus of an INS-
GAS mouse (A).  Example of negative (B)
A B
 
 
Both aspirin and celecoxib reduced blood vessel density in the fundus of INS-GAS 
mice, but it was not significant (fig. 5.13).  An example of the type of blood vessel 
staining seen with CD34 is shown in fig 5.14; the blood vessels are present between 
the gastric glands. 
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5.3.3 Discussion 
 
In the INS-GAS model, neither aspirin nor celecoxib had an effect on proliferation 
and although blood vessel density was reduced by both agents, neither did so 
significantly.  These results support the theory that it is G17 that is driving the 
increase in COX-2 seen in this model and that in a hypergastrinemic environment 
G17DT immunisation is more successful in reducing the effects of COX-2 over-
expression than the COX inhibitors, aspirin and celecoxib. 
 
 
5.1.1 Study to determine the effect of H. felis in INS-GAS mouse model (short 
term) 
 
Mice were given either 1 x 10
8
 cfu/ml of the relevant strain of bacteria in brucella 
broth or an equivalent volume of brucella broth as described in section 2.7 on days 1, 
3 and 5 of the study.  Mice were terminated after 4 weeks and their stomachs removed 
and sectioned (section 2.5.1).  H. felis (ATCC49179), which has no cag pathogenicity 
island (Viala, Chaput et al. 2004) and has been well-documented as an accelerant in 
cancer progression in INS-GAS mice (Wang, Dangler et al. 2000) was the strain used. 
 
 
Gastric unit length 
 
Image analysis software was used to measure gastric unit length as a crude assessment 
of proliferation. 
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Fig. 5.15 The effect of H. felis infection on gastric unit length in 4wk old 
INS-GAS mice compared to placebo.  Mean results for 5 animals per 
group are shown along with standard error bars.
 
 
Fig. 5.15 shows that infection of INS-GAS mice with H. felis resulted in a 1.7-fold 
increase in gastric unit length compared to placebo. 
 
 
Serum gastrin levels 
 
Wang et al (Wang, Dangler et al. 2000) showed that hypergastrinemic mice (INS-
GAS) have increased parietal cell number and acid secretion up to approximately 4 
months.  Thereafter, both parietal cell number and acid secretion gradually decrease 
and there is an increase in expression of transforming growth factor-α (TGF−α) and a 
progression towards gastric cancer.  This sequence of events is exacerbated by 
Helicobacter infection. 
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Fig. 5.16. Comparison of serum gastrin (G17) levels in FVB mice and 4 week 
old INS-GAS mice infected with either placebo or H. felis. Mean results for 5 
animals per group are shown along with standard error bars. *p<0.005 using a 
one way ANOVA.
^ Data from thesis by Mo El-Zaatari 2008
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Serum gastrin levels were measured in the FVB (the background for INS-GAS mice) 
and INS-GAS mice either infected with H. felis or placebo.  Infection resulted in a 
significant (p<0.05) increase in serum gastrin levels in INS-GAS mice compared to 
FVB, and there was an increase although not significant between the infected INS-
GAS and the placebo. this may be because this model already has elevated serum 
gastrin (Fig. 5.16). 
 
 
5.1.2 Long term infection with H. felis 
 
Based on the results obtained in section 5.1.1, a long term 9 month study was set up 
using H. felis to infect INS-GAS mice. 
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Due to work previously published (Wang, Dangler et al. 2000) it was decided to 
concentrate on analysis in the fundus region of the stomach as lesions have only been 
shown there and not in the antrum. 
 
Pit
Sub mucosa
Isthmus
Neck
Fundus
Fig. 5.17 H and E staining of the fundic region of a normal (FVB) 
mouse.
 
 
Fig. 5.18 H and E staining showing examples of the fundus from 9 month old INS-
GAS mice (A and B) and the fundus from INS-GAS mice infected with H.felis (C 
and D).
A B
C D
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The fundic region of a normal (FVB) mouse stomach is comprised of organised 
fundic (gastric) glands.  The fundic glands are simple, branched, tubular glands that 
extend from the bottom of the gastric pit to the muscularis mucosa.  In a normal 
stomach the glands are of a uniform length (fig 5.17).  However, hypergastrinemia 
causes fundic hypertrophy with thickened folds (fig. 5.18A and B arrow) and loss of 
parietal cells in the upper two thirds of the gland.  Infection with Helicobacter species 
such as H. felis in the INS-GAS mouse causes increased disruption to the glands 
resulting in irregular tubules and lesions (microacini formation) (fig. 5.18C and D 
arrow), and inflammatory infiltrate (fig. 5.18C open arrow). 
 
 
Proliferation 
 
In order to assess cellular proliferation, 1 hour before termination mice were given 
BrdU by intravenous injection.  BrdU is taken up by cells, which are in the S-phase of 
mitosis, and gives a snap-shot of the number of proliferating cells at termination 
(Boswald, Harasim et al. 1990).  Immunohistochemistry with a specific BrdU 
antibody was then used to visualise the cells, which had taken up the BrdU.  For each 
field of view the number of cells per gland and the number of stained cells in each 
gland were counted, in order to calculate a percentage of stained cells per gland.  For 
each section up to 10 fields of view were analysed dependent on sample size and the 
mean value taken.  The same was done for pre-cancerous lesions.  These reading were 
then reported as the BrdU labelling index i.e. the mean percentage of proliferating 
cells per gland/lesion, data is summarised in fig 5.19.   
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Fig. 5.19.  The effect of H. felis infection on proliferation.  Fig. A shows the 
effect of H. felis infection on the proliferation of the gastric glands in INS-GAS 
mice compared to uninfected INS-GAS mice and FVB mice.  Fig. B shows the 
effect of H. felis infection in INS-GAS mice compared to uninfected INS-GAS 
mice in the normal gastric gland and in pre-cancerous lesions.  Mean results 
for 5 animals per group are shown along with standard error bars.  *p<0.05, 
**p<0.001, ***p<0.001 using a one-way ANOVA.
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A. Pre-cancerous lesion in an 
uninfected INS-GAS mouse (x20)
B. Pre-cancerous lesion in an H. felis
infected INS-GAS mouse (x20)
C. Pre-cancerous lesions in an H. felis
infected INS-GAS mouse (x10)
Fig 5.20  Proliferation in pre-cancerous lesions of 9 month old INS-GAS mice with 
and without H. felis infection.  
 
Fig. 5.19A shows that, compared to Friend virus B-type (FVB) mice, INS-GAS mice 
have a significantly higher BrdU index in the normal gastric gland (p<0.05) equating 
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to greater proliferation.  Proliferation is further increased in the INS-GAS model 
compared to the FVB model by infection with H. felis (p<0.001).  There is also an 
increase, although not significant, in proliferation of H. felis infected INS-GAS mice 
compared to uninfected INS-GAS mice.  Infection of INS-GAS mice with H. felis 
also resulted in a significant increase in proliferation in pre-cancerous lesions 
(p<0.001).  Fig 5.20 shows that the proliferating cells are mainly confined to the pre-
cancerous lesions of H. pylori infected and uninfected INS-GAS mice, with a greater 
number of proliferating cells comprising the lesions of H. pylori infected mice.  The 
pre-cancerous lesions are recognisable by their lack of glandular structure and the 
increased size of the cell nuclei. 
 
 
Apoptosis 
 
An antibody to Bcl-2 was used as a marker of apoptosis.  The Bcl-2 protein prolongs 
cell survival and is therefore considered to be a suppressor of apoptosis.  There is 
evidence to suggest that Bcl-2 is up-regulated in gastric pre-malignant lesions and 
down-regulated after malignant change (Anagnostopoulos, Stefanou et al. 2005). 
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Fig. 5.21  Bcl-2 staining in the normal glands and close to the pre-cancerous 
lesions in the infected mice compared to uninfected. Mean results for 5 animals per 
group are shown along with standard error bars.  *p<0.01, **p<0.05, using a one-
way ANOVA. 
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A. H. felis infected INS-GAS 
mouse stomach
B.  Uninfected INS-GAS 
mouse stomach
Fig. 5.22 Bcl-2 staining in the normal gastric glands and the interstitial tissue of 
pre-cancerous lesions in INS-GAS mice either infected with H. felis (A) or 
uninfected (B).
 
 
Results are summarised in fig 5.21 and show that in both the normal gastric glands 
and in the interstitial tissue surrounding the precancerous lesions, infection with H. 
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felis resulted in an increase of Bcl-2 staining correlating to a significant reduction in 
apoptosis compared to uninfected controls (p<0.05).  This fits with the increased 
proliferation shown in the precancerous lesions of infected mice in fig. 5.6, because if 
cells are proliferating then they will not be undergoing apoptosis.  No staining was 
observed within the pre-malignant lesions but staining was present in the interstitial 
tissue, comprising of stromal and inflammatory cells, next to the lesions (fig. 5.22A).   
 
 
5.1.3 Discussion 
 
There are few examples of spontaneous gastric adenocarcinomas in rodents.  For these 
reasons a number of chemical carcinogens have been used to induce carcinogenesis 
including; polycyclic aromatic hydrocarbons and N-nitroso (Pritchard and Przemeck 
2004). 
 
With the WHOs classification of H. pylori as a gastric carcinogen in 1994 a number 
of animal models were set up to investigate this phenomenon.  Studies in Mongolian 
gerbils showed the induction of gastric carcinoma in the absence of other stimuli 
(Hirayama, Takagi et al. 1996; Watanabe, Tada et al. 1998), but in mice there were 
mixed results with best infection rates seen with H. pylori Sydney Strain1 (SS1) 
which does not initiate a strong immune response and H. felis which does not infect 
humans (Court, Robinson et al. 2002). 
 
In this work I have confirmed these findings showing short term infection with H. 
felis causes increased gastric unit length and serum gastrin levels in INS-GAS mice 
compared to uninfected controls and that longer term H. felis infection results in a 
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significant increase in proliferation and decrease in apoptosis in pre-malignant lesions 
of INS-GAS mice. 
  145
 
 
 
 
Chapter 6 
 
Therapeutic 
intervention in the 
ApcMin/+ mouse model 
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6.0 The Apc
Min/+
 mouse as a model of therapeutic intervention in intestinal cancer 
progression 
 
Due to rodents, such as rats, having almost no spontaneous colon cancer, a number of 
rat models have been developed whereby rats are given carcinogens to promote colon 
tumours.  The most commonly used carcinogens are dimethylhydraize derivatives.  
Dimethylhydraize is metabolised to azoxymethane (AOM) and methylazoxymethanol 
in rats, which induces tumours that share many histopathological characteristics of 
human tumours (Corpet and Pierre 2003).  Shared characteristics include; mutated K-
ras and β-catenin genes (Dashwood, Suzui et al. 1998).  They also show 
microsatellite instability, but unlike human tumours they rarely have a mutated Apc 
gene and never p53 mutations (De Filippo, Caderni et al. 1998) added to this they 
have a low tendency to metastasize.  Other colon carcinogens used in rat models 
include specific nitrosamines and hetercyclic amines, such as 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine (PhIP), which induce Apc mutations and microsatellite 
instability (Canzian, Ushijima et al. 1994), but no K-ras or p53 mutations (Kakiuchi, 
Ushijima et al. 1993) (Makino, Ushijima et al. 1994).  However, AOM is favoured as 
it is the least expensive, most potent and easiest to use.  In a carcinogen induced 
tumour model the chemopreventative agent can be given prior to carcinogen exposure 
and during the initiation phase or, during the promotion-progression phase or through 
both phases.  The main end point in most rat studies is development of colon tumours 
(Corpet and Pierre 2003). 
 
In 1992 a mutant mouse, Min, was shown to have multiple intestinal neoplasia 
(Moser, Pitot et al. 1990).  This mouse was subsequently shown to have a mutated 
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Apc gene, similar to that seen in patients with FAP and many forms of sporadic 
cancers.  This model was seen as promising due to its mimicry of the rapid 
development of adenomatous polyps that affect humans with the germline inactivation 
of one Apc gene (Corpet and Pierre 2003).  However, unlike humans the Min model 
seldom shows signs of adenocarcinomas, and no typical aberrant crypts foci (ACF) 
arise from the intestinal mucosa and therefore the ACF to carcinoma progression is 
not established.  Another difference is that K-ras mutations are not observed in Min 
mouse polyps, whereas they are in many human tumours (Shoemaker, Luongo et al. 
1997), and p53 inactivation, which is frequent in human cancers do not increase 
tumour burden in Min mice (Fazeli, Steen et al. 1997). 
 
The Min mouse model is favoured over the AOM rat model as a way of evaluating the 
effects of chemoprevention and diet as it avoids carcinogen handling and has a shorter 
assay time; however, it is more expensive.  Treatments are typically given at 4-5 
weeks of age when tumours may already be present; the timing mimics that of clinical 
intervention trials.  The major drawback of the Min model as a model of human colon 
cancer is that their tumours occur predominately in the small intestine not the colon 
(Corpet and Pierre 2003). 
 
The Apc
Min/+
 mouse is one of the most commonly used mouse models for 
investigating intestinal tumorigenesis.  Adenomatous Polyposis Coli (APC) is classed 
as a tumour suppressor gene due to its ability to regulate the cellular levels of the 
protooncogene β-catenin.  Other functions of the APC gene are thought to include, 
microtubule dynamics, cell cycle control, cell adhesion and chromosomal stability.  
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The mouse APC protein exhibits 90% amino acid homology to that of the human 
APC protein. 
 
There are several variations of the Apc
min/+ 
mouse model; each has different truncating 
mutations of the APC gene.  The variation used for this work was a fully penetrant 
dominant mutation induced in a C57BL/6J mouse by ethylnitrosourea, which causes a 
base substitution mutation in the Apc gene, which creates a stop codon truncating the 
polypeptide at J:830.  These mice develop multiple polyps in their small intestine and 
some in their large intestine; these polyps bleed, which is exhibited as anaemia 
resulting in pale feet and snout areas (fig 6.1) at the end point of the study. 
 
Fig. 6.1  Example of an Apcmin mouse with pale snout and feet and a normal 
C57/B1 mouse with pink snout and feet (A).  Small intestine of a Apcmin mouse 
with multiple polyps (B).
A B
Pale snout 
and feet
Normal C57/B1 
mouse
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Fig.6.2 H and E sections showing the progression from normal large intestine  
through polyp development to adenoma in APCmin mice (A-D represent mice at 
4, 8, 12 and 16wks respectively). 
A B
C D
 
 
The normal large intestine is made up of straight tubular glands termed crypts of 
Liebrakuhn, which extend down from the lumenal surface to the muscularis mucosa.  
The crypts are comprised of simple columnar absorptive cells, mucus secreting goblet 
cells, stem cells at the base and endocrine cells (fig 6.2.A).  Mutation in the Apc gene 
causes hyperproliferation in the crypts, which is the first step in the development of 
polyps, with the loss of uniform structure (fig 6.2. B and C).  Fig. 6.2C shows a large 
lymphoid follicle an indictor of an immune response.  Finally, polyps can further 
progress to adenomatous polyps with greater loss of structure and reduced cytoplasm 
within the epithelial cells (fig 6.2.D). 
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6.1 The effect of G17DT on cancer progression in Apc
Min/+
 mice 
 
It was hypothesised that by immunising Apc
Min/+
 mice with the anti-gastrin 
immunogen G17DT, which binds to and neutralises G17 and gly-G17, that cancer 
progression could be slowed or even prevented in this model. 
 
 
6.1.1 Proliferation 
 
Proliferation was measured using BrdU as previously described in section 5.1.1.1.  
For each field of view the numbers of stained cells and the total number of cells were 
counted per crypt and the percentage of stained cells per crypt calculated.  Also in the 
polyps the percentage of stained cells were calculated. 
 
Fig. 6.3 Comparison of the levels of proliferation in the crypts of the large (A) and 
small (B) intestine of Apcmin mice when treated with G17DT.  Mean results for 5 
animals per group are shown along with standard error bars.  *p<0.005 using a one 
way ANOVA.
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Fig 6.4 Example of BrdU stained proliferating cells in colonic crypts of APCmin
mice treated with DT (A) and G17DT (B).
A B
 
 
In the crypts of the large intestine (Fig. 6.3A) the proliferation in the DT treated group 
remained fairly constant from 8-16 weeks with a decrease in the proliferation of the 
G17DT group at 12 weeks (0.5 fold) and a significant decrease at 16 weeks (3 fold 
p<0.005).  Fig. 6.3B shows that there was a decrease in proliferation in the crypts of 
the small intestine of the G17DT treated groups at all time points compared to DT 
groups.  Although there was not a significant difference between the groups at 
individual time points, when the data was considered as a set there was a significant 
decrease in the G17DT group compared to the DT over time (p<0.001 using 2-way 
ANOVA).  Fig. 6.4 shows there were less BrdU labelled cells in the DT-treated 
sample compared to the G17DT treated and that in the DT treated sample there were 
proliferating cells above the bottom third of the crypt, the area were proliferation is 
normally observed. 
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Effect of G17DT Treatment Compared to DT Over 
Time on the Proliferation of Polyps in the Small 
Intestine of APCmin Mice
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Fig. 6.5 Comparison of the levels of proliferation in the polyps of the large (A) and 
small (B) intestine of Apcmin mice when treated with G17DT.  Mean results for 5 
animals per group are shown along with standard error bars.  There were no polyps 
present at 4wks in the large intestine. *p<0.005 using one way ANOVA.
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A B
C
Fig 6.6  Examples of proliferating cells stained with BrdU in polyps in the large 
intestine of 16 week old APCmin mice treated with DT (A and B) and G17DT (C).
 
 
At 4 weeks there were no polyps in the large intestine of either group.  As shown in 
fig 6.5A at 8 and 12weeks the level of proliferation in the polyps was similar in the 
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G17DT compared to the DT, and then at 16 weeks there was an increase in 
proliferation in the DT group, but proliferation in the G17DT group remained similar 
to that of 8 and 12 weeks.  There was a significant 5.3-fold increase (p<0.005) in 
proliferation at 16 weeks in the DT group compared to G17DT.  The polyps in the 
small intestine (Fig 6.5B) showed increased proliferation over time in both groups 
with slightly less in the G17DT groups, except at 4 weeks when proliferation was 
slightly higher in the G17DT group compared to DT.  There was no significant 
reduction in proliferation at any of the time points, but when the data was considered 
as a set there was a significant decrease in the G17DT group compared to DT over 
time (p<0.001 using 2-way ANOVA).  A visual comparison of proliferation in the 
polyps at 16 weeks is shown in fig. 6.6. 
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6.1.2 Apoptosis 
 
As described in section 5.1.2.2 Bcl-2 was used as a marker of apoptosis. 
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Fig. 6.7  The level of Bcl-2 protein expression in the large intestinal crypts and 
polyps of APCmin mice. Mean results shown for 5 animals per group along with 
standard error bars.  
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A B
C D
E F
Fig. 6.8 Examples of Bcl-2 staining in crypts of APCmin mice 
treated with DT (A) and G17DT (B) and polyps treated with DT 
(C and D) and G17DT (E and F).
 
 
In the DT treated Apc
Min/+
 mice the level of Bcl-2 staining steadily increased over the 
time course of the study in both the crypts and the polyps of the large intestine.  This 
was also the case in the polyps of G17DT treated mice, which remained slightly 
higher than in the DT treated groups.  In comparison, in the crypts the level of Bcl-2 
staining was higher in the G17DT treated mice at 4 and 12 weeks and lower at weeks 
8 and 16 (p=0.061) (fig 6.7).  In the crypts, staining was mainly in the cells close to 
the luminal surface and in the polyps stained cells tended to be present in small 
clusters, but with no clear defined position within the polyp (fig 6.8). 
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6.1.3 BVD 
 
BVD was assessed as previously described using CD34 staining.   
 
A
B
Fig. 6.9  The effect of G17DT immunisation on BVD around the crypts (A) and 
within polyps (B) of the large intestine of Apcmin. Mean results for 5 animals per 
group are shown along with standard error bars.  *p<0.001 using a one-way 
ANOVA. 
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Fig. 6.10 Examples of CD34 staining of blood vessels (arrows) in the large 
intestine of 16 week old APCmin mice. Normal crypts treated with DT (A) and 
G17DT (B) and polyps treated with DT (C) and G17DT (D).
A B
C D
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In the DT treated animals the BVD in the crypts and the polyps was around 15 at the 
first time point, increased to 30 in the crypts at the remaining time points, and to 35 in 
the polyps at weeks 8 and 12 with a decrease back to levels similar to those at week 4, 
at week 16.  G17DT significantly (p<0.001) reduced and maintained BVD at the 
initial value of 15 for the duration of the study in the crypts and when taken as a set 
there was a significant (p<0.005 using 2-way ANOVA) decrease in the G17DT group 
compared to DT.  In the polyps, G17DT significantly (p<0.001) reduced BVD 
compared to DT at weeks 8 and 12 and maintained this level at week 16, but this was 
not significant due to the reduction seen in the DT group, over time when the data was 
taken as a set there was a significant (p<0.005 using 2-way ANOVA) decrease in the 
G17DT treated groups compared to DT (summarised in fig 6.9).  Examples of blood 
vessel staining are shown in fig.6.10.  The pattern of blood vessel distribution is 
similar in both groups but there are visibly less blood vessels in the G17DT group 
compared to the DT.  In the sections of the large intestine without polyps blood 
vessels are present between the crypts and in polyps they are most dense in the central 
stalk. 
 
 
6.1.4 COX-2 protein expression 
 
Due to the results seen for proliferation and BVD in the large intestine and this being 
the area that G17DT is known to have more of an effect, it was decided to concentrate 
on the COX-2 expression in the large intestine. 
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Effect of G17DT Compared to DT Over Time on COX-2 
Protein Expression in the Crypts of the Large Intestine
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Fig. 6.11  Comparison of COX-2 protein expression in normal crypts (A) and 
polyps (B) of the large intestine of Apcmin mice treated with G17DT or DT.  Mean 
results for 5 animals are shown along with standard error bars.
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Fig 6.12 Examples of COX-staining in the large intestine of 16 week old 
APCmin mice.  Normal crypts treated with DT (A) and G17DT (B) and polyps 
treated with DT (C) and G17DT (D).
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C D
 
 
There was no significant decrease in COX-2 protein expression at any of the time 
points, in either the crypts (fig. 6.11) or polyps (fig 6.11B) of the large intestine when 
treated with G17DT compared to DT.  COX-2 staining was most intense in the pit 
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region of both the crypts and the polyps with diffuse interstitial staining; there was 
also occasional nuclear staining (see fig 6.12). 
 
 
6.1.5 Discussion 
 
Previous work within our group has shown that when hypergastrinemia was induced 
by administration of omeprazole, a protein pump inhibitor, the effects could be 
reversed with G17DT immunisation (Watson and Smith 2001).  Polyps of both the 
large and small intestine of Apc
Min/+
 mice have been shown to express the gastrin 
gene, progastrin and gly-gastrin (Watson S.A 1998).  Therefore this model offered an 
interesting environment in which to test the role of G17DT, since it inhibits gly-G17, 
and could potentially inhibit autocrine pathways established by these tumours. 
 
In contrast with gastric adenocarcinomas where G17 and G34 are linked to 
proliferation and tumour development and progastrin is expressed at low levels 
(Henwood, Clarke et al. 2001), in colorectal carcinogenesis progastrin plays a more 
active role and therefore, although G17DT neutralises gly-G17, which is important in 
colorectal cancer progression (Siddheshwar, Gray et al. 2001) its inability to affect 
progastrin can be seen as a weakness in it effectiveness for treating colorectal cancer 
progression and may explain why less significant results were obtained in the Apc
Min/+
 
model compared to the INS-GAS model. 
 
As previously discussed angiogenesis is a key process in carcinogenesis and therefore 
the ability of G17DT to significantly reduced BVD in the large intestine of the 
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Apc
Min/+
 mouse compared to DT is further evidence of G17 and gly-G17s role in the 
angiogenic process of colorectal cancer progression. 
 
Mutations in the APC gene are considered to be initiators in the colorectal 
carcinogenesis sequence, which leads to induction of COX-2 expression.  Oshima et 
al (Oshima, Dinchuk et al. 1996) showed a 86% decrease in polyp burden in Apc
Min/+
 
mice with a disrupted COX-2 gene.  Currently the molecular mechanisms, which lead 
to COX-2 over-expression in colorectal cells are not fully understood. 
 
Studies have shown that gastrin and the CCK-2 receptor are linked to increased COX-
2 levels in colon carcinoma cells (Williams, Shattuck-Brandt et al. 1999; Guo, Cheng 
et al. 2002) and hypergastrinaemia, due to H. pylori infection, has been linked to 
increased COX-2 expression in colon tissue suggesting that gastrin may regulate 
COX-2 expression in colorectal cancer.  However, in comparison with the results seen 
in the INS-GAS mice treated with G17DT no reduction in COX-2 protein expression 
was seen in the Apc
Min/+
 mice treated with G17DT compared to DT treated.  G17 has 
been shown to transactivate the COX-2 promoter through the CCK-2i4sv receptor in 
human colon cancer cell lines Colo320 and COS-7 (Huang, Ansorge et al. 2007).  A 
possible explanation for the lack of reduction of COX-2 protein expression in this 
work could be that it is progastrin that is involved in the up-regulation of COX-2 in 
colorectal cancer progression and not G17 or gly-G17 in the Apc
Min/+
 mouse model.  
This theory fits with the work by Konturek et al (Konturek, Rembiasz et al. 2006) that 
showed colorectal cancer patients exhibited significantly higher serum progastrin 
levels than healthy individuals and that this hyperprogastrinemia decreased after 
COX-2 inhibition with celecoxib treatment, also implying that it is gastrin expression 
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which is up-regulated by COX-2 and not the other way round.  There is also evidence 
that colorectal cancer cells are capable of producing and releasing large quantities of 
progastrin fragments since plasma concentrations of progastrin dramatically reduce 
when the cancer is removed but concentrations of G17 and G-34 do not (Konturek, 
Bielanski et al. 2002).   
 
Since G17DT decreased angiogenesis in the Apc
Min/+
 mouse model, but did not effect 
COX-2 protein expression, unlike in the INS-GAS mouse model, it would suggest 
that the decrease in angiogenesis may not be a direct consequence of a reduction in 
COX-2. 
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6.2  The effect of COX inhibition on cancer progression in the Apc
Min/+
 mouse 
model 
 
It was hypothesised that the use of a general COX inhibitor, such as aspirin, and a 
specific COX-2 inhibitor, such as celecoxib, could slow and even prevent 
polyp/tumour progression in this model. 
 
 
6.2.1  Polyp burden in the small and large intestine 
 
At termination the number of polyps in the small and large intestine were assessed 
using a dissecting microscope, results shown in fig. 6.13. 
 
Fig. 6.13  Comparison of polyp burden in the small and large intestine of 
APCmin mice when treated with COX inhibitors compared to placebo. 
Mean results for 5 animals per group are shown along with standard 
error bars.  *p<0.001 using one way ANOVA.
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In the small intestine there was a decrease in polyp burden in both the aspirin and 
celecoxib treated groups, with a significant reduction (p<0.001) of just over 50% in 
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the celecoxib group compared to placebo.  In the large intestine the polyp burden was 
very low and might explain why no significant reduction was observed. 
 
 
6.2.2 Proliferation 
 
Proliferation was measured using BrdU as previously described in section 3.1.1.1.  
The percentage staining was assessed to give a labelling index separately in the polyps 
and the normal intestinal tissue. 
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Fig. 6.14 The effect of treating APCmin mice with aspirin and celecoxib on 
proliferation in the intestine.  Fig. A shows the effect in the large intestine and fig. 
B in the small intestine.  Mean results for 5 animals per group are shown along 
with standard error bars.  *p<0.01, **p<0.005, ***p<0.01 using one way ANOVA.  
G17DT data taken from section 6.1.1.
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A B
Fig 6.15 BrdU staining of proliferating cells in the large intestine in APCmin
mice given placebo (x10) (A) or celecoxib (x20)(B).
 
 
In the large intestine (fig. 6.14A) there was a significant decrease in proliferation in 
the polyps in the aspirin (p<0.01) and celecoxib (p<0.005) treated groups and 
celecoxib also caused a significant (p<0.01) decrease in the proliferation of normal 
large intestinal tissue.  In the small intestine (Fig. 6.14B) there was a slight increase in 
proliferation in the polyps with both treatments and no effect was seen in the normal 
tissue.  Example of BrdU staining in the large intestine can be seen in fig 6.15. 
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6.2.3 Cox-2 protein expression 
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Fig. 6.16 The effect of Aspirin and Celecoxib on COX-2 protein expression in the 
large (A) and small (B) intestine of APCmin mice.  Mean results shown for 5 
animals per group along with standard error bars.  *p<0.001,**p<0.005, ***p<0.01, 
****p<0.01 using one way ANOVA. G17DT data taken from section 6.1.4.
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Fig. 6.17 Example of COX-2 protein staining in the large intestine of APCmin
mice treated with placebo (A) or celecoxib (B).
A B
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COX-2 protein expression was significantly reduced in both the small and large 
intestine by aspirin (p<0.001 and p<0.01 respectively) and celecoxib (p<0.005 and 
p<0.01 respectively) as illustrated in fig. 6.16.  An example of COX-2 protein staining 
in the large intestine was shown in fig. 6.17.  In both the placebo and the celecoxib 
treated mice the pattern of staining is similar, but the staining was less intense in the 
celecoxib treated mouse. 
 
 
6.2.4 Blood vessel density 
 
As previously described CD34 was used to stain and assess blood vessel density as a 
measure of angiogenesis.   
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Fig.6.18   The effect of treating APCmin mice with Aspirin and 
Celecoxib on blood vessel density in colonic crypts.  Mean results 
shown for 5 animals per group along with standard error bars.  
*p<0.001 using one way ANOVA.  G17DT data taken from section 
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A B
Fig. 6.19  Example of CD34 staining of blood vessels in the intestine of a 
APCmin mouse at x20 (A) and x40 (B).  Arrows indicate blood vessels, 
transverse vessels appear as circles and longitudinal vessels appear as 
tubes.
 
 
Blood vessel density was decreased in the small intestine by both aspirin and 
celecoxib, but not significantly.  However, the decrease in the large intestine was 
significant for both treatments (p<0.001), although not to the same extent as seen in 
the previous study with G17DT (fig. 6.18).  Fig.6.19 shows examples of blood vessel 
staining in Apc
Min/+
 mice. 
 
 
6.2.5 Discussion 
 
As in the INS-GAS mouse model we used COX inhibition in the Apc
Min/+
 model to 
further explore the relationship between COX expression and colorectal cancer 
progression using aspirin and celecoxib treatment.. 
 
In contrast to the INS-Gas model, in the Apc
Min/+
 mouse both celecoxib and aspirin 
significantly reduced proliferation in the polyps, BVD in the large intestine and COX-
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2 protein expression in the large and small intestine.  Also celecoxib reduced the 
polyp burden in the small intestine, no reduction was seen in the polyp burden of the 
large intestine but this is likely to be due to the low number of polyps that form in the 
large intestine of this model.  Aspirin also reduced proliferation in the normal crypts 
of the large intestine.   
 
COX inhibitors work by blocking the conversion of arachadonic acid to 
prostaglandins by COX enzymes, COX-1 and -2.  Although the enzymes are not used 
up during the reaction they do need replenishing after use and therefore if they are not 
used then more is not produced, which explains why COX inhibitors also causes a 
reduction in COX protein. 
 
The results achieved in the Apc
Min/+
 model with COX inhibition would further suggest 
that G17 is not significantly involved in the progression of colorectal cancer in this 
model.  Also of note is the fact that only aspirin reduced proliferation in the normal 
crypts suggesting a role for COX-1 in colorectal cancer progression since aspirin has 
been shown to be more effective at inhibiting COX-1 than COX-2 (Vane and Botting 
1998).  COX-1 and not COX-2 have been shown to be expressed in the normal crypts 
of Apc
Min/+
 mice by Chulada et al (Chulada, Thompson et al. 2000) and studies have 
indicated that COX-1 can metabolically activate procarcinogens to mutagenic 
intermediates, an activation, which can be inhibited by aspirin (Marnett 1992). 
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Chapter 7 
 
DISCUSSION 
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7.1 Gastrin as a multi modal growth factor 
 
Gastrin impacts on a number of biological functions in addition to its central role in 
acid secretion including pro-proliferative and anti-apoptotic activities. It is these 
extended functions which have led to it being investigated in the malignant setting. In 
a recent review, gastrin-mediated carcinogenic pathways were detailed (see below for 
summary diagram fig.7.1).  Included in these activities was the pro-proliferative, anti-
apoptotic and pro-angiogenic pathways that were investigated in a variety of models 
and tissue types in the present thesis. 
 
Gastrin
CCK-2 
receptor
Cell proliferation
•Cyclins
Increased invasive 
enzyme expression
•MMPs
Promotion of 
angiogenesis
•HB-EGF
•COX-2
Cell 
migration/adhesion
•FAK
•Integrin
Circumvention of 
apoptosis
•PKB/AKT
•NF-κB
Fig. 7.1 Gastrin mediated carcinogenic pathways.  Gastrin mediates gene 
expression which is associated with cell division, invasion, angiogenesis and anti-
apoptotic activity.  FAK=focal adhesion kinase.  Adapted from Watson et al 2006.
 
 
The present studies have addressed the prognostic role of gastrin and CCK-2R in 
patient specimens and examined the therapeutic role of gastrin neutralisation in 
transgenic models of GI carcinogenesis, dissecting out the role of the closely 
associated carcinogenic enzyme, COX-2. The latter is particularly timely due to the 
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side effect profile associated with a number of COX-2 inhibitors, which appeared to 
be key therapeutics as GI chemopreventative agents, particularly for neoplasia arising 
within the colon. 
 
 
7.2 Choice of models and tissue to investigate the role of gastrin in GI 
carcinogenesis 
 
(i) Model of Gastric carcinogenesis and Helicobacter interactions in this process.   
With the WHOs classification of H. pylori as a gastric carcinogen in 1994 a number 
of animal models were set up to investigate its role in carcinogenesis.  Studies in 
Mongolian gerbils showed the induction of gastric carcinoma in the absence of other 
stimuli (Hirayama, Takagi et al. 1996; Watanabe, Tada et al. 1998), but in mice there 
were mixed results with best infection rates seen with H. pylori Sydney Strain1 (SS1) 
which does not initiate a strong immune response and H. felis which does not infect 
humans (Court, Robinson et al. 2002). 
 
The Division of Pre-Clinical Oncology’s in vivo unit have a breeding colony of INS-
GAS mice which offered the opportunity to further investigate the down-stream 
pathways associated with hyper-gastrinaemic induction of neoplasia, to define the role 
of anti-gastrin therapy (G17DT) in malignant progression of this model and to also 
further determine the role of Helicobacter infection in the hypergastrinaemic 
environment. 
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In humans H. pylori infection has been shown to cause hypergastrinaemia, either by 
cytokine induced stimulation of G-cells to release gastrin or as a result of a feed-back 
loop due to parietal cell loss and hypochlorhydria (Weigert, Schaffer et al. 1996).  
Various groups have demonstrated that when this model is infected with H. felis the 
process of gastric carcinogenesis is accelerated, with infected mice showing marked 
gastric hypertrophy and invasive carcinomas of the fundus at 9 months compared to 
uninfected mice, which do not show these changes until 20 months (Fox, Rogers et al. 
2003; Fox, Wang et al. 2003).  A finding which is supported by results presented in 
this work, which showed long term infection with H. felis caused a significant 
increase in proliferation and decrease in apoptosis in INS-GAS mice compared to 
uninfected controls. 
 
(ii) Model of colon carcinogenesis 
As discussed in section 6.0 the Apc
Min/+
 mouse model is the favoured model for 
determining chemo-preventative effects in colorectal carcinogenesis and this is also a 
model that I had access to through the Division of Pre-Clinical Oncology’s in vivo 
unit.  Previous work within our group has shown that when hypergastrinemia was 
induced by administration of omeprazole, a protein pump inhibitor, the effects could 
be reversed with G17DT immunisation (Watson and Smith 2001).  Polyps of both the 
large and small intestine of Apc
Min/+
 mice have been shown to express the gastrin 
gene, progastrin and gly-gastrin (Watson S.A 1998).  Therefore this model offered an 
interesting environment in which to test the role of G17DT, since it inhibits gly-G17, 
and could potentially inhibit autocrine pathways established by these tumours. 
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(iii) Oesophageal carcinogenesis tissue 
Although there are animal models available for oesophageal cancer, such as, Wistar 
rats which have undergone surgery and exhibit gastric reflux (Kumagai, Mukaisho et 
al. 2003), I did not have access to these models through my department.  However, as 
a result of collaboration with Dr. Ragunath in Gastroenterology, Division of 
Medicine, University of Nottingham, oesophageal pinch biopsies and serum were 
obtained from patients attending an endoscopy clinic for Barrett’s oesophagus.  This 
then allowed the investigation of a number of parameters including anti-apoptotic and 
pro-angiogenic markers in relation to serum gastrin and CCK-2 receptor levels.   
 
(iv) Pancreatic cancer tissue 
As with oesophageal cancer, there are model of pancreatic cancer, such as, the 
hamster-BOP model, Syrian hamsters that have pancreatic adenocarcinomas induced 
by the injection of the carcinogen N-nitrosobis-2-oxopropylamine (Takahashi, 
Furukawa et al. 1990), but again I did not have access to this.  Instead, in 
collaboration with Mr. Dileep Lobo in GI Surgery, Division of Surgery, University of 
Nottingham, I was able to obtain human pancreatic TMA’s containing normal 
pancreas, negative lymph nodes, positive lymph nodes, pancreatitis and pancreatic 
cancer tissue for which survival data was also available.  This offered the ideal 
opportunity to evaluate a number of factors including; CCK-2 receptor expression, 
anti-apoptotic factors and COX-2 and explore correlations. 
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7.3 Gastrin isoform sensitivity through the GI tract and activation of down-
stream pathways 
 
Barrett’s, gastric and pancreatic cancer have all been linked to the amidated form of 
gastrin; in addition glycine extended gastrin is thought to play a role in Barrett’s and 
pancreatic cancer.  This contrasts with colon cancer where the main forms of gastrin 
that are involved are progastrin and glycine extended gastrin (Wang, Dangler et al. 
2000; Watson and Smith 2001; Ptak-Belowska, Pawlik et al. 2007; Beales and 
Ogunwobi 2009). 
 
(i) Barrett’s oesophagus 
High levels of CCK-2 receptor have previously been reported in Barrett’s tissue 
(Haigh, Attwood et al. 2003) and this has been confirmed in this work.  However the 
high levels of circulating serum gastrin due to PPI treatment may have contributed to 
the down regulation of the receptor seen in IM and HGD compared to CLO. 
 
This work has highlighted a role for the CCK-2 receptor in promoting angiogenesis 
through VEGF-R2, by the positive correlation between CCK-2 receptor and VEGF-
R2, although no correlation was seen with another indicator of angiogenesis, HB-
EGF, which our group has previously shown can be up-regulated by gastrin (Clarke, 
Dickson et al. 2006).  VEGF-R2 has also been linked to tumour proliferation and cell 
survival possibly by inhibiting apoptosis through the up-regulation of Bcl-2 (Masood, 
Cai et al. 2001; Liang, Brekken et al. 2006). 
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The up-regulation of Bcl-2 in the progression of Barrett’s metaplasia to dysplasia 
(Shimizu, Vallbohmer et al. 2006) has been further confirmed in this work along with 
the novel finding that XIAP is up-regulated in Barrett’s progression and in individual 
patients there were positive correlations between Bcl-2 and XIAP expression.  
Another key finding was the positive correlation between serum gastrin and XIAP, 
and positive correlations between p-Akt and both serum gastrin and CCK-2 receptor, 
further strengthen the link between gastrin and its receptor and anti-apoptotic markers, 
supporting other work carried out in our group which showed activation of Akt by 
gastrin in Barrett’s tissue (Harris, Clarke et al. 2004).  It is therefore feasible to 
hypothesise that in Barrett’s oesophagus high levels of gastrin acting through the 
CCK-2 receptor may increase VEGF-R2 expression which in turn up-regulates Bcl-2 
and XIAP. 
 
(ii) Gastric cancer 
The normal regulation of gastric acid secretion in the stomach by gastrin is achieved 
through a cellular sequence whereby gastrin released by the antral G-cells stimulates 
ECL cells to secrete histamine, which in turn stimulates parietal cells to secrete 
hydrochloric acid (Waldum, Sandvik et al. 1991).  Gastrin exerts its effects via the 
CCK-2 receptor which has been shown to be expressed on both ECL and parietal cells 
(Schmitz, Goke et al. 2001).  As previously discussed the INS-GAS mouse has 
elevated levels of serum gastrin G17, which leads to increased gastric acid secretion 
and also increased numbers of parietal and ECL cells (Wang, Dangler et al. 2000).   
 
In this model therapeutic intervention with G17DT, which neutralises G17 and gly-
G17, significantly reduced proliferation and BVD as well as suppressing COX-2 
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protein expression over time.  Other groups have shown that COX-2 positively 
correlates with angiogenesis in gastric cancer (Murata, Kawano et al. 1999; Mao, 
Wang et al. 2007).  It is therefore reasonable to hypothesise that the reduction in BVD 
seen by G17DT intervention is mediated through a reduction in COX-2. 
 
(iii) Pancreatic cancer 
This work has confirmed the finding by Caplin et al (Caplin, Savage et al. 2000) that 
the CCK-2 receptor is expressed on pancreatic cancer cells and not normal pancreatic 
cells.  A novel finding of this work was the expression of the CCK-2 receptor on 
endothelial cells and an increase in this expression in pancreatic cancer tissue 
compared to normal pancreas, along with a positive correlation between tumour 
recurrence and CCK-2 receptor expression both generally and localised to endothelial 
cells.  In gastric cancer, gastrin-producing tumour cells have been linked to cancer 
recurrence (Stephens, Hopper et al. 2007), but there is currently no other data on this 
relating to pancreatic cancer.  Also of importance was the finding that there was a 
negative correlation between CCK-2 receptor expression and survival. 
 
These negative patient outcomes linked to CCK-2 receptor expression may in part be 
mediated by XIAP expression.  In gastro-oesophageal cell lines gastrin has been 
shown to increase XIAP expression (Harris 2005) and my work has shown a positive 
correlation between CCK-2 receptor expression and XIAP.  There was also a positive 
correlation between CCK-2 receptor expression on endothelial cells and XIAP which 
may impact on angiogenesis, possibly through VEGF-R2, since VEGF has been 
linked to up-regulation of XIAP (Tran, Rak et al. 1999) and my work in Barrett’s has 
shown a correlation between VEGF-R2 and serum gastrin. 
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The other anti-apoptotic marker assessed, Bcl-2, did not show any correlation with the 
CCK-2 receptor parameters, but the levels and pattern shown in this study were inline 
with those published by Campani et al (Campani, Esposito et al. 2001). 
 
(iv) Colon cancer 
The Apc
Min/+
 mouse has increased levels of progastrin and gly-G17, which is 
expressed in polyps of both the small and large intestine (Watson and Smith 2001); 
these unprocessed forms of gastrin have been shown to promote proliferation in the 
colon (Wang, Koh et al. 1996; Koh, Dockray et al. 1999)  The MTI/G-Gly Apc
Min/+
 
mouse which expresses the glycine extended form of gastrin shows increased polyp 
size and number compared to the standard Apc
Min/+
 mouse (Koh, Bulitta et al. 2000).  
The normal colon does not appear to express the classical CCK-2 receptor, suggesting 
that the actions of G-gly are modulated independently of the classical CCK-2 receptor 
possibly through pathways involving c-jun and/or PI-3 kinase (Todisco, Takeuchi et 
al. 1995; Kowalski-Chauvel, Pradayrol et al. 1997).   
 
The main finding of this work in Apc
Min/+
 mice was that therapeutic intervention with 
G17DT reduced BVD, highlighting a role for gly-G17 in angiogenesis and 
proliferation over the time course of the study.  However, unlike the INS-GAS model 
there was no reduction in COX-2 protein expression. 
 
The differences in the types of gastrin expressed and the receptors they work through, 
help to explain why G17DT intervention had greater potency in reducing markers of 
cancer progression in the INS-GAS mouse model than the Apc
Min/+
 model.  Since, 
immunisation with G17DT elicits the production of antibodies which cross-react with 
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and neutralise G17 and gly-G17, therefore preventing them stimulating cells and 
effectively the downstream targets of gastrin, G17DT immunisation does not 
neutralise progastrin (2003); therefore, this is a limiting factor in colonic but not 
gastric setting as progastrin plays a role in carcinogenesis in the former but not latter 
(Siddheshwar, Gray et al. 2001; Konturek, Bielanski et al. 2002)   
 
 
7.4 Clinical relevance of gastrin in transgenic mouse models 
 
This work has demonstrated the ability G17DT to significantly reduce indicators of 
carcinogenesis in animal models of gastric and colonic cancer that over express 
different forms of gastrin and follow similar progression to human cancers.  The data 
achieved from the animal models in this work indicate that anti-gastrin treatment 
targeted at G17 is a feasible chemo-preventative route in gastric cancer, but that in 
colonic the inhibition of different forms of gastrin may be required. 
 
 
7.5 Clinical relevance of gastrin in patient tissue samples 
 
Barrett’s oesophagus and pancreatic cancer progression are both linked to G17 and 
gly-G17, with G17 promoting growth of oesophageal and pancreatic cell lines in vitro 
(Haigh, Attwood et al. 2003) and gly-G17 inhibiting apoptosis (Todisco, 
Ramamoorthy et al. 2001; Beales and Ogunwobi 2009).  In Barrett’s oesophagus the 
inhibition of apoptosis by gly-G17 has been showed to be mediated through the 
JAK/STAT3 pathway, but not via the CCK-2 receptor (Beales and Ogunwobi 2009).  
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Also, unlike G17, gly-G17 does not appear to be involved in COX-2 expression in 
Barrett’s (Abdalla, Lao-Sirieix et al. 2004).  In pancreatic caner G17 stimulates 
tumour growth through the CCK-2 receptor, but as with Barrett’s gly-G17 appears to 
work through a mechanism independent of the CCK-2 receptor (Seva, Dickinson et 
al. 1994). 
 
The poor prognosis for Barrett’s patients that progress to oesophageal 
adenocarcinoma is due to late diagnosis, by which point the cancer is advanced and 
metastasis has often occurred (Schlansky, Dimarino et al. 2006).  It is for these 
reasons that individuals with Barrett’s undergo regular endoscopy surveillance, as this 
is more sensitive than less invasive techniques such as barium swallow, faecal occult 
blood testing and brush cytology (Gerson and Triadafilopoulos 2002).  While 
surveillance programmes have been effective in the prophylactic treatment of some 
cancers, such as cervical (Spitzer 2007), current research would suggest that it is 
unlikely to be the case with oesophageal adenocarcinoma progression from Barrett’s 
oesophagus.  Although new advances in endoscopy techniques, such as narrow band 
imaging (NBI), are offering a more reliable detection of dysplasia (Hamamoto, Endo 
et al. 2004), the way forward may be to also use biomarkers to classify Barrett’s 
patients in conjunction with endoscopy assessment.  Based on the data presented in 
this work a possible biomarker would be CCK-2 receptor protein levels, since 
Barrett’s patients tend to be hypergastrinaemic and an increase in gastrin receptor 
leads to an increase in anti-apoptotic and proangiogenic pushing Barrett’s to 
adenocarcinoma. 
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As previously mentioned the current mainstay of treatment for individuals with 
Barrett’s oesophagus is long-term PPI therapy.  This is mainly due to it being a 
condition that affects the elderly population, who are often unsuitable for invasive 
surgery (Krasner N. A 2005).  Although the ability of PPIs to relieve symptoms is 
well-documented, there is no clear-cut evidence on their ability to prevent neoplastic 
change (Lanas 2005), and work presented in this study even suggests that 
hypergastrinaemia as a result of PPI therapy may induce expression of pro-angiogenic 
and anti-apoptotic factors, which drive Barrett’s progression to oesophageal 
adenocarcinoma.  For example this work has shown a positive correlation between 
serum gastrin levels and the anti-apoptotic markers XIAP and p-Akt along with 
positive correlations between the CCK-2 receptor and p-Akt and the pro-angiogenic 
marker VEGF-R2. 
 
This study alone does not provide enough evidence to prohibit the current use of PPIs 
in the management of Barrett’s oesophagus, especially since neoplastic change in 
Barrett’s oesophagus can be driven by factors other than hypergastrinaemia.  It does, 
however, imply that clinical trials are needed to further establish the role of PPI-
induced hypergastrinaemia in oesophageal adenocarcinoma progression from 
Barrett’s oesophagus, with a view to changing clinical management of Barrett’s 
patients.  A possible management route would be to test the CCK-2 receptor status 
and serum gastrin levels of Barrett’s patients and give either CCK-2 receptor 
antagonists or immunise with G17DT to inhibit gastrin interactions on the 
oesophageal mucosa, which catalyse neoplastic changes but maintain the positive 
effect of PPIs on acid reflux.  Further work is therefore also needed in relation to the 
effect of CCK-2 receptor antagonists and G17DT on the efficacy of PPIs. 
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The poor prognosis associated with pancreatic cancer and the current lack of effective 
treatment therapies makes it an area in need of a fresh approach.  The data presented 
in this work supports the targeting of gastrin-induced cancer growth in the pancreas as 
a novel therapeutic target in a subset of patients that over-express the CCK-2 receptor.  
A randomised placebo-controlled study using G17DT showed marginal significant 
survival benefit and lower incidence of metastasis in the G17DT treated group 
(Gilliam and Watson 2007).  However, when trialled in combination with 
gemcitabine, the standard chemotherapy agent for pancreatic cancer (Diaz-Rubio 
2004), there was no survival advantage over gemcitabine alone, except on a subset 
analysis of patients with high antibody titres (Gilliam and Watson 2007).  The use of a 
CCK-2 receptor antagonist Gastrazole in a randomised controlled trial also increased 
survival although not significantly compared to control.  Survival was also not 
improved compared to 5-fluorouracil (Chau, Cunningham et al. 2006). 
 
Although these initial trials do not offer an immediate answer, they are indicative that 
further work is required with respect to the involvement of different forms of both 
gastrin peptides and CCK-2 receptor isoforms to further establish their significance in 
the pancreatic cancer environment and that to be effective, treatments of pancreatic 
cancer need to be more targeted to individual patients dependent on their CCK-2 
receptor status. 
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7.6 A comparison of gastrin neutralisation and inhibition of COX-2 in gastric 
and colonic carcinogenesis  
 
Work in vitro has shown gastrin via the CCK-2 receptor significantly stimulates 
COX-2 expression possibly by the ERK5/MEF2 pathway and other MAPK dependent 
pathways (Guo, Cheng et al. 2002). 
 
As discussed in section 1.6.3 COX-2 is involved in the synthesis of prostaglandin E2 
(PGE2) from arachadonic acid.  Prostaglandins play an important role in gastric 
mucosal integrity by helping protect the mucosa from excess acid, via an increase in 
the production of mucus as well as by directly inhibiting acid synthesis (Arakawa, 
Nakamura et al. 1990).  Normally COX-2 is expressed at low levels in the stomach, 
but in vivo studies have shown increased expression in the gastric epithelium after 
acid-induced damage and in vitro after growth stimulation (Tsuji, Kawano et al. 1996; 
Sawaoka, Tsuji et al. 1997).  Over-expression of COX-2 has also been reported in 
gastric lesions, and selective COX-2 inhibitors have been shown to delay gastric 
wound healing in rats, indicating a possible role in gastric ulcer healing (Sun, Tsuji et 
al. 2000).   
 
In this work the reduction in BVD seen in the G17DT treated INS-GAS mice may be 
mediated through a reduction in COX-2 (fig 7.2).  Since, immunohistochemistry 
showed that COX-2 protein was expressed in a number of cell types which do not 
express the CCK-2 receptor, gastrin may also indirectly up-regulate COX-2 in the 
gastric mucosa. 
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Fig. 7.2 Systematic representation of how immunisation with G17DT may reduce
proliferation and angiogenesis in a hypergastrinemic model.
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COX-2 has been shown to be up-regulated in human and rat intestinal tumours and is 
associated with an increase in metaplastic potential (Huang, Ansorge et al. 2007), 
which may be associated with up-regulation of the gastrin gene by β-catenin (fig. 7.3).  
A number of studies have shown a reduced risk of developing colorectal cancer in 
individuals who take NSAIDs  In Australia in 1988 it was observed that there was a 
reduction in the incidence of colon cancer in individuals who regularly took aspirin 
(Kune, Kune et al. 1988).  Since these initial observations several human studies have 
noted the protective effects inferred by NSAIDs (mainly aspirin), against colorectal 
cancer (Williams, Smalley et al. 1997).  Studies using the NSAID sulindac have 
shown a significant reduction in tumour load and size in patients with the inherited 
autosomal dominant disease FAP (Williams, Smalley et al. 1997).   
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In the INS-GAS mouse study G17DT maintained low COX-2 protein expression 
levels expected in the normal gastric mucosa through out the time course of the study 
compared to the DT treated group, which showed a rapid increase of COX-2 protein 
expression at 30 weeks.  This sudden increase of COX-2 protein expression at 30 
weeks in the DT treated group may be in response to inflammation and gastric 
mucosal damage caused by hypergastrinemia, demonstrating that G17DT 
immunisation may be protective against inflammation and mucosal damage in the 
stomach. 
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7.7 The role of COX inhibitors in gastric and colonic cancer models 
 
To further explore the relationship between COX expression and gastric and 
colorectal cancer progression the two mouse models were used to investigate the 
effects of aspirin and celecoxib treatment. 
 
Aspirin was chosen as it inhibits both isoforms of COX, whereas celecoxib is a COX-
2 specific inhibitor (coxib).  Aspirin irreversibly inhibits COX-1 mediated synthesis 
of thromboxane A2 (TXA2), the major component of blood clots, and due to the 
anucleated state of platelets they can not regenerate COX-1, resulting in inhibition of 
platelet aggregation.  This is in comparison to the reversible inhibition of COX-1 by 
other NSAIDs, which is dependent on the half life of the drug (Strand 2007).  Coxibs 
were designed to overcome some of the side effects of NSAIDs, like gastric bleeding 
and ulcers, which are thought to be caused by the inhibition of COX-1. 
 
In the INS-GAS model, neither aspirin nor celecoxib had an effect on proliferation 
and although BVD was reduced by both agents, neither did so significantly.  These 
results support the theory that it is G17 that is driving the increase in COX-2 seen in 
this model and that in a hypergastrinemic environment G17DT immunisation is more 
successful in reducing the effects of COX-2 over-expression than the COX inhibitors, 
aspirin and celecoxib. 
 
In comparison in the Apc
Min/+
 mouse both celecoxib and aspirin significantly reduced 
proliferation in the polyps, BVD in the large intestine and COX-2 protein expression 
in the large and small intestine.  Although celecoxib reduced the polyp burden in the 
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small intestine, no reduction was seen in the polyp burden of the large intestine but 
this is likely to be due to the low number of polyps that form in the large intestine of 
this model.  Aspirin also reduced proliferation in the normal crypts of the large 
intestine.   
 
The results achieved in the Apc
Min/+
 model with COX inhibition would further suggest 
that G17 is not significantly involved in the progression of colorectal cancer in this 
model, although hypergastrinemia induced by PPIs has been shown to promote 
adenoma progression in this model (Watson and Smith 2001), which would suggest 
that levels of G17 need to be above a certain threshold to exert an effect.  Also of note 
is the fact that only aspirin reduced proliferation in the normal crypts suggesting a role 
for COX-1 in colorectal cancer progression since aspirin has been shown to be more 
effective at inhibiting COX-1 than COX-2 (Vane and Botting 1998).  COX-1 and not 
COX-2 have been shown to be expressed in the normal crypts of Apc
Min/+
 mice by 
Chulada et al (Chulada, Thompson et al. 2000) and studies have indicated that COX-1 
can metabolically activate procarcinogens to mutagenic intermediates, an activation, 
which can be inhibited by aspirin (Marnett 1992). 
 
 
7.7.1 G17DT as a COX-2 inhibitor? 
 
The first coxibs to be granted US Food and Drug administration (FDA) approval were 
celecoxib (Cerebrex) in December 1998 followed by rofecoxib (Vioxx) in May 1999 
(Strand 2007).  The publication of two large scale clinical trials, Celecoxib Long-term 
Arthritis Safety Study (CLASS), which ran from September 1998 – March 2000 
(Silverstein, Faich et al. 2000) and the Vioxx Gastrointestinal Outcomes Research 
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(VIGOR), which concluded in 2000 (Bombardier, Laine et al. 2000), showed 
selective COX-2 inhibitors produced similarly efficacy, but fewer GI side effects than 
NSAIDs which led to the general acceptance of coxibs. 
 
A number of studies have linked coxibs to an increased risk of cardiovascular events, 
which led to the relabeling of rofecoxib 14 months after its original approval to 
include potential cardiovascular risk (Strand 2007).  Following the early termination 
of the Adenomatous Polyp Prevention On Vioxx study (APPROVe) due to a two-fold 
increase in the number of cardiovascular events in the rofecoxib group compared to 
placebo in August 2004 (Bresalier, Sandler et al. 2005), rofecoxib was withdrawn 
from the market (Strand 2007).  It has since been discovered that some data on the 
occurrence of myocardial infarction was omitted from the VIGOR study (Curfman, 
Morrissey et al. 2005).   
 
Increased risk of cardiovascular events has also been reported, with celecoxib in the 3 
year Adenoma Prevention with Celecoxib (APC) (Solomon, McMurray et al. 2005) 
and the Prevention of Spontanous Adenomatous Polyp (Pre-SAP) as well as 
valdecoxib and parecoxib (Strand 2007). 
 
There are currently three selective COX-2 inhibitors available (celecoxib, etoricoxib 
and lumiracoxib) all of which are considered safe in low doses, but further research is 
needed to determine cardiovascular risk at higher doses (Strand 2007). 
 
With the loss of confidence in coxibs a gap is emerging in the clinical setting for an 
alternative method of COX-2 inhibition as a preventative of GI cancer progression.  
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Based on the data presented here and work by others, G17DT is a strong contender for 
this role in the case of gastric cancer, since it has been shown to inhibit a number of 
key systems linked to cancer progression such as proliferation and angiogenesis.  
Added to this, clinical trials have shown it is well tolerated in patients (Watson and 
Gilliam 2001).  However, for colorectal cancer G17DT is unlikely to be the answer, 
since it does not appear to effect COX-2 expression in the colon unlike the gastric 
setting, although that is not to say that an alternative anti-gastrin treatment may not be 
effective, such as one targeted at progastrin.  There is also the option of using G17DT 
or alternative anti-gastrin therapy in conjunction with low dose coxibs, as a reduction 
in the dose of the coxib is also likely to reduce the risk of myocardial events and any 
loss in efficacy at inhibiting COX-2 would be countered by the anti-gastrin therapy.  
Studies in the gastric cell line MKN-45 have shown a synergistic effect on reducing 
proliferation and increasing apoptosis with coxib, NS-398 and CCK-2 receptor 
antagonist, AG-041R (Sun, Zhu et al. 2008) 
 
 
7.8 Gastrin neutralisation in a chemo-preventative setting 
 
The role of gastrin in GI cancers is a crucial yet diverse one, where although there are 
similarities between the different types of cancers it is not a case of one theory fits all.  
For these reasons it is important to explore different methods of gastrin neutralisation 
in a chemo-preventative setting.  The current options available are; monoclonal 
antibodies, CCK-2 receptor antagonists or a gastrin vaccine. 
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Monoclonal antibodies have been used in a number of cancer treatments including 
blocking growth signalling of EGF and as delivery systems for radio and chemo 
therapy (Gleissner, Schlenk et al. 2007; Omura 2008; Ulaner, Colletti et al. 2008). 
 
Barderas et al (Barderas, Shochat et al. 2008) have shown that monoclonal antibodies 
which block G17 from binding to the CCK-2 receptor can reduce proliferation in Colo 
320 WT, a colorectal cancer cell line that over-expresses CCK-2R, and also 
monoclonal antibodies directed against the N-terminal of G17 were more effective 
than those against the C-terminal.  The high affinity human anti-gastrin monoclonal 
antibody XPA067.06 has been shown to neutralise human gastrin in vivo quickly and 
over a prolonged time course (Hsu, Patel et al. 2008). 
 
The main draw back to monoclonal antibody therapy is that it requires constant 
administration over time, which leads to a number of side effects from the common 
such as, flu like symptoms, rashes, nausea and diarrhoea to rare yet more serious ones 
such as, infusion reactions, extremely low blood cell counts, heart failure and 
bleeding.  Therefore in its current form monoclonal antibody therapy, while useful in 
the treatment of terminal patients is not ideal for long term treatment due to the 
constant administration and side effects. 
 
Receptor antagonists are receptor ligands or drugs that bind to a receptor and do not 
provoke a biological response, but block or dampen an agonist mediated response.  
Therefore receptor antagonists have an affinity, but no efficacy for their receptors.  To 
block the effects of gastrin the antagonist needs to be targeted against isoforms of the 
CCK-2 receptor. 
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The CCK-2 antagonist Gastrazole has been shown to prolong survival in patients with 
advanced pancreatic carcinoma (Chau, Cunningham et al. 2006), but its 
administration by protracted venous infusion is likely to mean its clinical use is 
limited.  More promising are potent orally activated CCK-2 receptor antagonists, such 
as Z-360, which can reduce tumour size in MiaPaCa2 xenografts in nude mice and in 
PANC-1 xenografts in combination with gemcitabine (Kawasaki, Emori et al. 2008).  
In summary, while CCK-2 receptor antagonists, which require protracted venous 
infusion are not desirable in a clinical setting, those which are administered orally 
offer a favourable treatment route, although compliance with ongoing administration 
would need to be assured. 
 
Endocrine therapy, where a synthetic hormone or drug is given to block the body’s 
natural hormones, is one of the oldest methods of cancer treatment (Gonzalez and 
Lage 2007).  A vaccine such as G17DT that raises antibodies that neutralises gastrin 
species is a viable option for chemo-prevention of GI cancers, which have been 
shown to be stimulated by gastrin.   
 
In vivo, G17DT has been shown to produce strong antibody titres in rats injected with 
colon cancer DHDK12 cells, with titres in excess of those needed to neutralise serum 
G17, which may mean that these excess antibodies are available to neutralise cell-
associated G17 peptides (Watson, Michaeli et al. 1996).  G17DT has also been shown 
to be well tolerated in patients with gastric carcinomas, with no autoimmune reaction 
or immunological tolerance displayed (Gilliam, Watson et al. 2004).   
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Some of the draw backs to G17DT include the repeated injections required, which can 
lead to adverse reactions at the injection site and also because it’s an immunogen 
patients need to have a functioning immune system to generate a response. 
 
In severe combined immunodeficiency (SCID) mice injected with MGLVA1asc cells, 
a gastric ascities cell line derived from the human gastric carcinoma cell line 
MKN45G, G17DT had greater therapeutic effect than CI-988, a gastrin/CCK2 
receptor antagonist (Watson, Michaeli et al. 1999).  Possible reasons for this are that 
the antagonist has a lower affinity for gly-G17 than G17DT and that gly-G17 is 
mediated through an alternative receptor to the CCK-2 receptor and is therefore not 
blocked by this antagonist (Singh, Rae-Venter et al. 1985). 
 
In conclusion, based on the data presented in this report and the current literature the 
neutralisation of gastrin peptides and/or the blocking of its receptor offers viable 
therapeutic modalities for the treatment of GI cancers in a subset of patients that over-
express gastrin and/or its receptor.  Neutralisation of gastrin peptides in these 
individuals would result in the reduction of COX-2, proliferation, angiogenesis and 
XIAP and therefore slow or even prevent cancer progression.  Therefore, the research 
presented in this thesis has lead to the conclusion that the best way forward is to offer 
a targeted approach dependent on gastrin and CCK-2 receptor status.  Currently CCK-
2 receptor antagonists look like the optimal modality for achieving this, due to their 
low toxicity, oral administration and high activity. 
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7.9 Future work 
 
This work has added more weight to the importance of gastrin in a number of GI 
cancers, and the possible role of gastrin and /or its receptor as a therapeutic target.  
More work is need to establish the different pathways in which gastrin is involved 
within the different cancer types, especially the relationship between gastrin and 
COX-2.  To help understand this relationship I would propose mechanistic studies 
using relevant GI cell lines and treating with G17DT, COX inhibitors and 
combinations of G17DT and COX inhibitors and use western blot and RT-PCR to 
measure protein and gene expression levels of various markers including Bcl-2, Bax, 
PPARγ, COX-2 and gastrin (Chang, Song et al. 2006; Ptak-Belowska, Pawlik et al. 
2007), as well as to determine the relationship between VEGF-R2, Bcl-2, XIAP and 
CCK-2 receptor.  Also I feel it would be interesting to establish the mechanism by 
which gly-G17 reduces BVD in colonic cancer; this may be dependent on determining 
the receptor through which gly-G17 acts in the colon. 
 
For the Barrett’s work it could be beneficial if biopsies were available from 
subsequent endoscopies of the patients included in this study in order to observe 
possible progression to adenocarcinoma and relate this to parameters assessed in this 
thesis, to further strengthen the link between gastrin parameters and Barrett’s 
progression.  Another idea would be to obtain biopsies from individuals with 
oesophageal cancer and make a comparison betweens the ones that have progressed 
from Barrett’s and those that have not to compare the different environments. 
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At a clinical level I would propose screening of Barrett’s and pancreatic cancer 
patients for their CCK-2 receptor status and serum gastrin levels and considering 
treatment which included inhibition of the receptor probably as discussed earlier by a 
receptor antagonist. 
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